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3 
Cancer 
In 400 BC, Hippocrates, the Greek physician generally regarded as the “father of 
Medicine” was perhaps the first to recognize cancer as a separate disease entity 
which he denominated as “carcinos”. In Greek, the word refers to a crab. This 
invertebrate was probably associated with the disease because the finger-like 
spreading projections emanating from a growing cancer provoke associations with 
the morphological aspect of a crab. Referring to this concept of ‘carcinos,' as a 
disease entity in 28-50 BC, a Roman physician by the name of Celsus was probably 
the first to translate the Greek crab term to the Latin “Cancer” and this has been the 
name of this group of diseases ever since. Despite millennia of effort, however, the 
clinical problems associated with preventing and curing cancer have not been 
solved. 
In our time, a group of over a thousand diseases share the generic name cancer. We 
recognize different types of cancer but all arise from unusual properties acquired by 
the cells involved. Once established, cancers often affect a different part of the body 
as from whence they originate and involve the loss of the intrinsic mechanisms that 
inhibit cell proliferation. Multiplication of cells is an intricate process requiring 
elaborate biochemical coordination. In physiology compartment size is well-
controlled and limited by various forms of cell death, control from which cancer 
cells escape. In addition, tumor cells escape from the immune system surveillance, 
and thus instead of being killed, they proliferate rapidly at a geometric rate forming 
a mass of cells; a tumor. Also, cancer cells survive and multiply outside their normal 
tissue boundaries, invading neighboring tissues. Furthermore, cancer cells are highly 
mobile within the body and can affect different parts of the body. Following seeding 
they can initiate growth of a new cancer that can affect healthy tissue. Upon 
entrance of cancer cells into the lymph  and bloodstream, migration to a different 
part of the body is even further enhanced. The process of cancer spreading, i.e., 
metastasis, is the primary cause of mortality due to cancer. In this thesis I want to 
contribute to the battle against this disease. 
The urgency of such efforts is illustrated by that oncological disease accounts for 
annually 8.2 million cancer-associated deaths (2012 numbers) and 14 million newly 
diagnosed patients. Victories against other types of mortality now also make cancer 
an emerging global public health problem(1), a development also occurring in 
Nigeria, my home country. Most prevalent cancer types include the gastrointestinal, 
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prostate, liver, lung, breast, cervix, colorectal manifestations (2). Cancer can arise 
from any form of body tissue and occurs when a typical cell acquires six core 
biological hallmarks which turn it into a tumor cell. Hanahan et al.(3, 4), describe 
these six core hallmarks of cancer to include the ability of tumor cells to: 1) sustain 
continuous proliferation through constitutive activation of proliferative signaling 
pathways or disruption of negative feedback mechanism on cell proliferation, 2) to 
evade growth suppression through the inactivation of tumor suppressor genes, which 
in normal physiology generally turn of an increased signaling and control the cell 
cycle progression, 3) to resist cell death by the loss of pro-apoptotic factors and the 
upregulation of anti-apoptotic factors, 4) to enable replicative immortality through 
the extension of the telomeric DNA at the ends of the chromosome by telomerase 
enzymatic activity, 5) to stimulate angiogenesis to provide access of the tumor to 
nutrients and oxygen and for removal of metabolic wastes, 6) to undergo invasion 
and metastasis whereby tumor cells alter their shape and lose their adherence to 
other extracellular matrix and cells (Fig. 1A)(3). 
These six ‘core’ hallmarks are somewhat artificial as it is now becoming evident that 
tumor cells can also acquire other typical hallmarks of which reprogramming of 
their energy metabolism,  using glycolysis to produce energy even under aerobic 
conditions, is maybe the most evident. The latter are sometimes denominated as 
“emerging hallmarks.” 
  
Figure 1. The cancer hallmarks  (A) Schematic depiction of the six ‘core’ properties typically acquired 
by a tumor cell during its multistep development. These six properties are sustaining proliferation, 
evading growth suppression, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis. (B) Furthermore, tumor cells acquire two 
emerging hallmarks, reprogramming energy metabolism and avoiding the immune system, and two 
enabling hallmarks, genome instability, and tumor-promoting inflammation. (Adapted from 
reference)(3) 
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In this context, it is also important to mention the potential to escape immune system 
surveillance. Furthermore, the accumulation of mutation and genome instability 
results in an ever-expanding expansion of subclones of the tumor cells, which will 
be subject to selection (also in response to therapy). As mentioned many tumors 
promote inflammation, causing normal immune cells to infiltrate and also attack the 
tumor cells. But this beneficial effect is often counterbalanced by the resulting 
inflammation-dependent promotion of tumor growth, activation of pro-survival 
pathways and release of proangiogenic factors (Fig. 1B)(3). A block of differentiation 
can be distinguished as another hallmark of cancer, and this is caused by the ectopic 
expression or loss of key transcription factors. In this thesis, I try to take all of these 
factors into account in an effort to explain the cancer process. 
In essence, genetic and epigenetic alterations are the underlying causes for these 
cancer hallmarks to appear. These epigenetic changes prominently include DNA 
methylation and covalent histone modifications, whereas the genetic changes 
involve processes such as deletion, amplification, insertion, translocation or point 
mutations, in addition to changes in the expression levels of the affected genes or 
changes in enzymatic activity. In conjunction, these changes provoke the appearance 
of the above-described cancer hallmarks. The genetic alterations can be inherited or 
acquired due to exposure to environmental factors, like tobacco smoking, or can be 
associated with specific dietary habits (high-fat), contact with toxic chemicals or 
viral and/or bacterial infection. If these genetic changes provide the cells with a 
selective advantage, this results in their outgrowth within the local tissue. Further 
accumulation of genetic changes because of genome instability, can then promote 
tumor cells to acquire increased invasive and metastatic potential[2]. It is, however, 
fair to say that in many cases we only poorly understand how all these effects 
conspire to provoke disease.  
Understanding cancer thus represents one of the significant challenges for the 
scientific community in the present century. Some types of cancer have a more 
substantial impact on public health as they present with higher incidence and 
mortality, among them gastrointestinal cancer. In the general introduction of this 
thesis, I present an overview of the current knowledge on gastric cancer, addressing 
epidemiological, clinicopathological and biological aspects.   
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Gastric cancer 
Gastric cancer remains a significant public health problem globally, and it is among 
the leading causes of cancer-associated mortality world-wide(5, 6). Although only 
25–30% of gastric cancer patients will survive the five years following diagnosis, 
substantial heterogeneity of survival rates is reported in clinical trials, and this may 
relate to variations in the biological and genomic make-up, especially when Western 
and Asian populations are compared(7). Gastric cancer incidence dramatically varies 
across different geographical areas, being the highest in Japan, China, Far Eastern 
countries, Russia, Middle Eastern area, and in the Pacific coast of the South 
American continent and the being the lowest in Central Africa. Europe and North 
American regions share an intermediate-to-high incidence(8). Stomach and breast 
cancers have the highest incidence rates of all other cancers and are for instance 
among the most common causes of death in Iran(8). Conversely; there are low 
prevalence and incidence rates in sub-Sahara Africa(9-13). Gastric cancer patient’s 
prognosis is a function of disease stage progression, in which less than 20% progress 
to advanced stages in patients surviving five years following diagnosis. It appears 
important to individualize treatment and screening strategies for the high-risk 
groups. Several risk factors are responsible for the progression to advanced stages of 
gastric cancer(14-17). Gastric cancer risk is associated with Helicobacter pylori 
infection which accounts for 70% cancer incidence in the stomach, and accordingly, 
the eradication of this bacteria provides primary prevention for cancer 
development(2, 18). Generally, one can say that family history, intestinal 
metaplasia, salt intake, smoking, alcohol and H pylori infection are the most 
significant risk factors for developing the premalignant conditions that ultimately 
give rise to gastric cancer development(19-22). Japan and South Korea adopted a 
strategy of early detection among other approaches, which has resulted in a 
favorable decrease in incidence and prevalence rate. The median survival rate of 
full-blown gastric cancer is only 9 to 10 months. There is hope that profiling of 
immune and molecular details of the disease, as well as the introduction of immune 
checkpoints inhibitors, may increase the overall survival rate and the present thesis 
also aims to contribute in this respect. 
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Descriptive epidemiology of gastric cancer  
Global estimate: incidence and mortality 
The Global Burden of Cancer Study (GLOBOCAN 2008)(18) provides the most 
recent figures available for the worldwide cancer burden with 988,000 new gastric 
cancer cases accounting for 7.8% of the total global cancer burden. This makes 
gastric cancer the fourth most prevalent global cancer after lung cancer (1.68 million 
cases; 12.7% of all cancers), breast cancer (1.31; 10.9%), and colorectal cancer 
(1.24; 9.8%). More than 73% (728,000 cases) of gastric cancer cases occur in parts 
of Asia, and almost half the world’s total (47%) of gastric cancer occurs in China 
(Fig. 2). Europe contributes nearly 15% of to the global burden (146,000 cases) of 
gastric cancer, whereas Central and South America add a further 7% (65,000 cases) 
(see Fig. 2). 
 
Fig. 2. Mortality and new cases estimated number of global fraction proportion of 
gastric cancer. Available at: http://globocan.iarc.fr. Accessed January 7, 2013.) 
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Prognosis following a gastric cancer diagnosis is usually poor. This is evident from 
the pattern of mortality which shows great similarity that of the incidence of gastric 
cancer,, and the proportional breakdown of the key two indicators by continent does 
not seem substantially different (see Fig. 2). The above estimates represent the 
figures for cases of the histological type of cancer known as gastric adenocarcinoma, 
but other types of gastric cancer exist as well. Several studies recently estimated a 
worldwide total of lymphomas of gastric origin in 2008 to be 18,000 (i.e., less than 
2% of the number of adenocarcinomas)(23). Other gastric malignant histologies are 
even less frequent than this. Hence in this thesis, I focus on the adenocarcinoma of 
the stomach. 
A recent study by Hu cum suis indicated a relationship between metabolic syndrome 
and increased risk for gastric adenocarcinoma(24). The main finding of Hu and 
colleagues is an important issue, not only for clinicians who are faced by gastric 
cancer patients but also for health policy makers in Asian countries, who are 
challenged with the burden of gastric cancers in their populations. We know that the 
problem of gastrointestinal cancer is growing due to aging populations, smoking, 
obesity, and changing lifestyle in Asia(25, 26), which are all associated with 
metabolic syndrome. Thus controlling metabolic syndrome will remain essential for 
managing the cancer burden in the Asian population. As I am skeptical that 
important improvements in this respect will be made anytime soon, I feel that the 
need to develop more insight into gastric cancer pathogenesis and to develop new 
modes of treatments will remain necessary and this what I intend to aid through this 
thesis. I shall focus on H. pylori as a risk factor, the role of endoscopy in diagnosis, 
the potential of targeting Hedgehog signaling and the potential of checkpoint 
inhibitors in gastric cancers. The reason for these choices I shall try to explain 
below. 
Risk factors for gastric cancer  
Helicobacter  pylori 
It is assumed that H. pylori-infected individuals were once ubiquitous in the human 
population, but in many populations, the prevalence is successively declining as 
determined in birth cohorts and it is rare among children in Japan, Western Europe, 
North America, and Oceania(27). Risk factors associated with H. pylori infection, 
and thus gastric cancer, include overcrowding, poor sanitation and low 
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socioeconomic status(28, 29). The relationship H. pylori infection and gastric cancer 
remained controversial for some time until it was effectively ended in 1994, when an 
expert (IARC) working group convened and classified H. pylori infection as a 
carcinogen to humans, based on its association with gastric cancer and mucosa-
associated lymphoid tissue lymphoma (30). Although not really subject to debate 
anymore, this hypothesis was confirmed in 2009 by yet another second IARC 
working group(31), with the added precision that H. pylori causes noncardia gastric 
carcinoma thus implying that infection with H. pylori is not a risk factor for gastric 
cancer in its totality but restricted to the distal part of the stomach. A study recently 
estimated that 75% of noncardia gastric are associated with H. pylori infections(31). 
However, it now seems that the relationship between H pylori and gastric cancer 
may even have been underestimated, because of inaccurate assessment of H. pylori 
infection status. Indeed, it has been hypothesized the necessary causal factor for 
gastric cancer is H. pylori infection(32). Almost all of the epidemiologic evidence 
on the relationship between gastric cancer and H. pylori comes from a serologic 
assessment of H. pylori IgG. It is now widely accepted that retrospective serologic 
evaluation of gastric cancer with H. pylori infection cases has poor sensitivity so that 
case-control studies systematically underestimate the strength of the association. 
Atrophic gastritis causes this problem, a precancerous lesion, which leads to a 
reduction in infection burden to H. pylori and a subsequent decrease in IgG antibody 
titers to H. pylori, which may become serologically undetectable. For this reason, 
most of the evidence for the carcinogenicity of H. pylori is from prospective studies. 
The most comprehensive comparative risk estimates for H. pylori association with 
gastric cancer come from 12 prospective studies pooled analysis, which included 
cases of noncardia gastric cancer (762 ) and controls (2250). The combined (OR) of 
H. pylori infection was 2.97(2.34–3.77)(33). The same author included 274 cardia 
gastric cancer cases with the same control (827, ) with (OR) 0.99 (0.40–1.77) for H. 
pylori infection. When restricted cases in a pooled analysis of over ten years blood 
are drawn H. pylori diagnosis, an increased  Odd ratio of  5.93 (3.41–10.3) for non-
gastric cancer of noncardia origin but reduced odds ratio of 0.46(0.23–0.90) for 
cardia cancer. This subgroup analysis underscores both the difference between 
cardia and noncardia cancer and the need to account for the effect of gastric 
carcinogenesis on H. pylori measurement, even in prospective studies(31). It is 
important to note, however, that although H. pylori infection may explain most if not 
all gastric cancers, most people infected with the bacterium do not develop such 
cancer. Hence understanding what makes an H. pylori-dependent infection 
potentially hazardous is of utmost importance 
Chapter 1 
10 
The CagA pathogenicity island 
The diversity of the H. pylori genome is responsible for the differences in clinical 
prognosis. H.pylori can differ in quite a number of genetic factors expressed upon 
stomach tissue colonization; these factors include the virulence factors VacA and 
CagA and BabA, SabA, alphAB and HopZ which have all been reported to be 
associated with progression towards gastric cancer. The H. pylori virulence factor 
CagA (cytotoxin-associated gene A) is a 120–145 kDa protein encoded on a 40 kb 
cag pathogenicity island (denominated as PAI) and considered as one of the most 
relevant pathogenicity factors in relation to progression to gastric cancer. H. pylori 
strains are thus subdivided into CagA positive or negative strains. Approximately 
half of the H. pylori strains isolated in Western countries contain cag/PAI, whereas 
almost all of the East Asian isolates are cag/PAI-positive(31). A case-control study 
involving 778 gastric cancers from the non-cardia origin and 1409 matched controls 
revealed excess H. pylori CagA positive strains in the gastric cancer group resulting 
in an odds ratio (OR) of 2.01 CI (1.21–3.32) progression towards gastric cancer(34). 
Mechanistically the cag pathogenicity island is associated with the establishment of 
precancerous gastric lesions, implying a role for the bacterium in the early phases of 
progression towards full-blown disease. Plummer and colleagues(35), analyzed the 
results of a cross-sectional endoscopic survey of 2145 individuals from Venezuela, 
in which both DNA and CagA gene of H. pylori gene were determined by 
polymerase chain reaction on gastric biopsies. Infection with H. pylori cagA-
positive strains but not negative cagA-strains appeared associated with severity of 
the precancerous lesions in this study. Using individuals with normal gastric mucosa 
or superficial gastritis as controls, the OR for dysplasia was 15.5(6.4–37.2) for H. 
pylori cagA-positive strains compared to 0.90(0.37–2.17) for cagA-negative H. 
pylori. Gonzalez and colleagues (35), analyzed the results of a follow-up study of 
312 individuals from Spain with 12.8 years as an average follow-up time between 
two endoscopies, also involving the results of polymer chain reaction detection of 
cagA and genotyping of the H. pylori results. The relative risk for progression of 
precancerous lesions was 2.28 (1.13–4.58) for cagA-positive strains compared to 
cagA-negative strains. It is clear. However, that cagA alone does not explain the 
presentation of gastric cancer in the population in relation to H. pylori and this thesis 
I endeavor to identify other markers differing between H. pylori strains that may 
explain alternative gastric cancer risk. 
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Other Risk Factors 
Socioeconomic status (SES) and surrogate factors  
Developing countries share a higher burden of gastric cancer than in the developed 
world. This appears due to differences in socio-economic status. In developed 
countries, like The Netherlands, both incidence and mortality are currently 
decreasing, due in part to the slow disappearance of H. pylori that accompanied the 
uninterrupted access to better living conditions in people born after World War II. 
Indeed, within any country or population, noncardia gastric cancer is most often 
seen in lower socioeconomic groups and has been associated with many risk factors 
that act as a surrogate for lower SES, mainly low income, lower education, number 
of siblings, crowding, and lower occupational activity(36, 37). Hence, higher SES is 
inversely associated with gastric cancer of noncardia origin, whereas cardia gastric 
cancer is strongly associated with esophageal adenocarcinoma and both are 
associated with a higher SES. Many other factors involved in gastric cancer 
epidemiology are also associated with SES and probably confound some of the 
observed associations, although adjusting for H. pylori infection in a large European 
multicenter study, makes the effect of SES in non-cardia gastric cancer entirely 
disappear(38). Thus, although other factors such as fruit and vegetable consumption, 
cigarette smoking, and physical activity, may also confound any observed 
association with SES, it is clear that H. pylori  is a major driving force in the 
development of gastric cancer, justifying my efforts of linking specific substrains of 
this bacterium to clinical outcome of disease. 
Tobacco and alcohol 
In relation to the former, smoking is a recognized cause of gastric cancer but seems 
to act as a moderate risk factor, compared to other associated risk factors of gastric 
adenocarcinoma. A meta-analysis and systematic review, (including cohorts, case-
cohorts, and nested case-control studies and other prospective studies) produced a 
risk estimate for gastric cancer of 1.62 (1.50–1.75) in male smokers and an 
assessment of relative risk of 1.20(1.01–1.43) in female smokers as compared to 
self-reported never smokers(39). Meta-analyses studies have furthermore revealed 
that the risk for stomach cancer increases with increasing cigarette consumption (as 
expressed either as average number per day, number of pack-years, or as a function 
of a longer period of smoking)(40). Nevertheless, as compared to for instance lung 
Chapter 1 
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cancer, the effects of smoking are small with respect to development of cancer in the 
stomach and thus I decided not to investigate this aspect in the studies described in 
this thesis, but focus on other factors in their relation to gastric cancer. 
Food and nutrition 
In 2007 an expert panel assembled by the American Institute for Cancer Research 
scored the risk for cancer development in relation to diet and nutrition on a five-tier 
scale and concluded that an association between diet and gastric cancer exists(41). 
According to this panel, protective effects of diet on the development of gastric 
cancer emanating from various studies could be scored mostly as level 1 
(convincing) evidence, but a few studies were scored as level 2 (probably) evidence. 
Probable protective factors are abstaining from carbohydrate intake and ample 
consumption of vegetables and fruits. Likely risk factors are high salt intake and 
consistently salt-preserved foods. For other dietary factors, scores were level 3 
(limited evidence). Again, I decided to ignore this aspect of gastric cancer 
pathogenesis in my studies, as I found that other aspects were more deserving of 
study. 
Epstein-Barr Virus 
H. pylori is not the only infectious agent associated with malignant transformation in 
the stomach. Epstein-Barr virus (EBV) is present in 10% of gastric cancers. There is 
strong mechanistic evidence that EBV can provoke gastric cancer. EBV DNA 
appears incorporated in cancer cells as detected by the presence of antigen in gastric 
cancer(42). However, the epidemiological evidence that shows an association 
between gastric cancer and EBV is weak, mainly because of the difficulty of 
controlling for the confounding infection with H. pylori. For this reason, the same 
working group which concluded that H. pylori causes noncardia gastric cancer did 
not conclude that EBV causes gastric cancer(42) and as a consequence of this 
analysis I did not investigate EBV in relation to gastric cancer in this thesis. 
Genetic Factors 
Up to 3% of the total gastric adenocarcinoma burden is associated with an inherited 
predisposition syndrome(43). Among them, inherited gastric cancers of the diffuse 
type are prominent within this thesis I shall term as hereditary diffuse gastric cancer 
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(HDGC). The identification of a germline mutation inactivating the gene encoding 
for E-cadherin (CDH1) in a Maori family from New Zealand was the start point to 
understand HDGC pathogenesis. In HDGC families, abnormal E-cadherin gene 
carriage is found associated to an 80% risk (Lifetime) for Gastric cancer 
development, leading to recommendations for genetic testing, screening, and even 
total gastrectomy as a prophylactic strategy in CDH1 mutation carriers(43). Other 
inherited predisposition syndromes include Lynch syndrome, which shows an 
intestinal histology in 90% of the cases, and carries a lifetime risk of around 10% for 
gastric cancer (of note, this risk is much higher for colorectal or endometrial cancer); 
ovarian and breast cancer hereditary syndrome because of germline mutations of 
BRCA1 and BRCA2; p53 mutations that preceeded Li-Fraumeni syndrome; and the 
much rarer familial adenomatous and  juvenile polyposis syndromes which are 
associated with the hererozygotic carriage of APC gene germline mutations, 
BMPR1A and SMAD4 genes, and STK11 gene, respectively(44). The relationship 
with the BMP pathway and gastric cancer is intriguing. BMP pathway activity and 
Hedgehog pathway are closely linked, and in contrast to the BMP pathway, 
exaggerated Hedgehog pathway activity is subject to treatment by FDA and EMA-
approved pharmacological inhibitors. This is one of the factors (see also below) that 
drove me in the course of this research to explore the potential of the Hedgehog 
pathway in gastric carcinogenesis. 
Other Miscellaneous Factors 
Pernicious anemia can result from an autoimmune disorder characterized by atrophic 
damage restricted to the gastric body mucosa (gastric atrophy type A). This 
condition confers significant risk for gastric cancer development, with a similar 
incidence rate as seen in gastric atrophy caused by H. pylori (gastric atrophy type 
B)(45). The associated risk appears H. pylori infection independent, although the 
potential interaction between infection and pernicious anemia has not yet been 
thoroughly studied. Prior gastric surgery for benign disorders (mainly gastric ulcer) 
was an established risk factor for adenocarcinoma development before the discovery 
of H. pylori. It is not clear if a prior gastric surgery is itself associated gastric cancer 
risk factor in the remnant stomach (e.g., acting synergically with H. pylori  through 
mechanical adverse effects of the surgery, i.e., bile reflux) or if it is merely a 
surrogate for long-term infection with H. pylori with the more aggressive CagA 
positive strains(46, 47). Ionizing radiation has been shown to provoke risk for cancer 
development, including gastric carcinoma(40). The best evidence comes from the an 
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atomic-bomb survivor longitudinal study involving 38,576 Nagasaki and Hiroshima 
citizens in Japan that were followed up between 1980 and 1999. Increased risk for 
gastric cancer in persons professionally exposed to ionizing radiation, e.g., 
astronauts has not been established. In contrast, in this thesis, I shall also reflect on 
the potential of space travel to convey lessons for better treatment of gastric disease. 
The Hedgehog Signalling 
Hedgehogs constitute a family of morphogens of pivotal importance for gestation in 
general and stomach development in particular. Intriguingly, gastric Hedgehog 
signaling remains active in the adult phase of life and where it is responsible, 
amongst other functions, for maintaining gastric pit-gland asymmetry. In this sense, 
the stomach is a beautiful example as to illustrate how morphogen signaling 
contributes to morphostasis in adults. 
The importance of Hedgehog signaling in many forms of cancer in conjunction with 
its link to gastric developmental processes has prompted a substantial research effort 
investigating the potential usefulness of targeting Hedgehog signaling in gastric 
oncogenesis.  As a result, in gastrin-mediated compartment expansion and viral and 
Helicobacter-dependent gastric carcinogenesis, the role of Hedgehog signaling is 
now relatively well understood. Furthermore, when the malignant disease is 
established, the evidence indicates that hedgehog signaling may provoke drug 
resistance. Now that the hedgehog inhibitor Vismodegib has come available, which 
has proved useful in other kinds of cancer (especially basal cell carcinoma), it is 
tempting to propose clinical trials using this compound for patients who have gastric 
cancer and accordingly various of such studies have now been initiated. In this 
thesis, I aim to comprehensively investigate this angle to explore the potential of 
targeting Hedgehog in preventing and combating gastric carcinogenesis. 
Role of Hedgehog Signalling in Gastric Homeostasis 
Ever since its initial detection in Drosophila, Hedgehog is associated with foregut 
development. The mammalian genome expresses three (3) Hedgehog ligands. In the 
mucosa of the embryonic foregut, Sonic Hedgehog is profoundly present[52]. All 
over the gut but especially in foregut-derived organs such as the lung, Sonic 
Hedgehog is expressed both in embryogenesis as well as in adults [53-56], while in 
the small intestine adjacent to the stomach expression is profoundly less marked (see 
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Table.1)[52, 57]. Functionally, Sonic Hedgehog controls maturation and 
differentiation of epithelial cells in the adult stomach[57-59].  
During the progression from the inflamed stomach to gastric cancer, an important 
step is the loss of acid-production by the parietal cells followed by replacement of 
these parietal cells by mucus-secreting cells that express spasmolytic polypeptide 
(SP) or trefoil factor 2.[60]. This process is named, especially in mice but also in 
human subjects, SP-expressing mucosa (SPEM) and this is a type of oxyntic gland 
atrophy[61, 62]. Together with the atrophy of parietal cells in SPEM[56].  Sonic 
Hedgehog expression diminishes in parietal cells as well[63, 64]. The expanding 
SPEM compartment that replaces the parietal cell compartment also produces Sonic 
Hedgehog, but this remains inactive as the SPEM compartment fails to convert the 
unprocessed full-length 45-kilodalton preform of Sonic Hedgehog to its cleaved 19 
kD mature form that is capable of eliciting morphogenetic signaling.[65][59, 63] 
,[64, 66].  
Recent insight as to why gastritis may reduce processing of Sonic Hedgehog to its 
active form has been gained and has been linked to the absence of gastric acid under 
atrophic conditions[67, 68]. The hypochlorhydria associated with atrophy of parietal 
and zymogenic (chief cell) lineages affects the production of the zymogens. 
Especially reduced serum levels of pepsinogen I (or pepsinogen A) (when compared 
to pepsinogen II (or pepsinogen C)) are noted in patients with atrophic gastritis [69-
75] and assessment of the levels of the two zymogens in serum is clinically useful 
for indicating pre-neoplastic changes in the stomach[75]. Pepsinogen A is produced 
primarily in the mouse corpus by parietal cells, whereas pepsinogen C produced by 
both mucous neck and chief cells throughout the stomach, which may account for 
the differential sensitivity of the two pepsinogens for gastric atrophy[67]. In the 
stomach, upon acidification Pepsinogens A and C are converted to the enzymatically 
active aspartic proteinases, pepsin A and pepsin C, through intramolecular self-
cleavage[75, 76]. Pepsin A prefers to cleave proteins at hydrophobic and aromatic 
amino acid residues, particularly at phenylalanine (F), when the pH is less than two. 
By contrast, pepsin C act on a broader range of substrate peptides and is less pH 
sensitive when compared to pepsin A[76, 77]. Experiments employing site-directed 
mutagenesis show that pepsin A cleaves the nascent 45-kilodalton Sonic Hedgehog 
polypeptide at residue 200 (SGGCF200|P) to generate the active 19-kilodalton form, 
whereas pepsin C does not cleave Sonic Hedgehog[67].  This provides a mechanistic 
explanation as to why SPEM is associated with reduced Sonic Hedgehog signaling. 
Chapter 1 
16 
The relationship between Sonic Hedgehog and both physiology and 
pathophysiology call for further studies investigating the usefulness of targeting 
Sonic Hedgehog signaling for combating gastric cancer and delineating the 
mechanistic details of its signaling as to obtain better insight in the fundamental 
mechanisms underlying the action of Sonic Hedgehog. 
Regulation of Gastrin and Gastric Acidity by Hedgehog ligands 
This notion is further supported by studies examining the impact of Hedgehog 
signaling on gastric physiology in vivo. An example is a transgenic mouse that 
secretes an endogenous inhibitor of Hedgehog ligands called Hedgehog-IP under 
control of the H+, K+-ATPase β subunit promoter, which is specific for parietal 
cells(48). The results show reduced secretion of gastric acid by the parietal cells. 
Hypochlorhydria, in general, stimulates gastrin gene expression through a decrease 
in somatostatin production by the enterochromaffin-like cells of the stomach (49). 
Accordingly, the Hedgehog-IP model displays increased plasma gastrin with 
concurrent decreased somatostatin production. Hence the loss of Hedgehog 
signaling is sufficient to activate the standard feedback mechanisms associated with 
loss of parietal cells that are typically attributed to gastrin and somatostatin and are 
linked to oncological transformation in the stomach(50). Furthermore, both antral G 
and D cells possess primary cilia, organelles protruding from the plasma membrane, 
which are intimately linked with transduction of Hedgehog signals and it is thus 
likely that these cells are subject to Hedgehog effects(51, 52). In apparent 
agreement, transgenic overexpression of GLI2, a transcription factor active in 
canonical Hedgehog signaling, suppresses gastrin gene expression(53). It would thus 
be interesting to study the cilium-specific effects of Hedgehog signaling (i.e., those 
effects of Hedgehog that do not involve the first Hedgehog receptor Patched but do 
involve the second Hedgehog receptor Smoothened –see later this thesis) as these 
may provide further insight into the link between Hedgehog and gastric physiology. 
In the present thesis, I aim to do so, albeit in an artificial model system.  
Cross-Links between Hedgehog Signaling, Chronic Inflammation leading to 
Gastric Cancer 
The further imperative for studying Hedgehog signaling in the context of this thesis 
comes from the significant role of this morphogen not only in gastric development 
and homeostasis but also from its role in neoplastic transformation(54). Although 
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the extensive literature on the action of Sonic Hedgehog proteins and their 
downstream targets exists, the body of contemporary biomedical literature has not 
yet been systematically analyzed about the role of the morphogen in gastric 
pathophysiology. Nevertheless, it is clear that Sonic Hedgehog is highly expressed 
in gastric cancer cell lines(55). Although increased levels of Sonic Hedgehog have 
been reported in gastric cancers, its specific role in gastric transformation appears 
elusive but carries significance because of the availability of Hedgehog antagonists.  
In this context is important to note that the phenotype of infiltrating myeloid cells in 
inflammatory reactions changes over time as to generate MDSCs (myeloid-derived 
suppressor cells). The latter are a heterogeneous group of immune cells from the 
myeloid lineage that possesses strong immunosuppressive activities rather than 
immuno stimulatory properties. Although their mechanisms of action are not clear 
yet, it is clear that cancer tissues with high infiltration of MDSCs are associated with 
poor patient prognosis and resistance to therapies. Importantly MDSC generation 
requires Hedgehog signaling. Expression of GLI1 (a pivotal transcription factor in 
canonical Hedgehog signaling), is an early indicator that the myeloid cells recruited 
during chronic inflammation are transforming towards a MDSC phenotype in the 
stomach(56-59). The ability to track these cell types in the pre-neoplastic state 
broadens options for the more efficient screening of subjects predisposed to develop 
gastric cancer eventually as well as to expand opportunities for prophylactic therapy 
once atrophic gastritis develops, including antagonists of mTOR (mechanistic 
antagonist of rapamycin)(60-62). Although Hedgehog antagonists been used for 
other cancer types, their use in clinical trials for gastric cancer is still in its infancy 
(63). Where initiated, those tests appear to focus on targeting CD44-positive gastric 
stem cells to treat metastatic disease(64). In this thesis, I shall systematically address 
the potential promise of such work. 
Immune checkpoint blockade and Gastric Cancer 
MDSC may well have a negative influence on the course of gastric cancer by 
impairing immune responses to the oncological process. But also aberrant activation 
of other immune controlling mechanisms may well have important negative 
contributions here. Such mechanisms are now often called “checkpoints” which 
refers to a broad spectrum of either co-receptors or ligands that are widely expressed 
by immune cells. Importantly, such checkpoints regulate immune cell activation. 
The “inhibitory checkpoints” represent those molecules that play an important role 
Chapter 1 
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in preventing over-activation of the immune system and are important to 
maintaining self-tolerance. In this way, potentially deleterious immune attack by the 
host immune system can be constrained, but it is clear that at least some cancers 
pervert this system to escape immunosurveillance. It is well possible that in the 
context of the gastric cancer cell immune microenvironment, co-inhibitory receptors 
may pose a threat to the host’s health by preventing an immune response against 
gastric cancer. Both co-inhibitory receptors and ligands are highly expressed in a 
large number of malignancies. This high expression allows for successful evasion of 
antitumor immune responses. One of the most promising tumor immunotherapy 
strategies is to interrupt these immune “brakes” by blocking antibodies that prevent 
interactions between receptors and their cognate ligands. As shown by recent 
clinical trials, targeting either the PD-1/PD-L1 or CTLA-4 pathways have yielded 
exciting results. However, there remains insufficient study and understanding of 
specifically gastric cancer in this respect, especially when compared to other 
malignancies such as melanoma or lung cancer. This consideration has prompted me 
to explore this aspect of the gastric cancer process as well. 
The scope of this thesis 
The pivotal role of H. pylori in progression to gastric cancer calls for better 
understanding of the relation between its genetic make-up and such progression but 
also a comparison of diagnostic strategies in countries with a relatively high and low 
incidence of infection with the bacterium. As stated above, the importance of 
Hedgehog signaling in many forms of cancer and especially in conjunction with its 
link to gastric cancer developmental processes, has prompted a substantial research 
effort investigating the potential usefulness of targeting Hedgehog signaling in 
gastric oncogenesis. As a result, in gastrin-mediated compartment expansion, viral 
and Helicobacter-dependent gastric carcinogenesis, the role of Hedgehog signaling 
is now relatively well understood. Furthermore, when the malignant disease is 
established, the evidence indicates that hedgehog signaling may provoke drug 
resistance. Now that the hedgehog inhibitor Vismodegib has come available, which 
has proved useful in other kinds of cancer (especially basal cell carcinoma), it is 
tempting to propose clinical trials using this compound for patients who have gastric 
cancer and accordingly various of such studies have now been initiated. As such, 
this thesis seeks to summarize clinical experiences and outcomes in the ongoing 
clinical trials of Hedgehog inhibitors, but I also try to obtain insight into the 
fundamental aspects of signaling by Hedgehog ligands. A similar situation holds 
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true concerning immune checkpoints inhibitors in Gastric cancer. Thus I study the 
use of anti-PD-1, anti-PD-L1, and anti-CTLA- 4 monoclonal antibodies in gastric 
cancer. In addition, I aim to link the genetic makeup of H. pylori infection to disease 
progression. Finally and speculatively I also aim to investigate the potential 
usefulness of unconventional model systems for a better understanding of the 
mechanisms potentially constraining immune activity, which may further boost 
effectivity of such immunocheckpoint-targeting drugs. The results of these efforts 
will be integrated into a final discussion as well. In conjunction I hope this thesis 
will foster new thinking on the management of gastric cancer. 
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Abstract 
Ever since its initial discovery in Drosophila, hedgehog signaling has been linked to 
foregut development, The mammalian genome expresses three Hedgehog 
paralogues, sonic hedgehog (Shh), Indian Hedgehog, and desert hedgehog. In the 
mucosa of the embryonic and adult foregut, Shh expression is the highest. It has now 
become clear that hedgehog signaling is of pivotal importance in gastric 
homeostasis. Aberrant activation of hedgehog signaling is associated with a range of 
pathological consequences including various cancers. Also in gastric cancer, clinical 
and preclinical data support a role of Hedgehog signaling in neoplastic 
transformation, and gastrointestinal cancer development, also through cancer stroma 
interaction. Technological advance are facilitating monitoring Hedgehog signaling 
broadening options for the more efficient screening of individuals predisposed to 
eventually developing gastric cancer and targeting Hedgehog signaling may provide 
opportunities for prophylactic therapy once atrophic gastritis develops. Nevertheless, 
convincing evidence that Hedgehog antagonists are of clinically useful in the 
context of gastric cancer is still conspicuously lacking. Here we analyze review the 
role of Hedgehog in gastric physiology and the potential usefulness of targeting 
Hedgehog signaling in gastric cancer. 
Mini-abstract 
Hedgehog signaling has a pivotal role in gastric development and homeostasis but 
also appears to associated with neoplastic transformation, and further development 
towards invasive carcinoma in the stomach. Thus monitoring Hedgehog signaling 
may provide an opportunity for more efficient screening of subjects predisposed to 
developing gastric cancer. Targeting Hedgehog signaling may be useful for 
prophylactic therapy once atrophic gastritis develops. Although Hedgehog 
antagonists have been used for other cancer types, data documenting its clinical 
usefulness in gastric are conspicuously lacking, and studies aimed at providing 
definitive answers here are called for.  
MeSH keywords 
Patched,  Receptors; Smoothened Receptor; Zinc Finger Protein GLI1, Precision 
Medicine 
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Introduction 
Hedgehog proteins are fundamental regulators of embryological development, and 
tissue homeostasis in adult organisms. Disturbed hedgehog signaling is associated, 
amongst others, with a range of congenital disabilities, oncological malignancies and 
immunological defects[1]. Hedgehog proteins intercellular signaling molecules of 
unusual and fundamental relevance as also illustrated by their substantial 
conservation across the animal kingdom[2-5]. Initially recognized as a segment 
polarity gene in Drosophila, now numerous vertebrate paralogues have been found, 
and in mammals, these include Sonic Hedgehog (Shh), Desert Hedgehog (Dhh), and 
Indian Hedgehog (Ihh), with Shh being the most comprehensively characterized[5]. 
Although mainly associated with organogenesis and general and embryological 
formation of the intestines, in particular, Hedgehog signaling remains active until 
death, and serves to maintain lifelong histostasis in the intestinal tract and also the 
immune system[6-8]. The pathophysiological importance of Hedgehog signalling is 
illustrated by the observation that continuous hedgehog signalling is an essential 
permissive factor in endodermal cancer development[9-11]. With regard to the 
above, especially the stomach is relevant, where the morphogen not only maintains 
pit-gland asymmetry, but also fosters the development of gastric cancer, 
homeostasis, and neoplastic transformation[12-14]. Part of this nefarious 
functionality is related in the initiation of gastric inflammation due to Helicobacter 
infection[12]. As stated, although classically associated with gestation, the role of 
Hedgehog pathway has also important functionality beyond embryogenesis and a 
potentially vicious one with respect to oncological disease. In cancer, both autocrine 
Hedgehog signalling and paracrine signalling (through the tumor stroma that would 
thus nurture the tumour cells) of Hedgehog ligands is well-established[15, 16]. Both 
autocrine and paracrine Hedgehog signalling should be sensitive to pharmacological 
inhibitors and are thus tested in clinical trials in addition to an intense preclinical 
research effort[15, 17]. The importance of Hedgehog signalling gastric 
pathophysiology has led to hopes that pharmacological inhibitors of this signalling 
may become useful for combating oncological disease in the stomach and this 
consideration prompted us to review here the detailed molecular mechanism by 
which Hedgehog influences gastric pathophysiology and to evaluate the evidence 
that anti-Hedgehog strategies will prove effective in this respect. 
The physiological importance of Hedgehog signaling in the physiology of the 
proximal tract is illustrated by the phenotypes observed in mice with genetic loss of 
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Hedgehog paralogues. Genetic knockout of both Shh and Dhh provoke by 
malrotation of the gastrointestinal tract, oesophageal atresia, gastric overgrowth and 
other gross abnormalities[18-20]. The specific importance of Hedgehog signalling 
for the stomach in this respect is illustrated by the observation in mice from 
embryonic day 16 onwards as dichotomy occurs in that the foregut and at the level 
of antrum and pyloric border region which becomes dramatically more active with 
respect to Hedgehog signalling as compared to the adjacent duodenal tissues[21], 
and also is proposed to maintain pit-gland asymmetry in the stomach[7, 22]. Thus 
the relevance of Hedgehog signaling for gastric physiology seems evident. With 
regard to pathophysiology, Hedgehog signaling is suggested to be pivotal for gastric 
cancer progression in both of humans and animals, but a definite etiological role has 
not yet been shown for this pathway in gastric cancer. To further analyze the precise 
evidence available in this respect it is essential first to review the molecular details 
of the molecular signaling involved[23].  
Hedgehog signaling: An overview  
Hedgehog signaling in general is unusual and complicated, and an immense 
scientific effort has been necessary to unravel its general principles[15, 24-26]. 
Signaling is initiated by the different Hedgehog ligands, in casu Shh, Ihh and Dhh. 
In the classical Hedgehog signal pathway activation, these different ligands bind a 
common cognate membrane-bound receptor called Patched that has approximately 
1,500 amino acids. The protein transverses the plasma membrane twelve times and 
thus strongly resembles abc transporter proteins. In accordance both the  The N-
terminal and C-terminal domains of the protein reside at cytoplasmic side of 
membrane, The tertiary conformational of Patched allows Hedgehog ligands to bind 
via the interaction with two extracellular loops[15, 27]. There are two genes 
encoding Patched receptors in humans;  which are dominated as PTCH1 and 
PTCH2, and differ slightly with respect to their amino acid configuration in the N-
terminal region[15, 27]. While both PTCH1 and PTCH2 receptors are associated 
with numerous human cancers, with respect to gastric cancer especially PTCH1 is 
the relevant gene product. The function of Patched is to exclude a second receptor, 
called Smoothed from the primary cilium and retain Smoothened in a vascular 
compartment/ Binding of Hedgehog to PTCH release this inhibition enabling further 
downstream signalling[15, 28]. Figure 1 provides a graphical representation.  
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Following binding of Hedgehog to Patched. Smo translocates to the the primary 
cilium in the cell membrane. The subsequent signalling culminates in altered 
transcription through Gli transcription factors. The molecular details of Smoothened 
signalling to Gli is still partly obscure but involves the microtubule transport 
proteins[15, 29]. The Gli family are members of the Kruppel family of zinc finger 
transcription factors and a role for three different Gli proteins in Hedgehog 
signalling has been identified, Gli1, Gli2, and Gli3, each with a distinctive role[15], 
In the absence of Smoothened activation, GLI1 and GLI2 are transcriptional 
repressors, but following activation of the pathway these proteins are converted to 
transcriptional activators[15, 30]. The role Gli3 appears to be mainly as a negative 
regulator of Hedgehog signalling. It is thus possible to interfere with Hedgehog 
signalling at different levels, although clinically the use of Smoothened inhibitors 
has gained most attention. 
Role of Hedgehog Signalling in Gastric Homeostasis 
Ever since its initial detection in Drosophila, Hedgehog has long been associated 
with foregut development. Of the three mammalian Hedgehogs (3) Shh levels are 
most highly expressed h, in the mucosa of the embryonic foregut[31]. Also in other 
foregut-derived organs such as the lung, Shh expression is prominent, reflecting the 
embryonal situation[32-35]. Table 1 lists expression patterns in physiology and 
pathology. Interestingly high Shh expression in the stomach is lost upon 
development of intestinal metaplasia (Table.1), suggesting that gastric epithelium-
specific effects of the morphogen[12, 36]. Indeed Shh controls gastric epithelial cell 
maturation and differentiation in the adult stomach[7, 36, 37].  
During progression from the inflamed stomach to gastric cancer the epithelium goed 
through defined series of morphological transitions. First, the acid-producing 
parietal cells are lost and are replaced by mucus-secreting cells that express 
spasmolytic polypeptide (SP) or trefoil factor 2.7 [38]. Mostly in mice, but also in 
human subjects, the presence of SP-expressing mucosa (SPEM) defines gland 
atrophy[39, 40]. Together with atrophy of the parietal cells[35] Shh expression 
diminishes[41, 42] Although Shh expression diminishes along with the loss of 
parietal cells [16] the expanding mucous cell compartment or SPEM continues to 
produce Shh in both human subjects [37, 41] and rodents[42, 43] but appears to 
remain as the unprocessed pre-morphogen. Thus functionally expression is lost.  
Studies suggest that aberrant Hh signaling in cancer functions mainly as either 
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autocrine or paracrine regulator. Especially in stem cell niche Processing of Shh to 
its active form (19 kilodaltons) in parietal cells becomes compromised in the 
absence of gastric acid [44, 45] Atrophy of parietal and zymogenic (chief cell) 
lineages result in hypochlorhydria and reduced serum pepsinogen I (A) levels 
compared to pepsinogen II (C)[46-52]. These zymogens are proteins encoded by 
different gene loci that are used clinically to identify pre-neoplastic changes in the 
stomach[52]. Pepsinogens A and C are converted to the enzymatically active 
aspartic proteinases, pepsin A and pepsin C, through intramolecular self-
cleavage[52, 53]. Pepsinogen A is produced primarily in the mouse corpus by 
parietal cells, whereas pepsinogen C is mainly produced by both mucous neck and 
chief cells throughout the stomach[44]. This result is consistent with the exclusive 
expression of pepsinogen A in the human corpus and not the antrum, whereas 
pepsinogen C marks mucous cells of both the antrum and corpus 
(www.proteinatlas.org). Pepsin A prefers to cleave proteins at hydrophobic and 
aromatic residues, particularly at phenylalanine (F) when the pH is less than 2. By 
contrast, pepsin C recognizes a broader consensus site and uses more comprehensive 
pH spectrum than pepsin A[53, 54]. Explicitly, it's shown using site-directed 
mutagenesis that pepsin A cleaves the nascent 45-kilodalton Shh polypeptide at 
residue 200 (SGGCF200|P) to generate the active 19-kilodalton form, whereas 
pepsin C does not cleave SHH peptide[44]. This may account for absence of Shh 
expression in atrohic gastritis. 
Regulation of Gastrin and Gastric Acidity by Shh 
Several studies have examined the impact of blocking Hedgehog signalling in vivo, 
for instance by employing a transgenic mouse that secretes a natural -inhibitor of 
Hedgehogs called HHIP employing the parietal cell-specific H+, K+-ATPase β 
subunit promotor[65]. This approach showed that loss of Hedgehog signalling in 
parietal cells reduces H+, K+-ATPase gene expression and gastric acid 
secretion[65]. Usually, hypochlorhydria stimulates gastrin gene expression through a 
decrease in Somatostatin levels[66] Accordingly, increased plasma gastrin occurred 
in the HHIP transgenic mice, concomitant with reduced somatostatin expression. 
Both antral G and D cells possess primary cilia, organelles protruding from the 
plasma membrane, essential for transducing Hedgehog signalling[67, 68]. Therefore, 
gastric endocrine cells may well be capable of responding directly to Shh. 
Functionally, this idea is supported by the observation that that transgenic 
overexpression of GLI2 suppresses gastrin gene expression[69]. Taken together, the 
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production of Shh by parietal cells and the ability of gastric endocrine cells to sense 
the ligand through primary cilia are consistent with a central role for Hedgehog 
signaling in the feedback regulation of gastric acidity 
Modes of hedgehog signaling in gastric cancer 
Upregulation of Hedgehog signaling pathway is involved in tumour 
development[36]. De Sauvage and Rubin postulated models for Hedgehog signalling 
in human cancer development[36]. The type I cancers  are ligand-independent and 
involve constitutive stimulation of downstream signalling molecules (e,g, loss of 
Patched) and an example is basal cell carcinoma. Type II are cancers ligand-
dependent were both the autocrine, or juxtacrine signaling mechanisms are involved 
as seen in pancreatic tumors. In type III cancers also ligand-dependency is observed  
but this type displays paracrine type signalling[36]. Table 1 provides information on 
these type of tumours in the context of stomach cancer. Remarkably, these models 
ignore the involvement of non-canonical signalling mechanisms. A number of 
studies have evaluated the role of cyclin B1 interaction with Patched, in which a 
Ptch1-cyclin B1 complex is formed at the plasma membrane in a cyclin kinase-1 
(Cdk1)-dependent fashion[56, 57]. This results in a reduction in the mitotic index by 
the separation of cyclin B1/Cdk1 complex from the nuclear machinery resulting in 
decreased proliferation. Shh binding to patched release the complex and thus fosters 
cell cycle progression through G2/M phase checkpoint. Obviously Smoothened 
inhibitors do not affect this process. Another study documents Hedgehog-
independent activation of Patched through the action of proteases and in particular 
Caspase 3, splitting the C-terminal from Patched[36, 58, 59]. It islikely that such 
non-canonical signalling  
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Table 1: Small molecules related Hedgehog expression in Gastric Cancer. 
 
NOTE: NA: not available; Hh: Hedgehog; Gli: glioma-associated oncogene; Pitch: Patched; Smo: 
Smoothened; Shh: Sonic Hh; IHC = immunohistochemistry, ISH= in situ hybridization, LacZ reporter. 
RT-PCR real-time PCR. 
  
S/N Homologs Normal stomach Stomach Metaplasia 
Tumour 
Intestinal        Diffuse Techniques Ref 
1 Shh Gland Epithelium Undetectable elevated Undetectable IHC,RT-PCR 
IHC, RT-PCR 
RT-PCR,IHC,IMF 
(65) 
(66) 
(67) 
(68) 
2 Ihh Pit Epithelium Undetectable elevated Undetectable IHC, RT-PCR 
PCR,IHC,IMF 
 
(65) 
(55) 
3 Dhh Gland Epithelium Undetectable elevated elevated IHC, RT-PCR 
PCR,IHC,IMF 
(65) 
(55) 
4 Ptch1 Pit Mesenchyme Detected elevated elevated IHC, RT-PCR 
RT-PCR, IMF 
RT-PCR, LacZR 
(65) 
(55) 
(8) 
5 SMO Pit / Gland 
Mesenchyme 
Detected elevated elevated IHC, RT-PCR 
PCR,IHC,IMF 
(65) 
(55) 
 
6 Gli 1 Pit / Gland 
Mesenchyme 
Undetectable elevated elevated IHC, RT-PCR 
PCR,IHC,IMF 
 
(65) 
(55) 
7 Gli 2 Pit Mesenchyme Undetectable elevated elevated IHC, RT-PCR 
PCR,IMF 
(65) 
(55) 
8 Hip Detected Not Reported Undetectable Not Reported RT-PCR, IMF (55, 
65) 
9 BOC Pit Undetectable elevated elevated IHC, RT-PCR (65) 
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Cross-Links between Hedgehog Signaling, Chronic Inflammation and Gastric 
Cancer 
As stated, Hedgehog signalling in the stomach plays a significant role in gastric 
development, homeostasis, and neoplastic transformation[70]. Initially Shh was 
somewhat ignored in the context of gastric cancer, despite the evidence that Shh is 
highly expressed in gastric cancer cell lines[64]. Although increased levels of Shh 
have been reported in gastric cancers, its specific role in gastric transformation 
remains elusive but carries significance because of the availability of Hh 
antagonists. A link exists through the immune system; several studies show that in 
gastritis the phenotype of infiltrating myeloid cells changes over time to become 
myeloid-derived suppressor cells (MDSCs) and that this phenotypic switch requires 
Hedgehog signaling. More specifically, expression of GLI1, which targets Slfn4 
(mice) and SLFN12L and SLFN5 (humans), is an early marker for chronic 
inflammation-associated myeloid cells in their transition towards the MDSC 
phenotype. As MDSCs are important for immune-evasion for transformed cells, 
Hedgehog signaling can thus favor neoplastic development.  
 
Figure 1. A simplified model of the mammalian Hh pathway. In the ‘OFF’ state, Patch inhibits the 
activity of Smo. Inactive Smo is unable to inhibit Sufu, which promotes processing of the Gli 
transcription factors in favor of shorter, transcriptional repressor forms (GliR). In the ‘ON’ state, Hh 
ligands bind to and inhibit Patch, thus releasing Smo activity and in turn blocking Sufu. Gli processing 
is then shut down, leading to the accumulation of transcriptional activator forms (GlIA). 
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Hedgehog Signaling pathway inhibitors  
The Hedgehog signaling pathway is a significant target in cancer therapy. Various 
molecules that may inhibit the pathway have been evaluated in both preclinical and 
clinical studies. These inhibitors include: SMO inhibitors, ligand-receptor inhibitors, 
Gli targeted inhibitors, and these classes of molecules are adstructed in figure 2. 
SMO Inhibitors 
Cyclopamine, originally isolated from the flower veratrum californicum that causes 
birth defects when eaten by pregnant cattle, was the first compound that was used as 
a Hedgehog inhibitor and it targets SMO. Consequently, GLIs activation is 
inhibited. In the clinic, it is side effect-prone and exhibits substantial toxicity[79]. 
Frustratingly, mice studies involving rhabdomyosarcoma and osteosarcoma models, 
reveal no significant impact on cancer cells metastasis or growth[80, 81]. From 
mouse model studies, skin ulcerations and scrubby coat were reported as particularly 
noticeable skin toxicity; halted even studies initiated to ascertain cyclopamine 
therapeutic dosing[81]. Adverse effects of cyclopamine in conjunction with other 
limitations such as acid sensitivity and poor solubility have now halted its clinical 
development as a potential compound for the treatment of cancer and prompted 
efforts aimed at. Identifying molecules potentially more suited. This led to the 
development of the acid stable and water-soluble compound vismodegib (GDC-
0449), which was eventually approved by the FDA for the treatment of advanced 
(Locally), recurrent and metastatic skin cancer. Another semisynthetic novel 
analogue of cyclopamine (Saridegib (IPI-926) was developed with enhanced 
potency and metabolically stable[82]. Other inhibitors that impede SMO include 
LEQ506, PF-0449913, LDE-225 (erismodegib), and BMS-833923. It is important to 
note that such compounds will not impair Patched-dependent Smoothened-
independent non-canonical signaling. 
GLI inhibitors 
Also in view of resistance development against vismodegib through SMO mutation 
efforts have been made to target Gli. Two inhibitory compounds (GANT 58.  And 
GANT 56) were identified through cellular screens aimed at identifying compounds 
50906 Adamu v2.indd   42 30-05-18   21:34
Gastric cancer and the Hedgehog Signalling
43
2
Gastric cancer and Hedgehog signalling 
 
39 
 
Hedgehog Signaling pathway inhibitors  
The Hedgehog signaling pathway is a significant target in cancer therapy. Various 
molecules that may inhibit the pathway have been evaluated in both preclinical and 
clinical studies. These inhibitors include: SMO inhibitors, ligand-receptor inhibitors, 
Gli targeted inhibitors, and these classes of molecules are adstructed in figure 2. 
SMO Inhibitors 
Cyclopamine, originally isolated from the flower veratrum californicum that causes 
birth defects when eaten by pregnant cattle, was the first compound that was used as 
a Hedgehog inhibitor and it targets SMO. Consequently, GLIs activation is 
inhibited. In the clinic, it is side effect-prone and exhibits substantial toxicity[79]. 
Frustratingly, mice studies involving rhabdomyosarcoma and osteosarcoma models, 
reveal no significant impact on cancer cells metastasis or growth[80, 81]. From 
mouse model studies, skin ulcerations and scrubby coat were reported as particularly 
noticeable skin toxicity; halted even studies initiated to ascertain cyclopamine 
therapeutic dosing[81]. Adverse effects of cyclopamine in conjunction with other 
limitations such as acid sensitivity and poor solubility have now halted its clinical 
development as a potential compound for the treatment of cancer and prompted 
efforts aimed at. Identifying molecules potentially more suited. This led to the 
development of the acid stable and water-soluble compound vismodegib (GDC-
0449), which was eventually approved by the FDA for the treatment of advanced 
(Locally), recurrent and metastatic skin cancer. Another semisynthetic novel 
analogue of cyclopamine (Saridegib (IPI-926) was developed with enhanced 
potency and metabolically stable[82]. Other inhibitors that impede SMO include 
LEQ506, PF-0449913, LDE-225 (erismodegib), and BMS-833923. It is important to 
note that such compounds will not impair Patched-dependent Smoothened-
independent non-canonical signaling. 
GLI inhibitors 
Also in view of resistance development against vismodegib through SMO mutation 
efforts have been made to target Gli. Two inhibitory compounds (GANT 58.  And 
GANT 56) were identified through cellular screens aimed at identifying compounds 
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able to inhibit transcription mediated by GLI. Both compounds at the cellular level 
have been revealed. Understanding the mechanism of action of these compounds at 
a molecular level is still incomplete. GLI1 posttranslational modification by GANT 
61 impedes binding to DNA or changes the conformational structure of the GLI1-
DNA complex. In xenograft mice model of human prostate cancer cells inhibition of 
cancer cell growth is observed[83]. A study by Hyman et al. also succeeded in 
identifying four further Hedgehog inhibitors apparently acting downstream of 
Smoothened: HPI-1, HP-2, and HP-3 are thought to inhibit signaling by targeting a 
posttranslational modification of GLI or interaction between GLI and a co-factor. 
HPI-4 was thought to be the only agent that acts by perturbing ciliogenesis, although 
the mechanism by which HPI-4 disrupts ciliogenesis was not clarified[84]. Again, it 
is important to note that such compounds will not impair Patched-dependent 
Smoothened-independent non-canonical signaling. 
 
 
Figure 2. Molecular sites targeted by Hh signaling pathway inhibitors. These inhibitors target 
different components of Hh signaling, including Shh, Smo, and GLI1. These encompass natural 
compounds, their chemical derivatives, a monoclonal antibody, and chemicals identified from 
screening libraries. (Adapted from reference)(82) 
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A monoclonal antibody 5E1 (ch5E1) from murine-human chimeric has been proven 
to bind Shh and thereby to inhibit Hedgehog signaling[85]. A small molecule 
(Robotnikinin) was also identified as a Hedgehog signaling inhibitor in a 
microarray-based screening effort. Robotnikinin binds to Shh thereby inhibiting the 
activation of Hedgehog signaling [86]. Other new ligand processing blocking agents 
have been identified in high-throughput screens and appear to have different 
mechanisms of actions, including interfering with Shh palmitoylation by targeting 
Hh acyltransferase[87, 88]. These molecules have obvious potential as they also 
target non-canonical Hedgehog signaling. 
Gastric cancer Treatment using Hh pathway targeted agents. 
For gastric cancer treatment using Hh signaling targeted agents, only two clinical 
trials have been performed. A phase II multi-centered, randomized, a prospective 
clinical trial involving 124 participants was performed to determine the vismodegib 
efficacy, potency, and safety. For adenocarcinoma patients under FOLFOX 
chemotherapy, vismodegib an SMO inhibitor was administered in conjunction with 
this regimen. The study did not meet the primary endpoint with a no significantly-
improved progression-free survival between the placebo group and vismodegib 
group (9.3 months vs. 11.5; p = 0.34), although with a noticeable tendency for 
prolonged progression-free survival[89]. The lack of a statistically significant result 
may well stem from this study being underpowered. Lack of good biomarkers that 
can act as surrogates for progression-free survival can also be considered a 
confounding factor. CD44 immunopositivity has been established as a biomarker of 
gastric cancer stem cells. CD44 expression was analyzed in phase II clinical trial 
samples of gastric tumors and were associated with improved survival. Patients who 
received chemotherapy alone had poor survival together with high CD44 suggesting 
a potential role for CD44 as a biomarker in the treatment of patients with Hedgehog 
signaling targeting agents[78]. In addition a BMS-833923 maximum tolerable dose 
phase 1 clinical trial has been performed. Capecitabine and cisplatin were used in 
combination with BMS-833923 in drug naïve adenocarcinoma patients. The study 
was completed in 2013, but the findings have not yet been reported 
(NCT00909402). Thus a potential role for Hedgehog inhibition in gastric is far from 
evident and requires more clinical testing. 
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Clinical Applications 
Gastric cancer has long been seen as one of the most difficult gastrointestinal 
malignancies to treat. Encouragingly, recent progress with targeted therapies offers 
hope for patients with advanced gastric cancer and is substantially expanding the 
therapeutic armamentarium with regard to this infaust disease. As these treatments 
continue to be developed, we must focus on determination of predictive markers, 
and preferably co-develop drugs with these markers. The mechanisms underlying 
primary or acquired resistance to targeted agents also should be clarified to help 
further drug development[12]. Developing anti-Shh monoclonal antibodies as Shh 
antagonists is an area to explore where Hedgehog signaling pathway can be blocked 
at different levels[90]. Gastric cancer is a multigenic disorder influenced by 
Helicobacter pylori infection and salt intaker. Single nucleotide polymorphism 
(SNP) and copy number polymorphism (CNP) of genes encoding Hedgehog 
signaling molecules would be utilized for genetic screening of gastric cancer. Also, 
cDNA-PCR, microarray, and ELISA detecting aberrant Hedgehog signaling 
activation would be used for optional therapeutic choice. Genetic testing and precise 
selection of therapeutic options would contribute to the realization of personalized 
medicine. Several limitations account for poor treatment outcomes in gastric cancer 
patients amongst which include tumor heterogeneity. Due to traditional 
classification of gastric cancer into two categories in casu undifferentiated and 
differentiated types, obvious biological differences must exist. Additionally, 
molecular subgroups exist gastric cancer category; these include chromosomal 
instability tumors, stable genomically tumors, unstable microsatellite tumor and 
Epstein–Barr virus tumor-positive[91]. It is well possible that stratification for 
subtype is way forward with regard to Hedgehog inhibition for the treatment of 
gastric cancer. 
Conclusion and future directions. 
While there is good evidence that Smoothened inhibition may be useful for a 
selection of gastric cancers, we feel that its untargeted application on gastric cancer 
patients, in general, is likely to prove disappointing. In this sense efforts to select 
patients characterized by unusually high SMO expression in gastric tumor material 
with high probability to have cancers that are truly dependent on a functional 
Hedgehog pathway may likely yield positive results. As both approaches are 
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currently being attempted in clinical trials, it should prove interesting to see whether 
this notion holds true. 
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Abstract. 
Objectives: Checkpoint inhibitor therapy is revolutionizing the management of the 
oncological disease. Despite gastric cancer being a common malignancy with a 
relatively poor prognosis, checkpoint inhibitor therapy has attracted relatively little 
attention for the treatment of this disease. We decided to perform a systematic 
review focusing on the potential usefulness of checkpoint inhibitors in patients with 
gastric cancer by reviewing all clinical trials involving checkpoint inhibitors in 
gastric cancer up to the 9th of September 2017.  
Methods: We systematically review all randomized controlled trials on the 9th 
September 2017. We searched the. embase.com, Medline Ovid, Cochrane 
CENTRAL, Web of Science, Google Scholar, and databases of current ongoing 
randomized trials. A description assessment of randomized clinical trials (RCTs) 
was performed on Immune checkpoint inhibitors for PD1, CTLA-4 and PD-L1 
(Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Nivolumab, Pembrolizumab, 
and Tremelimumab) in gastric cancer patients. 
Results: The current body of biomedical literature describes 3621 gastric cancer 
patients being treated with checkpoint inhibitors and compared to patients receiving 
chemotherapy. The PD-1 inhibitors pembrolizumab and nivolumab in conjunction 
appear to substantially outperform conventional chemotherapy, with more extended 
overall survival median (OS; 10.0 vs. 6.0 mo), a more significant objective response 
rate of  36% versus. 13%, p=0.10, with a reduced adverse event rate (33 % vs. 22%), 
although other checkpoint inhibitors appear somewhat less effective.  
Translational impact: It seems that checkpoint inhibitor therapy in general, and 
PD-1-directed therapy, in particular, constitutes a rational therapeutic avenue for 
advanced gastric cancer. 
MeSH keywords: Immunomodulator therapy; Gastric cancer; Biologic therapy; 
Biomarker 
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Key Points 
Gastric adenocarcinoma is a very aggressive cancer with a variable response to 
neoadjuvant therapy and poor overall prognosis. Although neo-adjuvant 
chemotherapy or chemoradiation (nCRT),  combined with surgery significantly 
improves survival of patients, novel therapeutic options against these malignancies, 
especially for patients refractory to standard therapies, are urgently needed. 
Immune checkpoint-directed therapy is revolutionizing is oncological medicine, but 
its potential in gastric cancer is unclear. 
PD-1-directed therapy (e.g. Nivolumab or Pembrolizumab) is associated with 
increased survival in gastric cancer patients refractory to other treatments and thus a 
therapeutic option for this group of patients. Targeting PD-L1 or CTLA4 in gastric 
cancer remains an unproven strategy. 
In lung cancer patients likely to benefit from targeting PD-1 can be selected by 
staining cancer material for PD-L1. In gastric cancer, however, PD-L1 staining is 
not useful for selecting patients and should thus not be used for clinical decision 
making with respect to PD-1 inhibitors 
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Introduction: 
Gastric cancer(GC)  is a major public health problem and is the second most 
prominent cause of cancer-related death globally[1]. The incidence of GC, however, 
dramatically varies across different geographical areas, it being the highest in Japan, 
China, other Far Eastern countries, Russia, Middle Eastern area, and in the Pacific 
coast of the South American continent, whereas it is the lowest in Central Africa. 
Europe and North American regions share an intermediate-to-high incidence. 
Although only 25–30% of GC patients survive five years from the initial diagnosis, 
heterogeneity in survival rates is substantially and may relate to biological and 
genomic differences between Asian and Western populations[2]. The depressingly 
high mortality calls for better clinical management. 
Currently, chemotherapy remains the mainstay in the treatment of advanced disease 
and involves a plethora of cytotoxic agents comprising platinum agents, 
fluoropyrimidines,  anthracyclines, irinotecan and taxanes. At present combinatory 
chemotherapy regimens is the preferred first-line option as they result in better 
survival and response rates when matched to therapy involving single agents[3]. 
Nevertheless, it is fair to say outcomes are disappointing and alternatives are 
vigorously pursued. Strikingly, however, immunotherapy has been getting relatively 
little exposure in this respect. 
Generally speaking, immunotherapy and especially immune checkpoint-directed 
therapy are now revolutionizing the management of oncological disease (indeed in 
2013 the American Academy of science announced immunotherapy as the 
breakthrough of the year[4-6]). Cancers are antigenic and provoke immunity, but 
manage to escape their resulting destruction via a variety of mechanisms but also 
through activation of so-called checkpoints: inhibitory elements to limit self-
damaging autoimmunity. The most prominent of this immune checkpoint inhibitory 
antibodies are those against cytotoxic T-lymphocyte antigen 4 (CTLA-4), receptor 
of programmed cell death 1 (PD-1) and its cognate ligand programmed death-ligand 
1 (PD-L1). Figure 1 illustrates their mode of action and their efficacy includes a 
wide range of solid cancers in particular melanoma[7-9], cancer of the lung[10-12] 
and basal cell carcinoma[13]. Thus it is tempting to assume a possible efficacy for 
such checkpoint inhibitors for gastric cancer as well. Here we review the available 
public data and conclude that especially PD-1-directed therapy (Pembrolizumab, 
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Nivolumab) and PD-L1-directed cancer constitutes a novel avenue for the treatment 
of advanced gastric cancer. 
 
 
 
 
 
 
 
 
Figure 1 – Schematic depiction of T-cell co-inhibitory receptor expression and checkpoint 
inhibition.  Antigen presenting cells (APCs) express a specific antigen that is presented to cytotoxic T 
cells in a major histocompatibility complex peptide and Tumor cells. The immune cell receptor 
recognizes presented antigens and, together with binding of costimulatory receptors (eg, CD28); this 
primes to lymphocytes activation and subsequently elimination of tumor cell. Interaction of co-
inhibitory receptors of  T cells with their  corresponding ligands on APCs or tumor cells inhibits T-cell 
activation. Known co-inhibitory receptors are PD-1 (that act together with its ligand PD-L1) and 
CTLA-4. Inhibiting antibodies against these co-inhibitory receptors or their respective ligands can 
prevent their interaction and the subsequent inhibition of T-cell action.  
Methods  
Search strategy and data source 
A systematic search of available articles was conducted on the 9th September 2017, 
using an electronic database of embase.com, Medline Ovid, Cochrane CENTRAL, 
Web of science, Google scholar. We looked for Extra references by exploring the 
reference list of carefully chosen studies was performed by a skillful librarian 
[W.B]. The search was done by the guiding principle of Preferred Reporting Items 
Immuno checkpoint inhibition 
 
57 
for Systematic Reviews and Meta-Analyses (PRISMA) guiding principle (Fig. 
2)[14]. To evaluate primary research literature on the immune therapy checkpoint in 
the ongoing clinical trial, we used the following search terms ("('immune checkpoint 
inhibitor'/de OR 'checkpoint inhibitor'/de OR 'immune checkpoint modulator'/de OR 
'immune checkpoint'/de))).Immune checkpoint inhibitors for PD1, PD-L1, and 
CTLA-4, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, 
pembrolizumab and tremelimumab’’. The search was finalized by a manual 
screening of articles to be included in the study. Because of its unusual relevance to 
the subject, one single study appearing after the 9th September 2017 was included as 
well.   
Study selection,  
The population enrolled in clinical trials consisted of patients older than 18 yr who 
was diagnosed with the progressive phase of metastatic GC and were treated with 
either a mono or combined therapy of immune checkpoints inhibitors targeting 
either CTLA-4, PD-1, and  PD-L1. Only potential prospective randomized clinical 
trials, phase one, two and three clinical trials were included in the review analysis. 
Correspondence, letters to editor, systematic and meta-analysis review, 
nonrandomized clinical trial, case reports, editorials and conference abstracts were 
excluded. If various analyses of the same clinical trial were performed, the most 
current or most germane article was included. Primary outcome measures included 
Overall survival (OS), Objective response rate (ORR) and progression-free survival 
(PFS), conferring to the guideline of Evaluation Criteria in Solid Tumors 
Response[15]. Secondary outcomes included adverse events (AEs) and efficacy of 
PD-L1 expression status in tissues of gastric cancer origin. Restricted searched 
articles which have randomized trials done in humans. 
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Figure 2: Schematic flowchart of selection and search strategy Flow diagram 
showing literature search and result selection. 
705  RECORDS IDENTIFIED 
515 via Embase.com 
49   via Medline Ovid 
18   via Web of science 
55   via Cochrane 
68    via Google scholar 
Additional records identified through 
other sources 
(n = 0  ) 
Records after duplicates removed 
(n =2   ) 
Records screened 
(n =703   ) 
546 Excluded 
117  Other molecules 
expression 
 3       Helicobacter studies 
 6       Hepatocellular 
Cancer. 
11      Immunity report  
 4       Meetings and 
updates 
75     None-relevant 
articles 
 244   Other cancers 
 40     Other immune 
check points 
  6      Adverse effect of 
molecules 
  40    Review 
 
Full-text articles assessed 
for eligibility 
(n =157   ) 
Full-text articles 
excluded, with reasons 
 
67 Chemotherapy 
Treatment. 
 21 Prognostics and 
Biomarkers. 
 52 Other tumor. 
Studies included in 
qualitative synthesis 
(n = 17  ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =17   ) 
Chapter 3 
58 
 
 
 
 
Figure 2: Schematic flowchart of selection and s arch strategy Flow diagram 
showing literature s arch and result selection. 
705  RECOR S IDENTIFIED 
515 via Embase.com 
49   via Medline Ovid 
18   via Web of science 
55   via Cochrane 
68    via Google scholar 
Ad itional records identified through 
other sources 
(n = 0  ) 
Records af r duplicates removed 
(n =2   ) 
R cor s screened 
(n =703   ) 
546 Excluded 
117  Other molecules 
expression 
 3       Helicobacter studies 
 6       Hepatocellular 
Cancer. 
11      Immunity report  
 4       Meetings and 
updates 
75     None-relevant 
articles 
 244   Other cancers 
 40     Other immune 
check points 
  6      Adverse effect of 
molecules 
  40    Review 
 
Full-text articles assessed 
for eligibility 
(n =157   ) 
Full-text articles 
excluded, with reasons 
 
67 Chemotherapy 
Treatment. 
 21 Prognostics and 
Biomarkers. 
 52 Other tumor. 
Studies included in 
qualitative synthesis 
(n = 17  ) 
Studies included in 
qua itative synthesis 
(meta-analysis) 
(n =17   ) 
Immuno checkpoint inhibition 
 
59 
Data extraction  
Independent reviewers (I.A. and A.J.) evaluated relevant articles for eligibility. 
Moreover, discussion resolved any disagreement on included studies. The 
Randomized clinical trial study design, number of patients enrolled in the study, 
treatment regimen options, overall survival(OS), PDL-1 expression status, the 
follow up (media) and the OOR.  Included studies by one reviewer (I.A.) and later 
verified by a second reviewer (A.J.) to confirm their precision and accuracy. 
Data analysis. 
Data were presented using descriptive analysis. Means and standard deviation were 
used to described continuous outcomes, interquartile range and median were used. 
Proportions and frequencies were also used to present specific findings. Odds ratios 
for response rate, HR for OSS, and PFS was stated and if they report with 
confidence intervals (CIs). We could not perform quantitative analysis (Meta-
analysis) because of a limited number of studies. 
Results. 
Qualitative and systematic review analysis  
The search texts identified 705 articles and an additional study published after the 
end date for inclusion but being of particular relevance. After removing duplicate 
studies, we assessed all titles and abstracts. Finally, 17publications were identified 
as potentially germane and were retrieved for full-text appraisal. An additional 
study, outside the predetermined time-interval but of general relevance was included 
as well. Agreeing to these inclusion benchmarks, seven randomized phase 1–3 
clinical trials were carefully chosen for evidence analysis.  Randomised clinical 
trials (5) on ten sorts of treatment, including 979 patients, all the clinical trial are 
multicentric and announced in English. Trials using immune checkpoints (PDL-1, 
CTLA-4, and  PD-1). Drugs used in the clinical trial include Tremelimumab, 
Pembrolizumab (MK-3475), Nivolumab (MSB0010718C, Durvalumab 
(MEDI4736) and Atezolizumab (MPDL3280A)  as seen in Table. 1. The first 
screening of this literature suggested that these immuno-checkpoint-targeting agents 
were associated with manageable levels of toxicity and potential clinical benefit in 
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Figure 2: Schematic flowchart of selection and search strategy Flow diagram 
showing literature search and result selection. 
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Data extraction  
Independent reviewers (I.A. and A.J.) evaluated relevant articles for eligibility. 
Moreover, discussion resolved any disagreement on included studies. The 
Randomized clinical trial study design, number of patients enrolled in the study, 
treatment regimen options, overall survival(OS), PDL-1 expression status, the 
follow up (media) and the OOR.  Included studies by one reviewer (I.A.) and later 
verified by a second reviewer (A.J.) to confirm their precision and accuracy. 
Data analysis. 
Data were presented using descriptive analysis. Means and standard deviation were 
used to described continuous outcomes, interquartile range and median were used. 
Proportions and frequencies were also used to present specific findings. Odds ratios 
for response rate, HR for OSS, and PFS was stated and if they report with 
confidence intervals (CIs). We could not perform quantitative analysis (Meta-
analysis) because of a limited number of studies. 
Results. 
Qualitative and systematic review analysis  
The search texts identified 705 articles and an additional study published after the 
end date for inclusion but being of particular relevance. After removing duplicate 
studies, we assessed all titles and abstracts. Finally, 17publications were identified 
as potentially germane and were retrieved for full-text appraisal. An additional 
study, outside the predetermined time-interval but of general relevance was included 
as well. Agreeing to these inclusion benchmarks, seven randomized phase 1–3 
clinical trials were carefully chosen for evidence analysis.  Randomised clinical 
trials (5) on ten sorts of treatment, including 979 patients, all the clinical trial are 
multicentric and announced in English. Trials using immune checkpoints (PDL-1, 
CTLA-4, and  PD-1). Drugs used in the clinical trial include Tremelimumab, 
Pembrolizumab (MK-3475), Nivolumab (MSB0010718C, Durvalumab 
(MEDI4736) and Atezolizumab (MPDL3280A)  as seen in Table. 1. The first 
screening of this literature suggested that these immuno-checkpoint-targeting agents 
were associated with manageable levels of toxicity and potential clinical benefit in 
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advance gastric cancer. Hence we decided to continue with the further analysis of 
the available public data. 
Study characteristics; Expression, Clinical Associations, and Prognosis.  
Published articles including six studies on clinical trials including and 18 ongoing 
clinical trials with 3291 patients at the point of reference, with a most extreme 
example size of 451 and a base specimen size of 96 members. Most of the 
investigations accounted for are in Asia (Japan) and the United States, by the 
geographical variations in gastric cancer incidence. The first clinically tested 
immune checkpoint is CTLA-4, and two monoclonal antibodies (ipilimumab and 
tremelimumab) targeting this checkpoint have been developed for clinical use. 
Based on the experience in other cancers, relatively more attention is now given to 
the PD-1/PD-L1 checkpoint system that can be targeted by various biologicals 
including nivolumab, pembrolizumab for PD-1 and atezolizumab, avelumab, 
durvalumab for PD-L1 respectively. Although not supported by published evidence, 
it has already been tried to employ such medication for precision medicine, patient 
selected for experimental immuno-checkpoint inhibition based on high PD-L1 
expression (immunohistochemistry for PD-L1 behaves relatively well, hence the 
choice this marker appears mainly pragmatical). For instance, a phase I trial was 
conducted involving a cohort of 39 patients selected for PD-L1 immunochemical 
positivity as assayed employing the 22C3 antibody. Patients were treated after every 
two weeks with 10 mg/kg of pembrolizumab. There was a 22% overall response 
rate, but 53.1 % experienced some decrease in tumor size, which is a good result for 
advanced gastric cancer. Remarkably, an impressively long median response of 40 
weeks (range 20–48+) was observed resulting in 11.4 months of the overall survival 
rate[4]. As stated, these results are remarkable as the patient group involved is 
refractory to other treatments. A question that needs to be urgently addressed in this 
respect is the usefulness of triaging patients for PD-L1 expression[5]. The potential 
of targeting PD-1 in gastric cancer has recently been substantially bolstered by a 
phase III trial using nivolumab. This trial, which involved heavily pre-treated 
patients showed 26 percent twelve months survival in the Nivolumab group versus 
only eleven percent in the placebo group. The results of all published trails involving 
immune-checkpoint inhibition are provided in Table 1.These antibodies include: 
BMS-936559, atezolizumab (MPDL3280A),durvalumab (MEDI4736),and 
avelumab (MSB0010718C, which has proven efficacy in gastrointestinal 
malignancies[16-18]). Concerning the latter out of 346 eligible patients enrolled, 
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only 16 patients had gastric cancer with overall response rate outcome of 25%[21] 
(Table 1). Other studies are ongoing (table 2). Thus confidence in results will be 
boosted. Intriguingly, anti-CTLA4 strategies appear much less effective as 
compared to anti-PD1/PD-L1 strategies and it would be interesting to explore 
whether is a reflection of the fundamental biological immunology of advanced 
gastric cancer. Despite a lack of fundamental understanding as to the specific 
sensitivity of the gastric cancer to PD1-PD-L1 checkpoint inhibition, it is fair to say 
that It molecules targeting the latter system appear a promising novel avenue for the 
treatment of advanced gastric cancer. We shall discuss the various trials below. 
50906 Adamu v2.indd   65 30-05-18   21:34
Chapter 3
66
Chapter 3 
62 
Ta
bl
e 
1:
 M
ai
n 
fe
at
ur
es
 o
f i
nc
lu
de
d 
cl
in
ic
al
 tr
ia
ls
 w
ith
 im
m
un
e 
ch
ec
kp
oi
nt
 th
er
ap
ie
s i
n 
ga
st
ri
c 
ca
nc
er
 
C
lin
ic
al
 E
nd
 P
oi
nt
 
A
 p
ar
tia
l r
es
po
ns
e 
w
as
 o
bs
er
ve
d 
in
 o
ne
 p
at
ie
nt
 w
hi
le
 st
ea
dy
 p
ro
gr
es
sio
n 
w
as
 
ob
se
rv
ed
 in
 fo
ur
 p
at
ie
nt
s. 
Th
e 
ad
ve
rs
e 
ef
fe
ct
 su
ch
 a
s C
EA
.T
R
-T
E
A
E
s:
 ≥
 3
 T
R
-
TE
A
E,
 F
at
ig
ue
, t
hr
om
bo
cy
to
pe
ni
a,
 a
nd
 a
ne
m
ia
 w
er
e 
al
so
 o
bs
er
ve
d.
 A
ut
oi
m
m
un
e 
he
pa
tit
is
 a
nd
 h
ep
at
ic
 fa
ilu
re
 w
er
e 
ob
se
rv
ed
 in
 o
ne
 tr
ea
tm
en
t-r
el
at
ed
 d
ea
th
 p
at
ie
nt
. 
8.
87
 m
on
th
s (
IQ
R
 6
.5
7-
12
.3
7)
  w
as
 th
e 
fo
llo
w
-u
p 
m
ed
ia
n 
fo
r s
ur
vi
vi
ng
 p
at
ie
nt
s i
n 
th
e 
ni
vo
lu
m
ab
 g
ro
up
,  
5.
26
 m
on
th
s w
ith
 (9
5%
 C
I 4
.6
0-
6.
37
) i
s t
he
 o
ve
ra
ll 
su
rv
iv
al
 
m
ed
ia
n 
in
 th
e 
ni
vo
lu
m
ab
 g
ro
up
. T
he
 o
ve
ra
ll 
su
rv
iv
al
 ra
te
 o
f 2
6.
2%
 w
as
 o
bs
er
ve
d 
w
ith
in
 th
e 
ni
vo
lu
m
ab
 g
ro
up
 c
om
pa
re
 to
 1
0.
9%
 w
ith
in
 th
e 
pl
ac
eb
o 
gr
ou
p.
 T
he
re
 a
re
 
gr
ad
e 
4 
tre
at
m
en
t-r
el
at
ed
 a
dv
er
se
 e
ffe
ct
 in
 1
0%
 o
f t
he
 3
30
 p
at
ie
nt
s f
ro
m
 th
e 
ni
vo
lu
m
ab
 
C
en
tra
l r
ev
ie
w
: O
R
R 
22
%
 m
ed
ia
n 
re
sp
on
se
 p
er
io
d 
of
 4
0-
w
ee
ks
. O
ve
ra
ll 
re
sp
on
se
 
ra
te
: 1
1.
4 
m
on
th
s. 
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
: 1
.9
 m
on
th
s.P
D
-L
1 
as
so
ci
at
io
n 
an
d 
ov
er
al
l r
es
po
ns
e 
ra
te
 b
y 
ce
nt
ra
l a
nd
 in
ve
sti
ga
to
r r
ev
ie
w
 w
as
 2
2%
 (9
5%
 C
I 1
0-
39
) a
nd
 
33
%
 (9
5%
 C
I 1
9-
50
) r
es
pe
ct
iv
el
y.
 E
ig
ht
 w
ee
ks
 (r
an
ge
 7
-1
6)
 w
as
 re
co
rd
ed
 a
s t
he
 
m
ed
ia
n 
pe
rio
d 
of
 re
sp
on
se
. A
n 
ov
er
al
l s
ur
vi
va
l o
f 6
9%
 o
ve
r t
he
 p
er
io
d 
of
 6
-m
on
th
 
w
as
 re
co
rd
ed
 w
ith
 a
 P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l p
ro
gr
es
siv
e 
su
rv
iv
al
 ra
te
 (P
FS
) o
f 2
4%
 
ov
er
 a
 p
er
io
d 
of
 6
-m
on
th
 w
as
 a
ss
oc
ia
te
d 
w
ith
 O
R
R
 (1
-s
id
ed
 P
 =
 0
.1
0)
. 
C
en
tra
l r
ev
ie
w
: O
R
R.
 1
5 
%
 a
nd
 7
.3
 %
 p
ro
gr
es
sio
n-
fre
e 
su
rv
iv
al
 o
ve
r t
he
 p
er
io
d 
of
 
11
.6
 w
ee
ks
 a
nd
 1
4.
1 
w
ee
ks
 re
sp
ec
tiv
el
y.
 P
ro
gr
es
sio
n-
fre
e 
su
rv
iv
al
 w
as
 o
bs
er
ve
d 
in
 7
 
pa
tie
nt
s o
ut
 o
f t
he
 2
0-
se
co
nd
 li
ne
 p
at
ie
nt
s, 
an
d 
43
 o
ut
 o
f t
he
 5
5 
m
ai
nt
en
an
ce
 p
at
ie
nt
s 
w
ith
 e
va
lu
at
io
n 
of
 P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l. 
In
 th
e 
se
co
nd
 li
ne
 g
ro
up
 o
f 2
0 
pa
tie
nt
s, 
a 
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
 m
ed
ia
n 
of
 3
6.
0 
w
ks
 (9
5%
 C
I: 
6.
0,
 3
6.
0)
 w
as
 o
bs
er
ve
d 
fo
r 
PD
-L
1+
  e
xp
re
ss
io
n 
le
ve
l a
nd
 1
1.
6 
w
ks
 (2
.1
, 2
1.
9)
 fo
r P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l. 
Fu
rth
er
m
or
e,
 in
 th
e 
m
ai
nt
en
an
ce
 g
ro
up
 o
f 5
5 
pa
tie
nt
s, 
a 
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
 
m
ed
ia
n 
of
 1
7.
6 
w
ks
 (5
.9
, 1
8.
0)
  w
as
 o
bs
er
ve
d 
fo
r P
D
-L
1+
  e
xp
re
ss
io
n 
le
ve
l a
nd
 1
1.
6 
w
ks
 (5
.7
, 1
7.
7)
, f
or
 P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l. 
C
en
tra
l r
ev
ie
w
: O
R
R 
of
 2
5 
%
 P
D
-L
1 
as
so
ci
at
io
n 
an
d 
re
sp
on
se
. 
Pa
rti
al
 re
sp
on
se
 in
 o
ne
 p
at
ie
nt
 w
as
 o
bs
er
ve
d 
w
ith
 a
 P
D
-L
1 
as
so
ci
at
io
n 
an
d 
PF
S 
of
 
42
%
 w
ith
in
 2
4 
w
ee
ks
. P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l s
ta
tu
s w
as
 e
va
lu
at
ed
 in
 9
4 
pa
tie
nt
s 
w
ho
 h
ad
 a
 tu
m
or
. T
he
 P
D
-L
2 
EX
PR
ES
SI
O
N
 L
EV
EL
 e
va
lu
at
io
n 
w
as
 d
on
e 
in
 8
1 
pa
tie
nt
s w
ith
 a
n 
ex
pr
es
sio
n 
tw
ic
e 
hi
gh
er
 th
an
 P
D
-L
1 
ex
pr
es
sio
n 
fro
m
 p
os
iti
ve
 tu
m
or
 
pa
tie
nt
s c
om
pa
re
d 
to
 th
e 
ne
ga
tiv
e 
PD
-L
1 
tu
m
or
 p
at
ie
nt
s. 
Th
irt
ee
n 
ou
t o
f t
he
 3
3 
pa
tie
nt
s h
ad
 a
n 
O
R
R 
of
 3
9%
 w
ith
 p
os
iti
ve
 P
D
-L
1 
ex
pr
es
sio
n 
le
ve
l c
om
pa
re
 to
 th
e 
13
%
 (8
/6
1)
 o
f p
at
ie
nt
s w
ho
 e
xp
re
ss
ed
 n
eg
at
iv
e 
PD
-L
1 
in
 n
eg
 tu
m
or
s. 
O
R
R
; o
ve
ra
ll 
re
sp
on
se
 ra
te
, M
O
S;
 m
ed
ia
n 
ov
er
al
l s
ur
vi
va
l, 
PF
S;
 m
ed
ia
n 
pr
og
re
ss
io
n-
fr
ee
 s
ur
vi
va
l, 
w
; w
ee
k,
 m
; m
on
th
  
N
um
be
r o
f 
en
ro
lle
d 
pa
tie
nt
s 
18
 
33
0 
39
 
75
 
( 2
0-
se
co
nd
 
lin
e 
 
an
d 
55
- 
m
ai
nt
en
an
ce
) 
16
 o
f 3
46
 
1 
of
 1
71
 
Tu
m
or
 T
yp
e 
G
C
 
 
2n
d 
lin
e 
 
A
dv
an
ce
d 
G
as
tri
c 
or
 
G
as
tro
es
op
ha
ge
al
 Ju
nc
tio
n 
C
an
ce
r c
oh
or
t 
PD
L1
+ 
G
C
 C
oh
or
t 
Ja
pa
ne
se
 G
C 
A
ll 
co
m
er
s 
2 
co
ho
rts
 
G
as
tri
c 
Ca
nc
er
  
co
ho
rt 
w
ith
 
no
ne
 sp
ec
ifi
ed
 
PD
-L
1 
po
sit
iv
e 
st
at
us
 
G
C
 c
oh
or
t 
A
ll 
co
m
er
s 
Ph
as
e 
2 3 1b
 
1b
 
1 1 
D
ru
g 
Tr
em
el
im
um
ab
 
Ip
ili
m
um
ab
 
Pe
m
br
ol
iz
um
ab
 
A
ve
lu
m
ab
 
D
ur
va
lu
m
ab
 
A
te
zo
liz
um
ab
 
Ta
rg
et
 
C
TL
A
-4
 
C
TL
A
-4
 
PD
-1
 
PD
L-
1 
PD
L-
1 
PD
L-
1 
St
ud
y 
/R
ef
er
en
ce
s 
(N
C
T0
23
40
97
5)
 
(M
ED
I4
73
6)
 [1
, 2
] 
N
C
T0
22
67
34
3[
3]
 
(N
C
T0
18
48
83
4)
 
(N
C
T0
23
70
49
8)
 
(N
C
T0
18
48
83
4)
 
(N
C
T0
23
35
41
1)
 
[4
-1
1]
 
(N
C
T0
17
72
00
4 
) 
(M
SB
00
10
71
8C
) 
[2
,1
2]
 
(N
C
T0
16
93
56
2 
) 
(M
ED
I4
73
6)
 
[1
3,
 1
4]
 
M
PD
L3
28
0A
 
(M
PD
L3
28
0A
) 
[1
5-
17
] 
50906 Adamu v2.indd   66 30-05-18   21:34
Immunotherapy Checkpoint Inhibition
67
3
Immuno checkpoint inhibition 
 
63 
 
Ta
bl
e 
2.
 C
ha
ra
ct
er
is
tic
 o
f o
ng
oi
ng
 im
m
un
e 
ch
ec
kp
oi
nt
 c
lin
ic
al
 tr
ia
ls 
in
 g
as
tr
ic
 c
an
ce
r.
 
In
di
ca
tio
n 
De
fin
ed
 g
ro
up
, s
ec
on
d 
or
 th
ird
 
lin
e 
re
gi
m
en
 
De
fin
ed
 g
ro
up
, a
t l
ea
st
 se
co
nd
 
lin
e 
De
fin
ed
 g
ro
up
 ,n
on
- r
el
ap
se
d 
 
se
tt
in
g 
De
fin
ed
 g
ro
up
 , 
 n
on
- r
el
ap
se
d 
 
se
tt
in
g 
De
fin
ed
 g
ro
up
, t
hi
rd
 li
ne
 
se
co
nd
 a
nd
 th
ird
  l
in
e,
 A
sia
n 
an
d 
 
Ja
pa
ne
se
  
Ba
sk
et
 tr
ia
l 
Ba
sk
et
 tr
ia
l 
De
fin
ed
 g
ro
up
 , 
 n
on
- r
el
ap
se
d 
 
se
tt
in
g 
De
fin
ed
 g
ro
up
,  
hu
m
an
 e
pi
de
rm
al
 
gr
ow
th
 fa
ct
or
 re
ce
pt
or
 2
) -
po
sit
iv
e 
De
fin
ed
 g
ro
up
 
no
n-
 re
la
ps
ed
  s
et
tin
g 
M
ai
nt
en
an
ce
 a
ft
er
 1
st
 li
ne
 
De
fin
ed
 g
ro
up
 , 
 n
on
- r
el
ap
se
d 
 
se
tt
in
g 
Ep
st
ei
n–
Ba
rr
 v
iru
s -
po
sit
iv
e 
1s
t L
in
e,
 H
ER
2-
ne
ga
tiv
e,
 P
DL
1-
po
sit
iv
e 
En
ro
lli
ng
 
St
at
us
 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Ac
tiv
e,
 n
ot
 re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Co
m
pl
et
ed
 
Re
cr
ui
tin
g 
Re
cr
ui
tin
g 
Se
co
nd
  l
in
e 
St
ra
te
gy
 
Pe
m
br
ol
izu
m
ab
 in
 c
om
bi
na
tio
n 
w
ith
 ra
m
uc
iru
m
ab
 
Pe
m
br
ol
izu
m
ab
  i
n 
co
m
bi
na
tio
n 
w
ith
  P
EG
PH
20
 
Pe
m
br
ol
izu
m
ab
 
Pe
m
br
ol
izu
m
ab
  i
n 
co
m
bi
na
tio
n 
w
ith
 P
LX
33
97
 
Av
el
um
ab
 
Av
el
um
ab
 
M
PD
L3
28
0A
 w
ith
 b
ev
ac
izu
m
ab
  
ad
m
in
ist
er
ed
 a
s m
on
ot
he
ra
py
 o
r 
as
 c
om
bi
ne
d 
th
er
ap
y 
M
PD
L3
28
0A
 
M
PD
L3
28
0A
 a
nd
 G
DC
-0
91
9 
Pe
m
br
ol
izu
m
ab
  w
ith
  
tr
as
tu
zu
m
ab
 a
s  
co
m
bi
na
tio
n 
Pe
m
br
ol
izu
m
ab
  i
n 
co
m
bi
na
tio
n 
w
ith
  F
O
LF
O
X 
Tr
em
el
im
um
ab
  M
ED
I4
73
6 
Ip
ili
m
um
ab
 v
er
su
s.
 F
U
/B
SC
 
N
iv
ol
um
ab
 +
/-
 ip
ili
m
um
ab
 
N
iv
ol
um
ab
 
Pe
m
br
ol
izu
m
ab
 m
on
ot
he
ra
py
 o
r 
co
m
bi
na
tio
n 
w
ith
 C
T 
Pe
m
br
ol
izu
m
ab
 v
er
se
. p
ac
lit
ax
el
 
Cl
in
ic
al
 
tr
ia
l P
ha
se
 
1 1 1 1 1 1 1 1 1 1/
2 
01
/2
 
1b
/2
 
2 1/
2 
1/
2 3 3 
St
ud
y/
 C
lin
ic
al
 tr
ia
l i
de
nt
ifi
ca
tio
n/
Re
fe
 
Ro
y 
S 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/(
69
) 
Ph
ili
p 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/(
70
) N
CT
02
56
35
48
 
M
ur
o 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
01
84
88
34
 
(K
EY
N
O
TE
 0
12
)(7
1)
 
Ze
v 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
02
45
24
24
(7
2)
 
Ka
re
n 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
01
77
20
04
/(
73
) 
Ya
su
hi
de
 e
t a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
01
94
34
61
/(
74
) 
Ho
w
ar
d 
et
 a
l.,
 2
01
7/
pu
bl
ish
ed
/ 
N
CT
01
63
39
70
/(
75
) 
Da
vi
d 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
01
37
58
42
/(
76
) 
Je
ss
ic
a 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
02
47
18
46
/(
77
) 
20
16
/p
ub
lis
he
d/
 N
CT
02
31
89
01
 
20
16
/p
ub
lis
he
d/
 N
CT
02
26
88
25
 
Ro
na
n 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
02
34
09
75
(7
8)
 
Je
dd
 e
t a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
01
58
59
87
(7
9)
 
An
to
ni
a 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ 
N
CT
01
92
83
94
(8
0)
 
Je
ed
 e
t a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
02
48
87
59
(8
1)
 
Jo
se
p 
et
 a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
02
49
45
83
 
(K
EY
N
O
TE
 0
62
)(8
2)
 
At
su
sh
i e
t a
l.,
 2
01
6/
pu
bl
ish
ed
/ N
CT
02
37
04
98
 
(K
EY
N
O
TE
 0
61
)(8
3)
 
 
50906 Adamu v2.indd   67 30-05-18   21:34
Chapter 3
68
Chapter 3 
64 
Clinical trial studies of PD-1 blockade approach in gastric cancer  
It is evident within cancers evolutionary pressure exists to avoid attack by the 
immune system. To this end cancer cells can employ signals the body uses to control 
self-damaging autoimmunity. Especially PD-1 appears prominent in limiting 
immunity towards cancers cells. In physiology, PD1 guards against autoimmunity 
through a dual mechanism of promoting programmed cell death in cytotoxic T-cells 
while simultaneously reducing apoptosis in regulatory T cells. By engaging PD1 on 
anti-tumor immune cells through its cognate ligands, in particular, PD-L1 the cancer 
cell can corrupt anti-oncogenic immunity. Anti PD1 antibodies prevent this 
interaction by binding to the relevant immune cells. Accordingly, anti-PD-1 
antibodies have shown such anticancer efficacy in various cancers types[6]. 
Concerning this strategy, its safety and effectiveness were tested with 
pembrolizumab is patients from the Asian-Pacific patients who presented with 
progressive gastric or gastroesophageal junction tumors and exhibited a positive PD-
L1 expression status. Concerning the latter, the eligibility criteria were that patients 
should have or ≥ 1% cancer nest cell PD-L1 staining.  The design involved a gift of 
10 mg of pembrolizumab per kg once in two weeks for one year or until 
comprehensive response, advancement or unacceptable toxicity. The primary 
efficacy endpoint was evaluated after eight weeks medical imaging, whereas 
duration of response constituted a secondary endpoint. In this study, the overall 
response was 22% (95% CI, 10.39) and 33% (95% CI, 19.50) respectively, which 
although an encouraging result not markedly better as compared to studies 
employing unselected patients. Hence, the PD-L1 expression per se is suitable for 
selecting gastric cancer patients for PD-1-directed checkpoint therapy remains poor 
and other approaches need to be explored.  
In a clinical trial NCT02267343[19], involving the use of Nivolumab on gastro-
oesophageal junction or advanced gastric cancer refractory patient, the cohort with 
intolerant of, at least two preceding treatment regimens were recruited in a placebo-
controlled, double-blinded randomized clinical trial involving 493 patients who were 
assigned randomly to take nivolumab. 8.87 months (IQR 6.57-12.37)  was the 
follow-up median for surviving patients in the nivolumab group. 5.26 months with 
(95% CI 4.60-6.37) is the overall survival median in the nivolumab group. The 
overall survival rate of 26.2% was observed within the nivolumab group compare to 
10.9% within the placebo group. There is grade 4 treatment-related adverse effect in 
10% of the 330 patients from the Nivolumab arm of the study[19]. 
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Apart from targeting PD-1 on immune cells, inhibiting its cognate ligand PD-L1 on 
the tumor proper constitutes a therapeutic possibility.  Various studies have 
addressed this possibility by testing the efficacy and performance of Avelumab 
(NCT01772004 (JAVELIN), MSB0010718C) in chemotherapy-failing gastric 
cancer patients[6].  Twice every month, patients were given 10 mg/kg of avelumab 
until either progression, or intolerable toxicity occurred. Cancerous growth, OR, 
adverse events and PFS were evaluated once every six weeks, and results were 
related to PD-L1 expression as determined by immunohistochemistry. In total, 75 
Gastric cancer patients were treated with avelumab. Of these patients, seven showed 
a response and of these seven three were positive for PD-L1 as determined by 
histochemistry. It thus appears that PD-1 is the more attractive target for therapy in 
gastric cancer as compared to PD-L1 and again attempts at precision medicine, 
employing PD-L1 immunoreactivity as triaging agent mostly fail. In this context, it 
is interesting to note that in such studies PD-L1 expression is usually determined on 
material collected before the onset of conventional treatment. One can well imagine 
that chemotherapy etc. influences the expression of checkpoints. We thus call for 
studies investigating the potential of PD-L1 immunohistochemistry for selecting 
potential responders on material obtained immediately before anti-checkpoint 
therapy is initiated.  
Clinical trial studies of CTLA-4 blockade approach in gastric cancer.  
Apart from targeting the PD1/PD-L1 signaling system, CTLA4 is also a prominent 
immuno-checkpoint. CTLA4 is an immune checkpoint receptor that downregulates 
immune responses. The molecule is constitutively expressed in regulatory T cells 
but only upregulated in conventional T cells after activation. Ipilimumab targeted 
CTLA4 and was the first checkpoint inhibitor to reach the clinic, meeting substantial 
clinical success in metastatic melanoma. Results in gastric cancer were somewhat 
less encouraging. A recent study employing ipilumimab in unresectable Locally 
Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer did not provide 
evidence ipilimumab efficacy as monotherapy[20]. Another CTLA4-targeting 
antibody is tremelimumab. In this study, a partial response in one patient, and stable 
disease in four others (out of 18 participants) was seen, which does not compare 
well with results obtained with PD-1-directed strategies. Hence, the usefulness of 
CTLA4 immuno-checkpoint targeting is doubtful, although currently also 
combinations between anti-CTLA4 and anti-PD1 are being tested, which may still 
uncover potential synergism. 
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Adverse events  
It is pertinent to note that immune-modulating agents can exert some levels of 
toxicity[21, 22] and anti-immuno-checkpoint therapy of gastric cancer is not an 
exception. Unfavorable event outcomes were seen in several clinical trials which can 
be managed by the administration of corticosteroids although it is an 
immunosuppressive agent. Colitis resulting from checkpoint inhibitor therapy is 
sometimes managed by infliximab, an anti-tumor necrosis factor alpha agent. At the 
latter compound provokes T cell apoptosis, this is probably detrimental and should 
be avoided[23]. In a clinical testing involving pembrolizumab and Avelumab, a five 
total grade drug-related adverse event was observed in four patients, including loss-
of-appetite, fatigue, damage to peripheral nerves and peripheral ischemia. However, 
no fatalities as consequence of drug side-effects have been reported, and it is fair to 
say that although not little off-target effects can be efficiently clinically managed.  
Conclusions 
PD-1 inhibition is a useful clinical option for advanced gastric cancer patients failing 
other modes of treatment and performs better other forms of checkpoint inhibitor 
therapy in this disease and associated with acceptable toxicity. At present strategies 
to target anti-PD1 therapy to those patients most likely to benefit from such 
intervention based on tumor PD-L1 expression have largely failed. Hence the reason 
why only a minority of gastric cancer patients benefit from anti-PD1 therapy remain 
primarily obscure and require further investigation 
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Abstract 
Hedgehogs constitute a family of pivotal morphogens that exert their action through 
a well-characterized canonical pathway involving Gli transcription factors and as yet 
poorly characterized non-canonical signaling. To obtain more insight in the non-
canonical aspect of Hedgehog signaling, we perform a  comprehensive 
characterization of the cellular kinome in Hedgehog-challenged wild-type, Ptc-/-, 
Smo-/-, and Smo-agonist Purmophamine-challenged wild-type fibroblasts. We 
observe that whereas non-canonical Hedgehog signaling in general displays an 
absolute requirement for the presence of functional Ptc, an elaborate signaling 
network of both Smo-dependent and independent pathways is present that mediates 
actin reorganization through the activation of Src-like kinases, activates various 
proinflammatory signaling cascades and concomitantly canonical Wnt and Notch 
signaling while suppressing canonical BMP signaling. The observation that Ptc-
dependent Smo-independent non-canonical Hedgehog signaling increases 
Wnt/Notch provides an obvious explanation for the failure of Smo antagonists in 
combating gastrointestinal cancer and suggests that therapy should be directed at 
inhibiting Hedgehog-Ptc interaction. 
Keywords: Sonic; Hedgehog; Transcription; Cytoskeleton; Endocytosis. 
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Introduction 
Cell fate in the developing or adult body is determined by morphogens, molecules 
whose non-uniform distribution governs the pattern of tissue development often by 
providing positional information[1, 2]. Notable examples of morphogens include the 
Hedgehog-, Wingless-related integration site- (Wnt) and Bone morphogenetic 
protein- (BMP) dependent signals[3-6].  The intracellular signaling resulting from 
engagement of morphogens with their cognate receptors is involved in virtually all 
physiological and pathophysiological processes in the body, including 
embryogenesis, tissue regeneration, and carcinogenesis and thus understanding 
morphogen signaling is a scientific question of utmost importance[7, 8]. 
Unfortunately, morphogen-provoked signal transduction is often complex, and a 
special case to the point is signal transduction initiated by Hedgehogs[9]. 
Hedgehog proteins are a highly conserved family of intercellular signalling 
molecules. Originally identified as a Drosophila segment polarity gene required for 
embryonic patterning, several vertebrate homologues have now been discovered—
Indian (Ihh), Desert (Dhh) and Sonic Hedgehog (Shh), the most extensively 
characterised[10]. Hedgehog signals are fundamental regulators of embryological 
development, as illustrated by the dramatic embryological malformations seen when 
accurate timing of Hedgehog signals during gestation is corrupted[11]. Hedgehog 
remains active in the post-embryonic period, maintaining histostasis in a variety of 
tissues, including the gastrointestinal tract and the immune system[12]. Continuous 
hedgehog signalling is an essential permissive factor for many cancers and causative 
in basal cell carcinoma of the skin amongst others[13]. In humans, one-allelic loss of 
the inhibitory hedgehog receptor Patched is sufficient to produce the so-called 
Gorlin syndrome [14], associated with multiple basal cell carcinomas. Despite the 
importance of hedgehog signalling for human physiology and pathophysiology, the 
molecular details underlying this signalling remain only partly characterised. 
Hedgehog signal transduction is highly unusual, containing many features unique to 
this signaling system[15]. After synthesis, Hedgehog undergoes autocatalytic 
cleavage followed by lipid modifications resulting in the only protein in the animal 
kingdom that is sterolated and both secreted and palmitoylated[16]. The primary 
receptor for Hedgehogs is Patched, an intriguing receptor, as it does not convey the 
Hedgehog signal to the intracellular components of the pathway itself like a 
conventional receptor. Rather, binding of Hedgehog to Patched alleviates the 
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inhibitory effect of Patched on another membrane receptor, Smoothened. The 
alleviation of Patched inhibition is probably caused by internalization of Patched 
following binding of Hedgehog, but the signaling mechanisms involved remain 
obscure at best[2, 17]. Following removal of Patched-mediated repression 
Smoothened translocates to the primary cilium in a microtubule and kinesin-
dependent process, that is essential for Smoothened to initiate further signaling as 
evident from the potential from pharmacological inhibitors of this process to 
counteract canonical Hedgehog signaling[18, 19]. Subsequently, Smoothened 
mediates the activation of the latent transcription factor glioma-associated oncogene 
(Gli) via a process which is still largely unresolved but involves the kinase Fused 
(Fu) and the Suppressor of Fused protein (Su(Fu))[20, 21] . Gli proteins are the final 
transcriptional effectors of Hedgehog signaling, both in normal vertebrate 
development as well as oncological disease[22, 23]. Together this signalling cascade 
may be termed the canonical hedgehog pathway. It is obvious that enhanced 
knowledge of the signaling elements involved in this pathway should prove 
exceeding useful in defining novel rational therapy directed at disease emanating 
from aberrant activation of canonical Hedgehog signaling.  
Apart from canonical Hedgehog signaling, Hedgehog effects in physiology and 
pathophysiology also depend on so-called non-canonical signaling. For most 
morphogens, non-canonical signaling has been identified and effects observed are in 
general contrasting the effects derived from canonical signaling. An example is 
BMP signaling. In the colon BMP generally acts as a tumor suppressor[24]. In 
presence of canonical BMP-signaling abrogating SMAD4 mutations, however, a 
non-canonical BMP-induced signaling pathway becomes evident that stimulates 
epithelial-to-mesenchymal transition and metastasis via activation of Rho and 
ROCK and furthers the colon cancer process[25]. Likewise, non-canonical Wnt 
signal transduction mediates important aspects of the action of this morphogen in the 
body through activation of small GTPases like Rac, Rho and Cdc42 to regulate the 
activity of ROCK, MAPK and JNK as well as Ca++ signaling, also an effect 
important for colon cancer metastasis[26-28] . For Hedgehog also various modes of 
non-canonical signaling have been described, both downstream of Patched and 
independent of Smoothend as well as downstream of Smoothened. The most 
prominent example of the former concerns colorectal cancer stem cells[29]. 
Whereas canonical Gli-dependent Hedgehog signaling negatively regulates Wnt 
signaling in the normal intestine in and intestinal tumors[7, 30], Hedgehog signaling 
in colon cancer stem cells activates a non-canonical Patched-dependent but 
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Smoothened independent signaling that is required for survival of these cancer stem 
cells[29]. Tantalizingly, these results open the theoretical possibility to uncouple the 
anti-cancer effect of Hedgehog signaling on colorectal cancer in general[31] and the 
trophic effect of Hedgehog signaling on specifically colorectal cancer cells. In the 
absence, however, of knowledge on the molecular pathways that mediate these non-
canonical effects of Patched-dependent but Smoothened independent Hedgehog 
signaling, this possibility remains hypothetical only.  
Apart from Patched-dependent Smoothened-independent non-canonical Hedgehog 
signaling, Smoothened-dependent Gli-independent non-canonical Hedgehog 
signaling has also been described and likewise the molecular mechanisms involved 
are only partly understood. The interaction of Hedgehog with Patched stimulates the 
translocation of Smoothened to the primary cilium, which is required for the 
transcriptional Hh response. This translocation involves activation of phospholipase 
A2 following Smoothened activation and results in the enzymatic release of 
arachidonic acid from plasma membrane phospholipids. The thus released 
arachidonic acid binds to Smoothened and this interaction appears essential for 
cilium translocation of Smoothened and canonical Hedgehog signaling[32]. 
Arachidonic acid metabolites are powerful actin cytoskeleton remodeling agents[33] 
and while located outside the primary cilium Smoothened also mediates 
transcription-independent actin reorganization and chemotactic responses through 
the production of these metabolites[16, 34]. The physiological importance of this 
non-canonical response to Hedgehog signaling is illustrated by its pivotal role in 
Hedgehog effects in directing neurite projection[35], It has become clear, however, 
that non-canonical Hedgehog effects on axonal guidance involve activation of Src-
like kinases[36] but generally speaking it is fair to say that the molecular events 
underlying Smoothened-dependent non-canonical signaling remain unresolved.  
The above-mentioned considerations prompted us to characterize the kinase 
activities associated with Hedgehog challenge in general as well as those 
specifically associated with Patched activation and Smoothened activation in 
isolation. To this end we exploited the power of the peptide array-based kinome 
profiling in which peptide arrays of kinase-specific substrates are incubated with cell 
lysates and 33P-γ-ATP thus generating comprehensive descriptions of cellular 
kinase activities[37, 38]. The results provide a wealth of information on the effects 
of Hedgehog signal transduction on cellular phosphorylation events and reveal a 
Patched-dependent Smoothened-independent signal transduction cascade that 
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amongst other events provokes Wnt and Notch activation, the former probably 
through stimulation of phosphoinositide-3-OH-kinase (PI3K), stimulates the 
activation of various pro-inflammatory signaling events and results in the activation 
of protein kinase A (PKA), a potential feed forward inhibitory event with respect to 
canonical Hedgehog transduction. Smoothened-dependent events include inhibition 
of PKA, stimulation of various cytoskeleton reorganizing pathways as well as 
stimulation of AMP-activated kinase (AMPK). In conjunction, the results provide an 
intellectual framework that allows understanding of context-dependent Hedgehog 
signaling. 
Experimental procedures 
Materials 
Cyclopamine was from Biomol. Purmorphamine was from EMD Biochemicals 
(Darmstadt, Germany). Recombinant ShhN was from R&D Systems 
Cell culture 
Smoothened–/– fibroblasts (a gift from Dr. Taipale), Ptch1–/– and wild-type MEFs 
(gifts from Dr. Scott) were cultured in Dulbecco's modified Eagle's medium 
(DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, Invitrogen). 
For experiments, a confluence of 50% cells was allowed to grow in six-wells plates. 
Stimulation were done, if appropriate with two µg/ml Shh for 10 min. 
Kinome Profiling  
For peptide array analysis, we employed the Pepchip kinomics array. The protocol 
and associated analysis has been described in detail elsewhere[55] and is based on 
the original protocol of van Baal et al[56]. In short, cells were washed in ice-cold 
PBS and lysed in a non-denaturing complete lysis buffer (cells were lysed in 50μl 
lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
Triton X-100, 2.5mM sodium pyrophosphate, 1mM MgCl2, 1mM 
glycerophosphate, 1mM Na3VO4, 1mM NaF,1μg/ml Leupeptin, 1μg/ml Aprotinin, 
1mM PMSF). Subsequently the cell lysates were cleared by centrifugation and 
peptide array incubation mix was produced by adding 10 µl of activation mix (50% 
glycerol, 50 µM ATP, 0.05% v/v Brij-35, 0.25 mg/ml bovine serum albumin) and 2 
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µl [γ-33P] ATP (approx. 1000 kBq (Amersham AH9968). Next, the peptide array 
mix was added onto the chip, and the chip was kept at 37°C in a humidified stove 
for 90 min. Subsequently the peptide array was washed twice with Tris-buffered 
saline with Tween 20, twice in 2 M NaCl, and twice in demineralised H2O and then 
air-dried. The chips were exposed to a phosphor screen for 72 hours, and the density 
of the spots was measured and analyzed with array software (ScanAnalyze ). 
ScanAlyze software was used. Using grid tools, spot density and individual 
background were corrected and spot intensities and background intensities were 
analyzed. Data from at least 9 independent data points were exported to an excel 
sheet for further analysis. Control spots on the array were analyzed for validation of 
spot intensities between the different samples. Inconsistent data (i.e., SD between 
the different data points >1.96 of the mean value) were excluded from further 
analysis. For  each peptide the  average  and  standard  deviation  of  
phosphorylation  was  determined  and  plotted  in  an  amplitude‐based hierarchical  
fashion. For data analysis, first every peptide was given an “on” call or “off” call 
(Markov state analysis). To this end, first an average signal was calculated for each 
peptide using the three biological replicates (each consisting of two technical 
replicates) yielding an aggregate dataset for each the hematopoietic subsets. 
Subsequently, for each of the aggregate datasets, either “on” calls or “off” calls were 
given to each peptide substrate (Markov state analysis). In order to do this, we 
assumed that the subset of signals representing the 1-1-e fraction of peptides having 
the lowest phosphorylation of all peptides contained pure noise and did represent 
meaningful phosphorylation. The distribution of this noise was fitted as a single 
exponent, using the amplitude-sorted row number of these substrates as the X 
domain of the distribution and this single exponent was assumed to describe noise 
for the entire dataset. Now for all data points within the subset, when the actual 
amplitude observed minus 1,96 the standard deviation was in excess of the value 
expected from distribution describing the noise, a substrate was given an “on” cal (p 
< 0.05) in this Markov analysis. Subsequently results were collapsed on elective 
signal transduction categories and subjected to dichotomal significance analysis, 
contrasting Shh-stimulated cultures to parallel vehicle cultures or Purmorphamine-
stimualted cultures to parallel unstimulated cultures. If a significant result (p < 0.05) 
was detected, we considered the result as robust evidence of differential activation 
of signal transduction between Hedgehog-stimulated and unstimulated cultures and 
in the depiction of results the corresponding signal transduction categories have 
been highlighted with a red border. For those signal transduction categories in which 
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using this dichotomal testing based on number of Markov state “on” peptides did not 
result in statistical significance, the relative levels of phosphorylation were also 
tested using a paired T test, directly parametrically comparing phosphorylation of 
the corresponding spots. As we considered thus-discovered statistically significant 
differences between the relevant experimental conditions less robust, in the 
depiction of the results they have been highlighted with an orange border. Note that 
due to differences in the number of peptides allotted to the signal transduction 
categories apparently large differences in phosphorylation not always yield 
statistically significant results, while smaller differences can produce such results if 
the number of substrates in such categories is large. 
Results and discussion 
Hedgehog stimulation provoked rapid and marked reorganization of the 
cellular kinome  
The general approach as to this study, both technically and biologically is provide 
through Figure 1. We characterised the kinase signatures associated with Hedgehog 
stimulation of mouse embryonic fibroblasts (MEFs), which we have recently shown 
to constitute a powerful model for delineating signal transduction events[39]. We 
established that under our experimental conditions, these cells do not endogenously 
release Hedgehog (not shown). Cells were incubated for 10 min with either 1 µg/ml 
Shh or a vehicle control, and the cell lysates were employed for in vitro 
phosphorylation of peptide arrays using 33P-γ-ATP. Arrays consisted of 1024 
different undecapeptides, of which 48 are various technical controls, whereas the 
remaining 976 peptides provide kinase substrate consensus sequences spanning the 
entire mammalian kinome and which we have shown earlier to provide 
comprehensive insight in cellular signal transduction[40]. On each separate carrier, 
the array was spotted three times, to allow assessment of possible variability in 
substrate phosphorylation. The final physical dimensions of the array were 25 x 75 
mm, each peptide spot having a diameter of approximately 250 μm, and peptide 
spots being 620 μm apart. As a control for the specificity of the reaction 33P--ATP 
was used; no incorporation of radioactivity was seen. We then calculated the mean 
phosphorylation level for all substrates before and after the treatment (total number 
of data points is 9 for each group). The technical quality of the profiles was good, 
and we only allowed experiments in which the Pearson product moment correlation 
coefficient was more as 0.95 for the technical replicas. We decided to use these data 
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for analysis as to specific and divergent phosphorylation following stimulation with 
Hedgehog. To this end results were collapsed on elective signal transduction 
categories (see experimental procedures and [41]. The results are shown in Figure 2 
and detailed in Supplementary table 1. They show that Hedgehog challenge 
provokes fast and substantial remodeling of cellular signaling. Particularly notable is 
the upregulation of mTOR signaling which may fit recent data that indicate that 
mTORC1-mediated translation is a key component of hedgehog signaling and is a 
putative target for treating Hedgehog-driven cancers[42]. Other interesting points 
include an upregulation of g-protein-coupled receptor kinase enzymatic activity, 
which is line with observation in Drosophila that a G-protein-coupled receptor 
kinase controls Smoothened activity[43]. Strong regulation of PKA is also observed 
and may be in line with the notion that this kinase is a regulator of Hedgehog 
signaling[44], whereas the observation that PKC enzymatic activity is upregulated is 
conform the canonical mode of action of G-protein coupled receptor like 
Smoothened. A variety of pro-inflammatory signaling modules is activated as well 
(including Lyn, Fyn  and peptides that are consensus substrates for Bruton’s tyrosine 
kinase) but as embryonic fibroblasts are not immunologically-relevant cells, the 
importance of this observation is uncertain. Maybe unsurprisingly (in view of its 
role of a Wnt antagonist in the epithelium of the intestine[7, 30], we see strong 
inhibition of Wnt signaling in our model system following Hedgehog application 
although this observation is at bay with the data of Shin et al. that show that bladder 
stromal cells respond to Shh with Wnt activation[45]  and also to the recent report of 
Regan et al.[29] describing that Hedgehog can stimulate Wnt signaling in cancer 
stem cells. In addition, the upregulation of substrate peptides for p21-activated 
kinase (Pak) activity and related molecules indicates that Hedgehog stimulation 
stimulates actin reorganization and morphological changes. In conjunction these 
experiments show that the effect of Hedgehog on the cellular kinome is rapid and 
profound.  
Patched-dependent Smoothened-independent effects on cellular kinase activity 
The existence of Patched-dependent Smoothened-independent signal transduction is 
supported by various observations[46] and appears highly relevant in that it is 
essential for cancer stem cell survival in colorectal cancer[29]. To test whether such 
signaling is present in our model system we incubated MEFs with 3H-sucrose 
(which is membrane impermeable and is only taken up via endocytosis in most cell 
types) and challenged the cells with either a vehicle control or 1 µg/ml Shh, in the 
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presence or absence of the Smoothened inhibitor cyclopamine (Figure 3). We 
observed strong accumulation of radioactivity in both Hedgehog challenged cells, as 
well as in cells challenged with Hedgehog in the presence of cyclopamine. We thus 
concluded that endocytosis following Hedgehog stimulation does not require 
Smoothened activity and that hence our model system was suitable for investigating 
at least certain aspects of Smoothened-independent signal transduction. To further 
characterize these aspects we performed kinome profiling of Smoothened-/- 
fibroblasts (originally obtained from Drs. James Chen and Philip Beachy and 
previously described by Varajosalo et al[47], challenged with either a vehicle 
control or 1 µg/ml Shh for 10 min. The results are summarized in Figure 3 and 
Supplementary table 1 and reveal that the influence of Smoothened-independent 
Hedgehog-induced signaling on cellular kinase activity is substantial. Conspicuously 
lacking, however, is G protein-coupled receptor-associated signal transduction 
which is obviously in line with the absence of Smoothened-dependent events. In 
particular activation of cytoskeletal remodeling is seen following addition of 
Hedgehog, which correlates with a downregulation of activity of the Csk negative 
regulators of Src activity and may relate to the observed Smoothened-independent 
effects of Hedgehog on endocytosis described above, especially as kinase enzymatic 
activity directed against FAK-responsive peptides is co-activated[48, 49]. A 
prominent effect is increased mTOR activation whereas inflammatory signal 
transduction was also activated by Hedgehog in Smoothened-/- fibroblasts. 
Hedgehog in wild type fibroblasts provokes similar effects (see above) and thus 
these effects of Hedgehog signaling appear thus at least partially to stem from 
Smoothened-independent signaling. Similarly, activation of Wnt and Notch 
signaling is also seen and thus this aspect of Hedgehog signaling seems also 
independent of Smoothened. Interestingly, in the absence of Smoothened, Hedgehog 
activates rather than inhibits PKA, and it is tempting to speculate that this effect may 
relate to activating phosphorylation of Smoothened by PKA that has been described 
in Hedgehog signaling[50]. Control experiments revealed that the effect of 
Hedgehog on Patched negative fibroblasts was negligible (although generally 
speaking Patched-negative fibroblasts show more kinase activity as compared to 
control cells, potentially an effect of unleashed Smoothened signaling), suggesting 
that a contribution of Patched-independent Hedgehog-dependent signaling is non-
existent (Supplementary table 1). In conjunction these results reveal that an 
unexpectedly large proportion of Hedgehog signal transduction towards the cellular 
kinome is mediated though non-canonical Patched-depedent Smoothened-
independent signaling. 
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FIGURE 1. Outline of the study. A. Technical approach – kinome profiling. In this study, we aim to comprehensive 
characterize cellular kinase enzymatic activities. To this end appropriately stimulated cell cultures are washed with 
ice-cold PBS and lysed in a non-denaturing complete lysis buffer as to solubilize cellular kinases. Lysates are the 
transferred to arrays consisting of a substrate peptide library, spotted in triplicate as to assess technical 
reproducibility, which are spotted on a hydrogel-coated glass carrier. Upon addition of radioactive ATP and an 
activation mix, kinases –if enzymatically active- will phosphorylate substrate peptides. Incorporation of radioactive 
ATP into a substrate peptide is taken as a measure of enzymatic kinase activity towards a particular substrate. The 
broad variation in specific substrates used (see also supplementary data) allows obtaining a more-or-less complete 
description of cellular signaling, the so-called kinome. B. Biological approach. In this study, we first generate a 
description of the effects of Shh challenge on cellular signaling in general by comparing kinome profiling results of 
cultures challenged and not challenged by the morphogen. To delineate the contribution of possible non-Ptc-
dependent components to Hedgehog-dependent kinase events, the effect of Shh stimulation on fibroblast 
genetically devoid of Ptc is established as well. To identify signal transduction events that are downstream of Ptc 
but do not involve Smo, the Hedgehog provoked effects on the cellular kinome are studied in fibroblasts 
genetically deficient for Smo. Finally, to identify events that are solely dependent on the activation of Smo, we 
study the effects of the Smo agonist purmorphamine 
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FIGURE 2. Effects of Hedgehog stimulation on cellular signaling as determined by kinome profiling. Murine 
fibroblasts were stimulated with 1 μg/ml Shh. Subsequently cells were lysed and the resulting lysates were used to 
phosphorylate arrays of different kinase substrates employing 33P‐‐ATP and radioactivity incorporated in the 
different substrates was determined. Peptide substrates were allotted to elective signal transduction elements. 
The picture depicts the number of peptides significantly phosphorylated (which means the number of peptides 
that received a Markov “on” call - see experimental procedures) for each element. A darker color reflects more 
kinase activity towards substrate elements and the results reveal the effects of Hedgehog stimulation on cellular 
signal transduction, thus a black color means all peptides were significantly phosphorylated, whereas a white color 
means that no peptides allotted to this signal transduction in this experimental conditions were phosphorylated. 
Results were first statistically tested by a dichotomal analysis based on the number of Markov “on” calls observed 
in vehicle-and Shh-stimulated cultures. If statistically significant differences were noted the signal transduction 
category is highlighted with a red border and the level of significance observed is indicated in red. For signal 
transduction elements in which this very robust analysis fails to detect a statistically significant difference, a 
parametric test was performed. If this proved significant, the category is highlighted with an orange color and 
corresponding level of significance is depicted as well – in orange. The results provide a wealth of data on the 
effects of Hedgehog stimulation on cellular signaling. 
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FIGURE 3. Effects of Hedgehog on the uptake of [3H]-sucrose and the influence of Smoothened 
inhibition thereon. Fibroblast cultures were grown in twenty-four-wells plates and incubated in a 1 ml 
containing 200 nCi of [3H]-sucrose in the presence or absence of either 1 μg/ml Shh and 10 μM 
cyclopamine. At the end of the experiment cells were extensively washed with ice-cold PBS and lysed 
in NP-40 for subsequent scintillation counting, As sucrose can only enter cells through fluid phase 
uptake, this provides a reliable measure of cellular endocytosis. We observe that Hedgehog 
stimulates fluid phase uptake and this effect does not require Smoothened as it is not sensitive to the 
Smoothened inhibitor cyclopamine 
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FIGURE 4. Effects of Hedgehog stimulation on cellular signaling in Smo-deficient fibroblasts. Murine Smo-/- 
fibroblasts were stimulated with 1 μg/ml Shh. Subsequently cells were lysed and the resulting lysates were used to 
phosphorylate arrays of different kinase substrates employing 33P‐‐ATP and radioactivity incorporated in the 
different substrates was determined. Peptide substrates were allotted to elective signal transduction elements. 
The picture depicts the number of peptides significantly phosphorylated (which means the number of peptides 
that received a Markov “on” call - see experimental procedures) for each element. A darker color reflects more 
kinase activity towards substrate elements and the results reveal the effects of Hedgehog stimulation on cellular 
signal transduction, thus a black color means all peptides were significantly phosphorylated, whereas a white color 
means that no peptides allotted to this signal transduction in this experimental condition were phosphorylated. 
Results were first statistically tested by a dichotomal analysis based on the number of Markov “on” calls observed 
in vehicle-and Shh-stimulated cultures. If statistically significant differences were noted the signal transduction 
category is highlighted with a red border and the level of significance observed is indicated in red. For signal 
transduction elements in which this very robust analysis fails to detect a statistically significant difference, a 
parametric test was performed. If this proved significant, the category is highlighted with an orange color and 
corresponding level of significance is depicted as well – in orange. The results reveal an intricate web of Patched-
dependent Smoothened-independent non-canonical signal transduction events. 
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FIGURE 5. Effects of selective Smoothened activation by purmorphamine stimulation on cellular signaling in 
fibroblasts. Murine fibroblasts were stimulated with purmorphamine. Subsequently cells were lysed and the 
resulting lysates were used to phosphorylate arrays of different kinase substrates employing 33P‐‐ATP and 
radioactivity incorporated in the different substrates was determined. Peptide substrates were allotted to elective 
signal transduction elements. The picture depicts the number of peptides significantly phosphorylated (which 
means the number of peptides that received a Markov “on” call - see experimental procedures) for each element. 
A darker color reflects more kinase activity towards substrate elements and the results reveal the effects of 
purmorphamine stimulation on cellular signal transduction, thus a black color means all peptides were significantly 
phosphorylated, whereas a white color means that no peptides allotted to this signal transduction in this 
experimental conditions were phosphorylated. Results were first statistically tested by a dichotomal analysis based 
on the number of Markov “on” calls observed in vehicle-and Shh-stimulated cultures. If statistically significant  
differences were noted the signal transduction category is highlighted with a red border and the level of 
significance observed is indicated in red. For signal transduction elements in which this very robust analysis fails to 
detect a statistically significant difference, a parametric test was performed. If this proved significant, the category 
is highlighted with an orange color and corresponding level of significance is depicted as well – in orange. The 
results reveal a web of Smoothened-dependent signal transduction events clearly distinct from Patched-
dependent signaling. 
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FIGURE 6. Selected kinome profiling-detected Shh-provoked signal transduction events and the role of Patched 
and Smoothened therein. Blue elements are confirmed, whereas gray elements showed a trend but did not reach 
Bonferoni-corrected statistical significance. The results reveal that the role of Patched dependent Smoothened-
independent signal transduction is more prominent in transcription independent cellular effects of Hedgehog as 
previously thought. 
 
Cellular kinase response to selective Smoothened activation  
Subsequently we decided to investigate the effects of selective Smoothened 
activation in MEFs. To this end we employed purmorphamine, a purine derivative 
that directly targets Smoothened[45, 51] and employed the compound to challenge 
MEFs. The results are provided through Figure 4 and Supplementary table 1. We 
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observe that purmorphamine results in inhibition of PKA enzymatic activity, an 
effect which is also seen following stimulation of fibroblasts with Hedgehog and is 
thus dominant over the Smoothened-independent inhibition of its enzymatic activity. 
Intriguingly, purmorphamine results in a downregulation of Rho-associated protein 
kinase (ROCK). ROCK is important for a variety of cellular processes, but in 
particular for cytoskeletal reorganization[52]. It was earlier established that 
Smoothened is a powerful mediator of chemotactic responses, but only so when not 
located at the primary cilium[34]. At the primary cilium, Smoothened loses its 
capacity to stimulate chemotaxis. The apparent downregulation of ROCK activity 
following purmorphamine stimulation is thus best explained by a purmorphamine-
dependent recruitment of Smoothened to the primary cilium. The strong canonical 
responses to purmorphamine stimulation observed by others would agree with this 
notion, as would the marked downregulation of PKA activity in our profiles. In 
some aspects, the rapid Smoothened-independent effects and rapid Smoothened-
dependent effects on cellular kinase activities studied in our experimental set up, are 
similar, as both provoke mTOR activation and, in our model system, activation of 
Wnt signaling. In this sense, non-canonical signaling downstream of Patched and 
Smoothened may converge to produce the final phenotype. It is important to stress 
that our set up does not allow studying the effects of canonical Hedgehog signaling, 
which requires transcriptional responses. Generally speaking canonical signaling 
and non-canonical signaling by morphogens counteract each other and the effects 
observed in this study partially substantiate that notion for Hedgehog signaling as 
well. Not seen downstream of specific Smoothened stimulation were strong pro-
inflammatory responses, which therefore seem mainly Patched-dependent. 
Generally speaking, Patched-specific signaling events (i.e. the effects of Hedgehog 
stimulation on Smoothened-/- fibroblasts) were less pronounced as those provoked 
by purmorphamine stimulation as also evident from the number of peptides that 
became significantly phosphorylated (see experimental procedures), in casu 180 
peptides in Hedgehog-stimulated Smoothened-/- fibroblasts and 134 in 
purmorphamine-stimulated wild type fibroblasts. It thus appears that the major 
branch of non-canonical Hedgehog signaling is downstream of Patched but not of 
Smoothened. 
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Implications of Patched-dependent Smoothened-independent non-canonical 
Hedgehog signaling 
Literature data indicate that the final effect of Hedgehog in physiology and 
pathophysiology is resultant from the integration of canonical and non-canonical 
Hedgehog signaling[29, 46]. Aberrant Hedgehog signaling is an important factor in 
human disease and accordingly inhibiting Hedgehog signaling has received 
substantial attention and various trials employing pharmacological inhibitors of 
Hedgehog signaling have been developed. Especially Vismodegib and Sonidegib 
have met with success in diseases driven by canonical Hedgehog signaling, in 
particular dermatological cancer[53]. Despite the evidence, however, that Hedgehog 
signaling is important for many gastrointestinal cancers[54], trials in this type of 
disease have not yet proven successful. In view of our data presented above that 
Patched and not Smoothened is a major mediator of non-canonical Hedgehog 
signaling and the momentum-gaining notion that especially non-canonical 
Hedgehog signaling may be important for maintaining gastrointestinal cancer[29], 
this may not be surprising. Vismodegib and Sonidegib target Hedgehog signaling at 
the level of Smoothened and leave Patched-dependent non-canonical Hedgehog 
signaling unaffected. Especially in view of the Patched-dependent Smoothened-
independent Wnt signaling, one can easily imagine that especially the non-canonical 
branch of Hedgehog signaling is important in supporting growth in the 
gastrointestinal compartment. An implication of our results is thus that future 
Hedgehog-based therapy with respect to gastrointestinal cancer should be directed at 
counteracting the interaction of Patched with Hedgehog rather than the current 
strategy of targeting Smoothened. 
Conclusion 
Here we characterize the non-canonical aspect of Hedgehog signaling. We observe 
that such non-canonical signaling mainly involves Patched-dependent Smoothened-
independent signaling, with especially mTOR signaling, the activation of 
cytoskeletal remodeling and the activation of Wnt signaling being prominent 
elements. Thus, for efficient targeting of Hedgehog-dependent signaling, it may 
prove essential to target such signaling at the level of Patched and not Smoothened. 
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Abstract 
Atrophic gastritis (AG) and intestinal metaplasia (IM) are generally regarded as a 
precancerous condition associated with Helicobacter pylori and strongly predispose 
to the development of gastric cancer. Although the accurate diagnosis is essential for 
preventing gastric cancer, in practice many physicians rely solely on visual 
endoscopic inspection to rule out the presence of AG. It is thus important to verify 
the validity of such endoscopic inspection to the gold standard (histological 
diagnosis by the pathologist) in a variety of settings, also because incidence and 
presentation of AG is highly variable in geographical terms. This consideration 
prompted us to conduct a retrospective cohort study involving 248 patients of which, 
124 are from low-incidence Nigeria and 124 from high incidence Iran, all aged 
50±30 years. The extent of endoscopic atrophy was classified into five subgroups 
according to a modified Kimura–Takemoto classification system and was compared 
with histological findings of atrophy at five biopsy ,sites according to the updated 
Sydney system. The strength of agreement between endoscopic and histological 
atrophy was moderate and showed a substantial geographical discrepancy, indicating 
that relying solely on endoscopic screening for AG requires local validation. 
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Introduction 
Gastric cancer (GC) remains the second most leading cause of cancer-related deaths 
and ranks 4th in cancer incidence worldwide[1, 2]. Incidence rates and presentation 
of gastric cancer show, however, marked regional differences, European countries 
tend to have a low incidence[3]. In contrast, in Iran for instance stomach cancer 
together with breast cancer has the highest incidence and highest mortality of all 
types of oncological disease in this country[4]. In contrast, gastric cancer has a low 
prevalence in sub- Saharan Africa with the lowest incidence rates in Western 
Africa[5]. Thus, gastric cancer is constitutes a global health issue, but presentation is 
markedly different in various parts of the world, raising questions as to whether 
screening strategies should to be tailored according to geography. 
Appropriate screening is important as the prognosis of gastric cancer varies 
dramatically according to disease stage. The 5-year survival rate for advanced 
gastric cancer is less than 20%. In contrast, early gastric cancer (EGC) has a good 
prognosis, with reported 5-year survival rates being in excess of 90 % or even 95 
%[5, 6]. The main risk factors for gastric cancer are Helicobacter pylori infection, 
salt intake, smoking, alcohol, a family history of gastric cancer, atrophic gastritis 
(AG), and intestinal metaplasia (IM)[7]. Especially AG and IM are important as they 
are considered to be premalignant lesions of gastric cancer[7, 8]. Hence accurate 
detection of AG and IM is essential for effective combat of gastric cancer.  
AG and IM have multiple etiologies but the most important risk factor for these 
conditions is Helicobacter pylori infection[9-11] and according H. pylori eradication 
therapy provides a preventive effect with respect to gastric cancer development[12, 
13]. Thus it is especially important to establish that screening for H. pylori-
associated is adequate and appropriate irrespective of the geographical context. 
Currently the gold standard for the diagnosis of AG and IM is histological 
evaluation of biopsies by the pathologist[14]. In practice, however, in many cases 
physicians rely on endoscopic evaluation, especially for making a diagnosis of 
atrophy. Especially the endoscopic atrophy classification (EAC) according to 
Kimura and Takemoto[15, 16] is frequently been used to evaluate the atrophic 
degree of gastric mucosa. However, although intraobserver agreement for gastric 
mucosa atrophy using the Kimura-Takemoto Classification. tends good to excellent, 
interobserver agreement is moderate even in experienced endoscopists[17], 
suggesting that histology-free evaluation may be suboptimal. Surprisingly, however, 
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the correlation between endoscopic evaluation and histological final diagnosis has 
been relatively underexplored. Generally speaking published studies support that 
endoscopic evaluation performs well with respect to the detection of histological IM 
and AG[18, 19]. However, these studies were performed in specific east-Asian high 
risk cohorts and the extent as to which these results can be extrapolated to the global 
situation remains uncertain, Data in patients specifically following H. pylori 
eradication are not present at all. Thus there is paucity in studies assessing the 
accuracy of endoscopic detection of AG in different settings. 
The above mentioned considerations prompted us to investigate the concordance 
between histological diagnosis and endoscopic diagnosis employing the Kimura-
Takemoto Classification of AG in a variety of geographical settings. The results 
show that irrespective of the context endoscopic evaluation performs well. 
MATERIALS AND METHODS 
Study population 
The study population consisted of a total of 248 (Nigeria-cohort: 124, Iran-cohort: 
124) patients who underwent both upper gastrointestinal Zoom endoscopy and  
examination for detection of H. pylori. The Nigeria cohort was collected at the 
University of Abuja Teaching Hospital, Gwagwalada. Abuja. Nigeria and the Iran 
cohort at the Department of Medical Laboratory Sciences. Marand Branch, Islamic 
Azad University, Marand, Iran. Only patients presenting between January 2007 and 
August, 2017 were evaluated in this study. Exclusion criteria were as follows: 
patients with prior history of gastrectomy, endoscopic evidence of reflux 
esophagitis, peptic ulcer disease, or malignancy and patients who had been treated 
with antibiotics, proton-pump inhibitors, bismuth-containing compounds or 
histamine H2 receptor blockers within four weeks before the endoscopic procedure.  
Patients were also excluded if they had received H. pylori eradication therapy in the 
past or had been treated with any non-steroidal anti-inflammatory drug in the two 
weeks leading up to the endoscopic procedure. The protocol was approved by the 
Ethics Committee of the University of Abuja Teaching Hospital, Gwagwalada. 
Abuja. Nigeria and Department of Medical Laboratory Sciences. Marand Branch, 
Islamic Azad University, Marand, Iran. All patients gave written informed consent 
before entering the study. Two-hundred and forty-eight patients satisfied the criteria, 
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and systemic map biopsies were taken. In total, 131 men and 117 women; mean age, 
46 years; range, 20–80 years were studied.  
Histological examination 
Records of biopsy sampling and the subsequent histological analysis by the 
gastroenterological pathologist were retrieved and reviewed. Biopsy samples used 
for the analysis were those obtained using standard biopsy forceps from the five 
sites specified in the updated Sydney system (Figure 1) and had to be processed 
according to convention procedures. With respect to the latter, each tissue sample 
included was placed in a separate bottle of 10% formalin and embedded in paraffin 
for sectioning. Sections were stained with hematoxylin and eosin (HE) and 
evaluated according to established procedures. All the specimens were scored by 
expert gastrointestinal pathologists. For analysis of specimens with IM, PAS and 
Alcian blue 2.5 staining had to be used to identify the IM subtypes. Gastric atrophy 
was defined as apparent chronic inflammation of the gastric mucosa with 
concomitant loss of the gastric glandular cells and their replacement by intestinal-
like epithelium, pyloric-like glands, and fibrous tissue. In each single biopsy, 
atrophy was scored as a percentage of atrophic glands. Non-metaplastic and 
metaplastic atrophy were considered together. For each biopsy sample, atrophy was 
scored on a four-tiered scale (no atrophy = 0%, score = 0; mild atrophy = 1–30%, 
score = 1; moderate atrophy = 31–60%, score = 2; and severe atrophy >60%, score = 
3). The OLGA stage resulted from the combination of the overall “antrum score” 
with the overall “corpus score” [20]. In each specimen, IM was subject to Markov 
classification (absent or present), and “extensive intestinal metaplasia” was deemed 
present if IM appeared in two or more specimens of the same patient. A patient was 
considered to have incomplete IM subtype if the incomplete subtype appeared in at 
least one specimen. Gastric dysplasia was assessed according the revised Vienna 
classification[21]. In this study, the expert gastrointestinal pathologists were blinded 
to the age and sex of the subjects. The graded features were scored according to the 
updated Sydney system for atrophy[22]. Patients were considered positive for 
histological atrophy if the score was mild, moderate or marked in each location. 
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Endoscopy examination 
All of the endoscopic examinations were performed and assessed by one 
experienced endoscopist (G.A and K.D) who had been trained to evaluate EGA at 
the University of Abuja Teaching Hospital, Gwagwalada. Abuja. Nigeria and 
Department of Medical Laboratory Sciences. Marand Branch, Islamic Azad 
University, Marand, Iran respectively. Olympus video-scopes with conventional 
white light (model GIF-160; Olympus) were used. The endoscopic mucosal atrophy 
was evaluated according to the location of the endoscopic atrophic border described 
by Kimura and Takemoto[17]. This atrophic border is the boundary between the 
pyloric and fundic gland regions, which is endoscopically recognized by the 
difference in color and height of the gastric mucosa between the two sides of the 
border (Fig. 1). There are three grades of EGA: severe (O2 – O3), moderate (C3 – 
O1), and mild (C1 – C2). Six specimens were taken from each patient: five 
specimens were taken from specific locations according to the updated Sydney 
System and were put in separate boxes for pathologic examination; the 6th specimen 
used for rapid urease test was taken from the greater curvature of the antrum. 
Level of agreement definition  
The endoscopic findings of the extent of atrophy were compared with the 
histological findings of glandular atrophy at five biopsy sites (Figure 1). To be able 
to compare the extent of atrophy strictly, both classifications were modified to five 
grades according to definitions of those anatomical locations. Histological grading 
was scored as 1, none; 2, antrum (site 1 and/or 2); 3, angulus (up to site 3); 4, the 
middle body of the lesser curvature (up to site 4) and 5, the middle body of the 
greater curvature (up to site 5). Endoscopic atrophic grading according to the 
modified Kimura–Takemoto classification was scored as 1, none; 2; antral (C-1); 3, 
antral predominant (C-2); 4, corpus predominant (C-3, O-1, O-2) and 5, pan-atrophy 
(O-3) (Figure 3). Inasmuch as extensive atrophy is associated with a much higher 
cancer risk than limited atrophy, the Kimura–Takemoto classification was simplified 
to three grades of cancer risk oriented atrophy as: normal (no atrophy), limited 
atrophy (antral and antral predominant atrophy; C-1, C-2) and extended atrophy 
(corpus predominant and pan-atrophy; C-3, O-1, O-2, O-3). Agreement was defined 
as matching of endoscopic and histologic grades, with all other findings defined as 
disagreement. 
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Serum pepsinogen levels 
Fasting serum was collected from all subjects. The samples were centrifuged 
immediately at 4 °C and serum stored at −70 °C until used. Serum concentrations of 
pepsinogen (PG) I and II were measured using a latex-enhanced turbidimetric 
immunoassay, and the PG I to PG II ratios (PG I/II) were calculated. 
Helicobacter pylori  detection. 
Serum samples from all patients were tested by enzyme linked immunosorbent assay 
for the presence and concentration of IgG antibodies to H. pylori (HM-CAP; Enteric 
Products Inc., Westbury, NY). A concentration ≥1.8 was defined as positive 
(sensitivity 98.7%, specificity 100%).We also employ the gold standard for H. 
pylori detection by culture. Following collection of gastric biopsy, samples were 
homogenized and cultured onto Brucella agar supplanted with 5% sheep blood and 
antibiotics (Vancomycin, Amphotericin B and Trimethoprim). Culture plates were 
incubated at microaerophilic condition, 37 ºC and high humidity for 5-7 days. 
Organisms were identified as H. pylori based on colony morphology, gram staining 
and positive oxidase, catalase and urease tests. 
Statistical analysis 
STATA software (version 10.0; Stata Corp, College Station, TX, USA) was used. 
Chi-squared test and Fisher’s exact test were applied to evaluate endoscopic, 
histological, and serological parameters in patients with gastric atrophy. Agreement 
between endoscopic and histologic evaluations of the grade of gastric atrophy was 
assessed by determining the weighted kappa value. Factors associated with 
extensive atrophy were estimated by univariate logistic regression analysis. 
Covariates showing a significant association with extensive atrophy by the χ2 or t 
test were included in multiple logistic regression analyses. Odd ratios (ORs) and 
95% confidence interval (CI) were calculated to assess the strength of association 
between variables. A  P value < 0.05 was considered statistically significant. 
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RESULTS 
Demographic data 
A total of 248 patients aged 50±30 years were included in this study, including 124 
patients from Nigeria and 124 from Iran. Mean ± SD patient age was 46.4 ( ± 15.3) 
years. Of these patients, 131(52.8%) were male, 117 female;(47.2%). Gender ratio 
F/M :0.89 and 138 (55.6%) were serologically H. pylori-positive. The detailed 
characteristics of the two subgroups are shown in Table 1. There were significant 
differences between the groups from the Nigeria and Iran, especially with respect to 
the extent of atrophy. In the Nigerian population, only 60.% were diagnosed 
histologically of having corpus atrophy, whereas, in Iran, 54% had gastric atrophy 
while 57 (46.0%) showed no evidence of histological atrophy. Hence geographical 
origin influences disease presentation necessitating comparison of the relative 
performance of endoscopy with respect to the diagnosis of AG. 
Table 1: Demographic, endoscopic, and pathologic characteristics of study 
population with H pylori  associated gastric atrophy. 
 Nigeria (n = 124) (%) 
Iran (n =124) 
(%) 
Total (n =248) 
(%) 
P value (Nigeria 
vs Iran) 
Clinical parameters 
 
Sex 
Male 62 (50.0) 69 (55.6) 131 (52.8) 
0.37 
Female 62 (50.0) 55 (44.4) 117 (47.2) 
Age (yr)  
≥ 40 69 (55.6) 68 (54.8) 137 (55.2) 
0.89 
< 40 55 (44.4) 56 (45.2) 111 (44.8) 
Helicobacter pylori Ag  
Positive 40 (32.3) 88 (71.0) 128 (51.6) 
0.84 
Negative 84 (67.7) 36 (29.0) 120 (48.0) 
Helicobacter pylori IgG  
Positive 89 (71.8) 49 (39.5) 138 (55.6)  
0.00 
 Negative 35 (28.2) 75 (60.5) 112 (45.4) 
Serologic features (ng/mL), mean ± SD  
Pepsinogen I 49.9 ± 39.2 57.8 ± 38.1 53.1 ± 38.7 0.731 
Pepsinogen II  12.9 ± 7.2 12.1 ± 10.1 12.9 ± 8.65 0.621 
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Pepsinogen I/II ratio 5.4 ± 1.8 <5  0.471 
Endoscopic atrophy  
No atrophy 50 (40.3) 67 (54.0) 117 (47.2) 
 
 
 
0.00 
Antral (C-1) 43 (34.7) 36 (29.2) 79 (31.9) 
Antral predominant (C-2) 26 (20.9) 0 (0.0) 48 (19.4) 
Corpus predominant (C-3-O-2) 5 (4.03) 21 (17.0) 26 (10.5) 
Histological atrophy  
None 50 (40.3) 57 (46.0) 107 (43.1) 
0.00 
Antrum 38 (30.2) 41 (33.0) 79 (31.8) 
Angulus 20 (16.13) 26 (20.5) 46 (18.5) 
Lesser curvature of middle body 16 (12.9) 0 (00.0) 16 (6.5) 
Greater curvature of middle body 0 (0.0) 0 (00.0) 0 (0.0) 
Intestinal Metaplasia 85 (68.5) 63 (50.8) 148 (59.7) 
0.06 
Complete subtype 46 (37.1) 32 (25.8) 78 (31.4) 
Incomplete subtype 30 (24.2) 26 (20.9) 56 (22.5) 
Unidentified 9 (7.2) 5 (4.1) 14 (5.6) 
Agreement between endoscopic and histological atrophy 
The comparisons between endoscopic and histological atrophy scores are shown in 
table 2. Taking the study population in toto, of the 248 patients, 138 (55.0%) 
showed complete agreement between endoscopic assessment and final histological 
diagnosis. Importantly, the strength of agreement between the modified Kimura–
Takemoto classification and histological atrophy, as defined by the updated Sydney 
system, showed good reproducibility, with a weighted kappa value of 0.89 [95% 
confidence interval (CI) 0.68–0.96]. However, a total of 110 patients were 
endoscopically misdiagnosed, including 45 (18.14%) who were over-diagnosed and 
65 (26.2%) who were under-diagnosed. Of the 43 patients histologically diagnosed 
with atrophy in the middle of the body of the greater curvature, 21 (49 %) were 
under-diagnosed endoscopically. Moreover, 30 of 110 (127.3%) patients without 
histological atrophy were endoscopically over-diagnosed with antral or antral 
predominated atrophy. Thus generally speaking endoscopic assessment performs 
well but is not sufficient for accurate diagnosis 
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 Factors affecting Agreement 
To identify factors affecting the agreement between endoscopic and histological 
atrophy, univariate analyses were performed; factors analyzed included geopgraphy 
(Nigeria vs Iran), age, sex, H. pylori infection, endoscopic atrophy (no atrophy vs 
others) and PG I/II ratios. Factors significantly associated with reduced performance 
of endoscopy included Iran ethnicity (P < 0.001), older age (P < 0.001), a low 
pepsinogen I/II ratio (P = 0.015), the endoscopic dwetection of atrophy (P < 0.001) 
and H. pylori infection (P = 0.001) (Table 3). In contrast, age was not significantly 
associated with reduced Agreement (P = 0.138). Multivariate analysis showed that 
only three factors were independently associated with reduced agreement: Iranian 
ethnicity, older age and endoscopic atrophy (Table 4). Thus the performance of 
endoscopic evaluation is influenced by the geographical context. 
Table 3:  Factors that significantly associated with reduced concordance between 
endoscopic and histological atrophy with H pylori Associated gastric atrophy cases. 
 Agreement  
group  
(n = 180) (%) 
Disagreement 
group 
 (n = 58) (%) 
OR(95%CI) P value 
Country     
Nigeria 98 (51.6) 38 (65.5) 0.22 (0.23 -0.76) <0.001 
Iran 92 (48.4) 20 (34.5) 1  
     
Age (yr)     
≥ 40 109 (57.4) 30 (51.7) 0.14 (0.09 -0.40) P=0.148 
< 40 71 (42.6) 28 (48.3) 1  
     
Helicobacter pylori 
IgG 
    
Positive 111 (58.2) 32 (55.2) 0.40 (0.30 -0.55) P=0.001 
Negative 69 (36.3) 26 (44.8) 1  
Serologic features 
(ng/mL) 
    
Pepsinogen I 120 (63.2) 38 (65.5) 0.23 (0.20 -0.45) P=0.001 
Pepsinogen II 70 (36.8) 20 (34.5) 1  
Endoscopic atrophy     
No atrophy 89 (46.8) 22 (37.9) 1  
Others 101 (53.2) 36 (62.1) 0.38 (0.22 -0.67) <0.001 
Helicobacter pylori 
111 
Further assessments according to factors significant on multivariate analysis 
To further assess the disagreement between histological and endoscopic atrophy, 
patients were cross-tabulated by each factor found to be significant (Table 4). 
Although the performance of endoscopic evaluation was diminished in extensive 
atrophy in both populations, the geographical context influenced the extent of this 
misdiagnosis. More specifically, 24 (19.35%) of the 124 Nigeria patients were 
misdiagnosed, including 15 who were over-diagnosed with histological atrophy of 
the antrum or angulus. In contrast, 57 (45.2%) of the 126 Iranian patients, of all 
histological grades, were misdiagnosed, including 22 who were over-diagnosed and 
35 who were under-diagnosed. This further analysis supports the notion that the 
performance of endoscopic evaluation solely is significantly influence by the 
different presentation of disease in alternative geographical locations. 
Table 4. Factors that significantly associated with reduced concordance between 
endoscopic and histological atrophy with H pylori-associated gastric atrophy cases. 
 Adjusted OR (95%CI) P values 
Country   
Nigeria 1 <0.001 
Iran 0.23 (0.11–0.56)  
   
Age (yr)   
≥ 40 1 0.268 
< 40 0.6 (0.31–1.38)  
Helicobacter pylori IgG   
Positive 1  
Negative 0.32 (0.16–0.66) 0.008 
Pepsinogen I/II ratio   
> 3.0 1  
≤ 3.0 0.50 (0.67–3.35) 0.328 
Endoscopic atrophy   
No atrophy 1 0.256 
Others 0.09 (0.04–0.56)  
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Cancer risk-oriented atrophy grading 
When classified according to cancer risk-oriented atrophy grading defined above, 
110 (88.1%) of the 248 patients were concordant (Tables 5 and 6). The strength of 
agreement between endoscopic and histological assessment by cancer risk-oriented 
grading showed good reproducibility, with a weighted kappa value of 0.79 (95%CI: 
0.60–0.97). No marked differences between the two geographical locations involved 
appeared. Thus with respect to assessing cancer risk endoscopic evaluation performs 
well irrespective from the geographical context. 
Table 5. Endoscopic and histological atrophy cross tabulation according to 
populations with H pylori   associated gastric atrophy 
  Histological atrophy 
Total Weighted κ value 
Nigeria 
 None Antrum Angulus 
Middle 
body LC 
Middle 
body 
GC 
Endoscopic 
atrophy 
No atrophy 40 4 4 2 0 56 
0.79 
Antrum 8 30 5 0 0 40 
Antrum 
predominant 0 2 3 0 0 24 
Corpus 
predominant 4 0 10 12 0 6 
 
Total 52 36 22 14 0 124  
         Iran         
Endoscopic 
atrophy 
No atrophy 31 17 10 09 0 67 
0.96 
Antrum 10 12 4 10 0 36 
Antrum 
predominant 0 0 0 0 0 0 
Corpus 
predominant 8 3 0 10 0 21 
 
Total 49 32 14 29 0 124  
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Table 6: Risk factors-associated with cancer 
  
Histological atrophy Total Weighted κ value  
  
Normal Limited Extended 
 
Endoscopic 
atrophy 
Normal 70 5  75 
0.79 
 
Limited (C-1~2) 24 80 7 107 
 
Extended (C-3~O-3)  12 52 62 
 
 
Total 92 97 59 248 
 
 
concordance 
 
endoscopic over-
diagnosis 
 
endoscopic under-
diagnosis 
Association between OLGA Gastritis Stage, Endoscopic gastric atropy and 
Intestinal Metaplasia 
Intestinal metaplasia, extensive IM, and incomplete IM subtype also clustered to the 
subgroup of patients with high-stage OLGA gastritis (Table 8). 
Table 7. Association between endoscopic gastric atrophy and metaplasia 
Endoscopic gastric atrophy 
 
Moderate-to severe  
(n = 40) 
None-to-mild  
(n =38) P (X
2 test) Adjusted Odd ratios (95% CI) 
 
Complete IM 27.5% (11/40) 47.34% (18/38) <0.001 21.3 (8.7–35.2) 
 
Incomplete 
 
30.0% (12/40) 31.6% (12/38) <0.001 33.5 (7.4–37.3) 
 
Unidentified 
 
42.5 % (17/40) 36.84(14/38) <0.001 41.7 (4.1–74.1) 
IM, intestinal metaplasia 
Table 8.  The association between OLGA gastritis stage and intestinal metaplasia 
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 OLGA gastritis stage 
 Stage 0–II (n = 121) Stage III, IV (n = 47) p (Fisher’s exact) Odd ratios (95% CI) 
IM 49.58 (60/121) 38.29 (18/47) <.001 24.6 (05.7–72.5) 
Extensive 26.45 (32/121) 25.53 (12/47) <.001 22.6 (07.8–82.9) 
Incomplete  
subtype 18.18 (22/121) 21.27 (10/47) <.001 33.7 (04.5–62.8) 
Unidentified 
subtype 4.13 (7/121) 0 (0/47)   
Seven cases with unidentified IM subtype were all in OLGA gastritis stage 0–II. 
When we subsequently analyzed only patients with gastritis stage 0–II only, there 
was no homogenous distribution of IM subgroup: We rarely found patients with IM 
none-to-mild EGA, while it clustered to patients with moderate-to-severe 
endoscopic gastric atrophy (Table 7). We also found that there was an association 
between the gastric atrophy and the subtype of IM. From a total of 59.7% (148 /248) 
in our entire study population,  46(37.1%) and 32(25.8%) from Nigeria and Iran 
respectively had the complete subtype of IM while 30 (24.2%) and 26 (20.9%) 
patients from Nigeria and Iran respectively presented with the incomplete IM. In 
addition, 9 (7.2%) and 5 (4.1%) patients from Nigeria and Iran respectively were 
classified as indeterminate IM. Thus also with respect to the presentation of IM, 
important regional differences are apparent, further highlighting the necessity to 
tailor screening strategies to local needs. 
Discussion. 
The natural history of the development and progression of gastric cancer in general 
and especially the role of H. pylori infection in this process is now fairly well 
understood and involves sequence of gastric mucosal atrophy, intestinal metaplasia, 
and gastric cancer[23]. This has led to the realization that endoscopic screening in 
high-risk individuals is essential for preventing the associated mortality. The 
efficacy of such screening obviously depends on adequate diagnosis in which 
histological assessment of biopsies taken by the endoscopist remains the gold 
standard. The updated Sydney system was designed to assess histological gastritis 
and atrophy more objectively and has become the international standard[24]. 
Although this classification includes assessment of five biopsy sites, this extensive 
Helicobacter pylori 
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approach is not common in daily practice, because of patient discomfort, cost, 
logistic and time restrictions. Hence, many physicians rely to an important extent on 
endoscopic evaluation for the detection of AG. To which extent this is a problem is 
not well understood. A Swedish study found a sensitivity and specificity for 
moderate to severe atrophic gastritis in the gastric corpus of 67 % and 85 %, 
respectively[25] and concluded that macroscopic features as observed during 
gastroscopy are of very limited value in the evaluation of whether or not gastritis or 
H. pylori infection are present. A Korean study, however, reported that endoscopic 
and histological atrophic gastritis show relatively good correlations[16, 25]Hence 
further studies, investigating presentation in different geographical contexts are 
necessary to clarify to which extent endoscopic observation alone can accurately 
assess AG. The present study was initiated to fill this void. 
Our results show that the efficacy of endoscopy to detect AG is moderate and shows 
substantial regional variation, possibly caused by different presentation and 
incidence of AG at different locations around the globe. Generally speaking the 
performance of endoscopic screening is not good enough to rely on it alone and 
histological confirmation of the endoscopic diagnosis remains necessary. In 
conjunction with geographical variations in the performance of endoscopic 
observation to detect AG, it is fair to say that local validation remains essential. The 
agreement rate for atrophy was significantly higher for patients in the Nigerian than 
for those in Iran. Much more patients, however, in the Iranian cohort displayed 
extended atrophy, which is more easily misdiagnosed. The two populations also had 
different concordance between endoscopic diagnosis and microscopic diagnosis in 
the multivariate analysis, suggesting that this difference may be associated with 
differences in the background of the two populations. Indeed, the two populations 
differed in host genetic factors, diet, and bacterial virulence. For example, there are 
ethnic and.or geographical differences in the H. pylori cytotoxin associated gene A 
(CagA), one of the most important virulence factors for gastric mucosal injury and 
atrophy. The CagA gene is polymorphic and is primarily classified into East Asian 
and Western types based on sequences in its 3′ coding region[10]. Previous studies 
have clarified the differences in gastritis and atrophy among patients infected with 
East Asian CagA-positive, Western CagA-positive, and CagA-negative H. 
pylori[26]], with differences in virulence ppotentially provoking differences in 
agreement rates. In Iran the cagA gene genotype was found to predominate in gastric 
adenocarcinoma patients[27]. But obviously further studies, linking such variations 
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directly to concordance between endoscopic and histological diagnosis are necessary 
to substantiate this notion. 
We observed that older age predisposes for discordance between the endoscopic 
assessment and the histological diagnosis, The histological structures of the normal 
antral and corpus mucosa differ, with the border between these two areas located at 
the angulus. This anatomically defined border is difficult to detect clearly using 
conventional endoscopy[27, 28][27, 28][27, 28] although it can be better detected 
using high definition equipment. However, a slight difference in color between the 
antrum and the corpus may occur in the absence of histological atrophy. Mistaking 
this anatomical border for the atrophic border may result in over-diagnosis. We 
found that older patients, particularly older Iranians, tended to be over-diagnosed. 
Two possibilities may explain this finding. The first may have been bias in the 
endoscopist prompted by the notion that elderly Iranians are more likely to be 
infected with H. pylori. The second reason is that gastric mucosal blood flow 
decreases with age[29, 30], which may affect mucosal appearance. Because of the 
slight differences in mucosal color, the endoscopist may mistake normal for atrophic 
antral mucosa in older patients. It is clear, however, that special care should be taken 
in older patients and that the practitioner should not submit to the temptation to rely 
solely on endoscopic diagnosis.  
Conclusion 
Although routine endoscopy can assess precancerous conditions by evaluating the 
extent of gastric atrophy, agreement between endoscopic and histological atrophy is 
unclear and always requires local validation. Endoscopic atrophy grading can 
predict extensive histological atrophy and may serve as a practical assessment of 
precancerous conditions during endoscopy in routine clinical practice, especially for 
patients in Western countries. 
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Abstract 
Background: Although the causal relationship between Helicobacter pylori-
infection and the development of gastric cancer is firmly established, the exact 
nature of the virulence factors of H. pylori that predispose to gastric oncogenesis 
remains incompletely characterized. Such knowledge would aid stratification of H. 
pylori-infected individuals with respect to their risk to GC. We decided to 
investigate the association between H.pylori virulence genotypes and disease in a 
well-characterised cohort consisting of 109 H.pylori isolates from gastric biopsies 
originating from patients. Methods: The prevalence of genotype was assessed by 
PCR and related to clinical histopathological parameters. Results:  We were able to 
identify association between genotypes and clinical outcome. The relation of babA2, 
babB negative and iceA1 positive genotype as a single genotype and the 
development of cases to GC (Signet Ring Cell Carcinoma) was statistically 
significant (P <0.001).The cagE, cagA, iceA1 were found more commonly in 
patients with GC as compared with the other patient groups. The relation of the 
presence of iceA1 and the development of cases to GC was statistically significant 
(P=0.008), but babA2, babB alleles were not detected in these GC patients. These 
apparent negative association were still statically significant (P=0&0.005). 
Conclusion: Our results show an elevated prevalence of infection with H. pylori 
strains carrying known virulence genotypes with high genetic diversity. This 
highlights the importance of identifying gene variants for an early detection of 
virulent genotypes. Also, the results identify H. pylori genotypes associated with 
clinical outcome that may become potentially useful for patient risk stratification for 
GC. 
Keywords: Helicobacter pylori, pathogenicity factors, gastric cancer 
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1. Introduction 
Gastric cancer remains a prevalent disease worldwide with a poor prognosis. 
Helicobacter pylori plays a major role in gastric carcinogenesis. H. pylori 
colonization leads to chronic gastritis, which predisposes to atrophic gastritis, 
intestinal metaplasia, dysplasia, and eventually gastric cancer. Screening, treatment, 
and prevention of H. pylori colonization can reduce the incidence of gastric 
cancer[1]. Other interventions that may yield a similar effect, although of smaller 
magnitude, include promotion of a healthy lifestyle including dietary measures, non-
smoking, low alcohol intake, and sufficient physical activity[2]. Furthermore, 
increasing evidence suggests that host factors, including genetic make-up, are also 
important determinants for carcinogenesis in H. pylori infection[3]. Colonization of 
H. pylori has been associated with chronic gastritis because it can trigger fulminant 
inflammatory response which can lead to pathological conditions such as Gastric 
carcinoma and peptic ulcer disease[4]. Consequently a clinical need exists to stratify 
H. pylori-infected patients with respect to their propensity to develop H. pylori-
related pathology, especially for GC this is felt as a pressing concern. The 
importance of H. pylori virulence factors is evident from the serious clinical 
outcome associated with bacteria positive for the vacillating cytotoxic (vacA) and 
the cytotoxin-associated gene A (cagA) antigen[5]. However, these two virulence 
factors are insufficient to explain the variety in clinical presentation of pathology 
associates with H. pylori infection[6, 7].  A potential H. pylori virulence factor 
possibly important to explain this variance in clinical outcome is the cag 
pathogenicity island (cag-PAI). The cagA gene is a marker for the presence of the 
cag-PAI of approximately 40 kb, whose presence is associated with the more severe 
clinical outcomes.[8, 9] A type IV secretion system translocate cagA protein into 
gastric epithelial cells, where it is phosphorylated. When this modification occurs, 
cagA affects various cellular processes and signal transduction pathways, such as 
disruption of tight and adherent junctions that lead to pro-inflammatory and 
mitogenic responses–effects [8, 10]. One of the six cag-PAI genes is cagE, located 
in the right half of the cag-PAI, that has been shown to induce secretion of 
interleukin (IL)-8, from infected host epithelial cells[11, 12]. 
Another putative virulence factor is iceA, whose gene has two main allelic variants, 
iceA1 and iceA2. The expression of iceA1 is up-regulated on contact of H. pylori 
with human epithelial cells and may be linked with peptic ulcer disease.[13, 14] The 
blood group antigen binding adhesin (babA), a 78-KDa outer membrane protein 
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encoded by the babA2 gene, binds to Lewis b antigens and ABO antigen[15, 16] 
Although three bab alleles have been identified (babA1, babA2, and babB), only the 
babA2 gene product is functionally active[17] Studies in Western populations have 
associated the presence of the babA2 gene with gastric cancer[16, 18]. The aim of 
this studies is to assess the genotype of H. pylori strains infecting patients with 
chronic gastritis through the evaluation of the prevalence of several genes coding for 
virulence factors. 
Materials and Methods  
This research was approved by the regional Medical Research Ethics Committee of 
Azad University of Medical Science on 19 Jul 2016 (No: 1311/28772) and all 
patients provided written informed consent for this research. 
This study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki as Reflected in a prior approval by the institution's human research 
committee. 
Patients, Bacterial strains and cultivation 
Our cohort consisted of 109 clinical isolates of H. pylori, 49 (45%) were from 
female and 60 (55%)  
From male patients (sex ratio F/M: 0.82); the average age of the patients from which 
the isolates were obtained was 39 ±17 years. H. pylori was isolated employing 
gastric biopsies of patients presenting with gastritis, peptic ulcer or gastric cancer. 
Patients were not exposed to antimicrobial agents at least one week before 
endoscopy was performed. Following collection, gastric biopsy samples were 
homogenized and cultured onto Brucella agar supplanted with 5% sheep blood and 
antibiotics (Vancomycin, Amphotericin B and Trimethoprim). Culture plates were 
incubated at microaerophilic condition, 37 ºC and high humidity for 5-7 days. 
Organisms were identified as H. pylori based on colony morphology, gram staining 
and positive oxidase, catalase and urease tests.  
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DNA extraction from culture 
Genomic DNA of total H. pylori isolates was extracted using the QIAmp DNA mini 
kit (QIAGEN, Hilden, Germany) according to manufacturer’s protocol and stored at 
-20 ºC until use. 
Detection of genes 
In this study, PCR was used to detect the H. pylori specific ureC gene for 
confirming that the cultures represented a bona-fide H. pylori isolate, and the same 
technique was employed to establish presence or absence of cagE, cagA, iceA1, 
iceA2 babA2 and babB genes.   
All primer sets were selected from published literature (listed in Table 1). PCR 
reactions were performed in a volume of 50 µL containing 10 mmol/L Tris-HCl, 1.5 
mmol/L MgCl2, 0.2 mmol/L of each deoxynucleotide, 25 pmol of each primer and 
2.5 units of Taq polymerase (Geneone, Germany)[19, 20]. The thermal cycler 
program used consisted of the following steps; initial denaturation at 94ºC for 3 min 
followed by 35 cycles of 30 seconds at 94ºC (denaturation), 30 seconds at 58ºC for 
cagA and glmM [21]; 30 seconds at 53ºC for cagE; 48°C for babA2, 49°C for babB, 
57ºC For iceA1 and 48ºC and for iceA2  all annealing steps, followed by 30 seconds 
at 72ºC (extension step) and a final extension step was 3 min at 72 ºC[22]. 
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Table 1: Primer sequences for polymerase chain reaction 
Gene Primer Nucleotide sequence Size 
(bp) 
Ref 
ureC 
(glmM) 
Hp-F GGATAAGCTTTTAGGGGTGTTAGGGG 
294 
(84) 
HP-R GCTTACTTTCTAACACTAACGCGC 
cagE 
cagE-F TTGAAAACTTCAAGGATAGGATAGAGC 
508 
(85) 
cagE-R GCCTAGCGTAATATCACCATTACCC 
babA2 
babA2-F CCAAACGAAACAAAAAGCGT 
271 
(6) 
babA2-R GCTTGTGTAAAAGCCGTCGT 
babB 
babB -F ATGAAAAAAACCCTTTTAC 
496 
(86) 
babB-R CGAATTGCAAGTGATGGT 
cagA 
cagA-F AGGGATAACAGGCAAGCTTTTGA 
352 
(87) 
cagA-R CTGCAAAAGATTGTTTGGCAGA 
iceA1 
iceA1-F GTGTTTTTAACCAAAGTATC 
247 
(84) 
iceA1-R CTATAGCCASTYTCTTTGCA 
iceA2 
iceA2-F GTTGGGTATATCACAATTTAT 
229 
(84) 
iceA2-R TTRCCCTATTTTCTAGTAGGT 
Statistics analysis 
Data were analysed by SPSS version 16. The Fisher's exact test or the Chi-square 
test was used for analysis of categorical data. A p-value of <0.05 was considered 
statistically significant. 
Results 
Description of the patient cohort and isolation of study samples 
A total of 109 H. pylori samples were isolated from an initial number of 359 
biopsies included in this study (yielding an apparent infection rate of 30.4%), of 
which 60 (55%) were derived from male patients and 49 (45%) isolates came from 
female patients (sex ratio F/M: 0.82). The average patients’ age at the time of 
endoscopy was 39 ±17 years. From the 109 patients with established H. pylori 
infection, 81 patients had presented with a non-ulcer dyspepsia, nineteen patients 
with a peptic ulcer dyspepsia and nine patients with GC (Signet Ring Cell 
50906 Adamu v2.indd   130 30-05-18   21:35
H-pylori pathogenicity factors
131
6
H.pylori pathogenic factors 
 
127 
Table 1: Primer sequences for polymerase chain reaction 
Gene Primer Nucleotide sequence Size 
(bp) 
Ref 
ureC 
(glmM) 
Hp-F GGATAAGCTTTTAGGGGTGTTAGGGG 
294 
(84) 
HP-R GCTTACTTTCTAACACTAACGCGC 
cagE 
cagE-F TTGAAAACTTCAAGGATAGGATAGAGC 
508 
(85) 
cagE-R GCCTAGCGTAATATCACCATTACCC 
babA2 
babA2-F CCAAACGAAACAAAAAGCGT 
271 
(6) 
babA2-R GCTTGTGTAAAAGCCGTCGT 
babB 
babB -F ATGAAAAAAACCCTTTTAC 
496 
(86) 
babB-R CGAATTGCAAGTGATGGT 
cagA 
cagA-F AGGGATAACAGGCAAGCTTTTGA 
352 
(87) 
cagA-R CTGCAAAAGATTGTTTGGCAGA 
iceA1 
iceA1-F GTGTTTTTAACCAAAGTATC 
247 
(84) 
iceA1-R CTATAGCCASTYTCTTTGCA 
iceA2 
iceA2-F GTTGGGTATATCACAATTTAT 
229 
(84) 
iceA2-R TTRCCCTATTTTCTAGTAGGT 
Statistics analysis 
Data were analysed by SPSS version 16. The Fisher's exact test or the Chi-square 
test was used for analysis of categorical data. A p-value of <0.05 was considered 
statistically significant. 
Results 
Description of the patient cohort and isolation of study samples 
A total of 109 H. pylori samples were isolated from an initial number of 359 
biopsies included in this study (yielding an apparent infection rate of 30.4%), of 
which 60 (55%) were derived from male patients and 49 (45%) isolates came from 
female patients (sex ratio F/M: 0.82). The average patients’ age at the time of 
endoscopy was 39 ±17 years. From the 109 patients with established H. pylori 
infection, 81 patients had presented with a non-ulcer dyspepsia, nineteen patients 
with a peptic ulcer dyspepsia and nine patients with GC (Signet Ring Cell 
50906 Adamu v2.indd   131 30-05-18   21:35
Chapter 6
132
Chapter 6 
 
128 
Carcinoma (SRCC). There was no significant difference between the mean age and 
sex of patients with and without ulcers and cancer. We concluded that our cohort 
would enable analysis of the link between H. pylori virulence factors and clinical 
presentation. 
The presence of virulence factors is common in the clinical cohort 
The PCR-based amplification showed that the cagE, babA2 and babB positive 
strains had a prevalence of respectively 55.9%, 71.7%, 61.3% in our cohort, whereas 
cagA, iceA1 and iceA2 were detected in respectively 70.6%, 42.2%, 13.2% of the 
patients included in this study (Table 2). Thus, the virulence factors selected for this 
study are commonly detected in our patient cohort and allow statistical analysis as to 
their relation to disease manifestation. 
Specific H. pylori virulence factors show trends of being positively or negatively 
associated with patient’s clinical presentation 
In our study the frequency of cagE-positive isolates obtained from patients with 
non-ulcer dyspepsia, peptic ulcer dyspepsia or GC patients was 49.4%, 68.4% and 
88.9%, respectively, but this apparent positive association with more severe disease 
did not reach statistical significance (P = 0.198). The babA2 genotype was detected 
in 74%, 84.2%, and 0% of isolates from NUD, PUD and GC patients, The 
percentage of babA2- genotype within GC patients was significantly higher than that 
of cagA+ genotype (P <0.001). 
Also the percentage of babB+ were 65.4% and  63.1% for NUD and PUD cases 
respective ,but for isolates from patients with GC (0%), this apparent negative 
association was statically significant (P = 0.005). Conversely the prevalence of the 
iceA2 allele was observed in NUD patients (13.6%) and in PUD (15.8%) and in GC 
patients (0%), but No significant association was observed between iceA2 genotype 
and GC (P = 0.779). Similarly, in this study the distribution of iceA1 and clinical 
outcome was analyzed statistically and it was observed that the frequency of iceA1-
positive isolates in NUD, PUD and GC patients was 35.8% and 42.1% and 100%, 
respectively. The relation of the presence of iceA1 and the development of cases to 
gastric cancer was statistically significant (P =0.008). 
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Although, the cagA allele was observed in NUD (65.4%) cases and in PUD patients 
(78.9%) and in GC patients (100%), there was not statistically significant 
association between cagA and the gastric outcomes (P =0.134). A full overview of 
all virulence factors studied and their linkage to specific clinical manifestations is 
provided through Table 2.  
Table2: Relationship between clinical outcome and status of cagE, babA2, 
babB, iceA1, iceA2, CagA   (NUD: Non-ulcer dyspepsia, PUD: Peptic ulcer 
disease, GC: gastric cancer, Pv: p-value) 
Genotypes 
Number (%) of isolates 
 Total (n=109)      p-value 
NUD (n=81) PUD (n=19)       GC (n=9) 
cagE 40 (49.4%) 13 (68.4%)        8 (88.9%) 61 (55.9%)          0.198 
babA2 60 (74%) 16 (84.2%)             0 76 (71.7%)          0.001 
babB 53 (65.4%) 12 (63.1%)             0 65 (61.3%)          0.005 
 iceA1  29 (35.8%) 8 (42.1%)          9 (100%) 46 (42.2%)          0.008 
iceA2  11 (13.6%) 3 (15.8%)              0 14 (13.2%)          0.779 
cagA  53 (65.4%) 15 (78.9%)       9 (100%) 77 (70.6%)          0.134 
It is apparent from our data that, cagE, cagA and iceA1 are more common in 
patients with gastric cancer than in the other patient groups, whereas babA2 and 
babB alleles were absent in patients with GC.Combining different virulence 
factors allow stratification of the patient cohort with respect to patient 
stratification 
We examined eight different combinations based on analysis of babA2, babB and 
iceA1 genotypes (positive and negative) in patients as a single genotype (Table 3). 
We were able to identify an association between these genotypes and clinical 
outcome. The frequency distributions of the combination genotypes of H. pylori 
showed the relation of babA2, babB negative and iceA1 positive genotype and the 
development of cases to gastric cancer was statistically significant (P <0.001) 
among the patient groups. But there was not statistically significant association 
between other genotype combination and the gastric cancer (P ≥0.113). 
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The apparent absence of babA2 and babB alleles in GC patients raise, however, 
hopes that larger studies may establish the usefulness of these alleles in guiding 
patient management. 
Table 3: Combination of babA2, babB and iceA1 genotypes and clinical 
outcome 
(Presence of a gene= positive, absence of a gene= negative, Pv: p-value) 
babA2 babB iceA1 GC 
(n=9) 
NUD 
(n=81) 
PUD 
(n=19) 
Total 
(n=109) 
p-
value 
Positive Positive Positive 0 19 6 25 0.113 
Positive Positive Negative 0 15 3 18 0.121 
Positive Negative Positive 0 12 2 14 0.136 
Positive Negative Negative 0 9 4 13 0.196 
Negative Positive Positive 3 7 1 11 0.216 
Negative Positive Negative 0 11 2 13 0.157 
Negative Negative Positive 6 3 1 10 0.001 
Negative Negative Negative 0 5 0 5 0.253 
Discussion 
Various studies have observed substantial differences in incidence and/or severity of 
gastroduodenal pathologies related to H. pylori which may vary according to 
geographical regions [26]. Although many factors may contribute to these 
differences, an obvious contributing factor is the different distribution of pathogenic 
markers in circulating strains [18]. The clinical relevance of the putative virulence-
associated genes of H. pylori and geographical region remains controversial. Other 
factors that influence the risks for atrophy and cancer in the presence of infection 
may be related to the time when infection occurred, to other environmental factors 
and to the host genetic variation [27]. In particular single nucleotide polymorphisms 
in genes that influence bacterial handling via pattern recognition receptors appear to 
be involved, further strengthening the link between host risk factors, H. pylori 
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incidence and cancer[28]. In the present study we exploited this situation to study 
the relationship between selected virulence genes of H. pylori and the clinical status. 
Our results clearly support the notion that further studies aimed at establishing the 
negative predictive value of the presence of babA2 and babB alleles for GC 
development are warranted. 
The cagE is a pathogenicity biomarker of H. pylori. A survey of previous studies 
suggested  that the cagE prevalence is different around the world [29]. The general 
importance of cagE is best illustrated by its high frequency in GC patients as 
demonstrated by studies performed in patient populations derived from India 
(100%), Turkey (81.8%) and Thailand (93.8%)[30]. however, the prevalence of 
cagE gene in this study was only 55.9%, markedly different from the results 
obtained in the aforementioned countries [31]. In the present study cagE-positive 
isolates were slightly more detected in isolates from peptic ulcer dyspepsia patients 
PUD (68.4%) patients, but the potential significance of this finding, if any, remains 
to be established. The prevalence of cagA gene in our cohort is 70.6%, which 
resembles the situation in Western countries (Yamaoka et al., 2002), but is markedly 
lower than that observed in East Asian countries where cagA is present in more than 
90% of cases (Uchida et al., 2009). Like cagE, cagA-positive isolates were enriched 
in samples obtained from peptic ulcer dyspepsia patients, albeit not in a statistically 
significant manner. Nevertheless, our findings support previous studies (Uchida et 
al., 2009, Wu et al., 2003) and should prove interesting to include our data in a 
meta-analysis of virulence genes in this respect. Our results show that the prevalence 
of iceA1 and iceA2 genes in isolates was 42.2% and 13.2%, respectively.  These 
results are in agreement with previous studies showing that the iceA1 gene is 
prevalent in Japanese, Korean and The Dutch patients (Ito et al., 2000, Ko et al., 
2008, Shiota et al., 2013) conversely the iceA2 allele was predominant in the United 
States and Colombia. In our cohort, the relation of the presence of iceA1 and the 
development of cases to gastric cancer was statistically significant (P=0.008). But 
our data showed that there was no significant association between iceA2 and GC 
compared with PUD or NUD. However, several studies have reported different 
results, as the iceA2 gene was detected to be predominant genotype in these studies 
(Aghdam et al., 2014, Biernat et al., 2014). 
The babA is one of the mediators for the attachment to gastric cells by H. pylori[32]. 
More recent analysis of babA2 as a virulence marker has produced conflicting data 
on the usefulness of babA2 expression in predicting clinical outcome, which is most 
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incidence and cancer[28]. In the present study we exploited this situation to study 
the relationship between selected virulence genes of H. pylori and the clinical status. 
Our results clearly support the notion that further studies aimed at establishing the 
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likely dependent on the geographic origin of the H. pylori strains. Survey of 
previous studies on Portuguese, Thai and India populations showed that, babA2 is 
not a marker for peptic ulcer disease or gastric cancer [12, 26, 33]. However, several 
studies have reported different results for strains isolated from Turkey or Germany 
[26, 34]. Our study suggests that babA2 “although quite prevalent” is associated 
with reduced propensity to develop GC and is thus associated with less oncogenic H. 
pylori. Similar results were obtained concerning babB.   
Our results showed the relation of babA2, babB negative and iceA1 positive 
genotype and the development of cases to gastric cancer was statistically significant. 
Further studies are required to determine the functions of babA2 and babB and their 
relationship with disease outcome, and whether the presence of these alleles 
indicates the presence of bacteria unlikely to confer progression towards GC. 
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Abstract 
Among the most quoted reasons for defending spending by governments on space 
programs is the scientific knowledge and advances we gain that also have a positive 
impact back on earth, for which altered immunity in microgravity is one of these. 
Although the mechanisms involved remain primarily obscure and controversial, 
detection of these mechanisms may well be of importance that supersedes the field 
of microgravity research itself: autoimmune disease poses an ever more significant 
challenge to society, and novel therapeutic angles to combat immune system 
overactivation are urgently called for. Thus it is being claimed that the extensive 
efforts society makes about supporting space-based experimentation can be justified 
from the promise that identification of the molecular mechanisms by which 
microgravity interacts with the immune system will provide new clues as for how to 
therapeutically interfere with immune overactivity. Although data are limited, ,the 
effects on signaling most likely involve alterations in Rac signaling and thus 
microgravity provides new insight into the role of Rac and especially its downstream 
impact on cytoskeletal architecture in immune signal transduction. This has 
significant implications: both functional in studies which suggest that at least for one 
autoimmune disease, in case of Crohn’s disease defects in innate immunity are 
causative, leading to excessive innate responses. Thus indeed it is at least 
theoretically possible that useful information may be obtained from space 
experimentation on human immunity. 
 
Keywords: Microgravity; Immunity; Signal transduction; Space travel; Innate 
immunity; Adaptive Immunity 
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Introduction 
Earth’s gravitational field predominate life evolution and has contributed to all 
biological systems architecture determinedly. It is hence not astonishing that abrupt 
variations in microgravity can lead to divergences in the regular functions of life and 
immune system. According to Brian Crucian in the NASA biological studies. The 
immune system of space crew members can be impaired by things like microgravity, 
radiation, microbes, and altered sleep cycles. And if conditions persist for a more 
extended period during a space mission, it could mimic chances of higher risk of 
infection, autoimmune disease and hypersensitivity for space explorers. 
Microgravity influences the human body system actively which might lead to wide 
range of symptoms that are deconditioning such as immune system deterioration, 
impaired cardiovascular system performance, demineralization of the bone and 
neurovestibular altered perception[1]. In short-term, space traveler presented depression 
of immune system, T lymphocytes reduced activation and virus latent reactivation[2, 3]. 
Prevailing strategies to establish a framework of infrastructure for profitable spaceports 
with the goa,l of creating spaceflight accessible and affordable to retail consumers 
advocate that we can anticipate spaceflight to increasingly become open to the public in 
nearest future[4]. A  vital means to travel across the globe will be through suborbital 
flights. As increasing commercial enterprises are already booking spaceflight 
experiences for paying customers, physicians may expect patients are inquiring about 
the risks or fitness for space travel [4, 5]. There is a need for extensive medical 
screening of intended travelers since a trip to the International Space Station takes two 
to three weeks[6]. Furthermore, aside from the physiological[5] and clinical 
implications of human spaceflight[4], exposure to microgravity[7], as well as to the 
hastening forces during launch and landing[8], all this will have an impact on both 
human microbiomes and immune system. In addition to microgravity, humans 
encounter cosmic and solar radiation which is a unique environmental condition during 
spaceflight. Astronauts experience an increased risk of infection due to the impaired 
immune system as a result of changes in space ecological condition.  
The constant pathogenic organisms threat and the resulting evolutionary pressure to 
develop defenses against these challenges have resulted in an array of collaborative 
defensive cell systems, consisting of amongst others phagocytes and versatile B and T 
cell frameworks which are collectively summarized under the wide denominator 
immunity. The human immune system, similar to all cellular frameworks in our body, 
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developed in the consistent nearness of the earth’ gravitational field. Thus it is not 
inconceivable that acute absence of this external force, as occurs during space flight, 
would influence functionality in this system. Diminished activity of the immune system 
is a well-documented effect of microgravity on the human body, for which precise 
mechanisms have yet to be determined. Importantly, although this diminished activity 
of the immune system is likely to become a problem concerning the extended missions 
presently being premeditated and planned (particularly an operated mission to Mars 
may yield specific challenges in this respect), space-related immunosuppression is well-
endured. Over forty years of knowledge with manned space flight have now 
overwhelmingly established that man can effortlessly stay alive and work in 
circumstances that are weightless, notwithstanding the continued repression of the 
body’s immune functions. This suggests that simulating immunosuppression by space-
related circumstances on earth may be a reasonably straightforward approach to 
immune system suppression as would be beneficial in patients suffering from excessive 
immune activation, as is the case with an autoimmune disease. Some studies also 
confirmed that space-related immunosuppression even exists in simulated models of 
microgravity (sµg)[9] demonstrating immunosuppression in splenocytes. This 
illustrates the usefulness of sμg models in novel illuminating mechanisms that control 
T-cell function and in enhancing spaceflight research in general. Eventually, creating 
awareness into monitoring lymphocyte pathways gained from sμg and spaceflight 
research will profit not only future astronauts but also those on earth who suffer from 
immune maladies[10]. 
This promise of microgravity has driven us in the past years to heavily invest in 
developing experimentation suited for space research, employing immune cells isolated 
from human volunteer peripheral blood, and three times the team has delivered 
experiments to a space-going vehicle. The current review is directed in maximizing the 
scientific returns of this unique situation by providing the necessary scientific 
infrastructure about performing experiments and analyzing (employing advanced 
single-cell technology to extract as much information as possible) the wealth of data 
expected, delivering a relatively detailed picture of microgravity effects on signal 
transduction in human immunity. 
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Historical background of the concept that microgravity influences human host 
defense. 
Probably ever since the early days of a space probe, it has been suggested that extra-
atmospheric humans suffer from the reduced immune function. Although, as a 
consequence of the secrecy concerning this topic during the Cold War era actual 
medical data and scientific reporting on the early space exploration is difficult or even 
impossible to obtain (especially from the ex-Soviet Union). Some scarce scientific 
reports and informal communication do suggest, with regard to the Russian experience, 
immune dysfunction was a concern [11] and in the American experience it certainly 
was: the Mercury program-flown chimpanzee Enos died in 1962 from Shigella 
infection, quite soon after his space trip on November 29, 1961 (although now many 
investigators doubt whether his death was related to his space travel). Likewise, the 
death of the pig-tailed monkey Bonnie on biosatellite 3 (the first primate satellite) 
raised, at the time, wide-spread concern concerning the immunological safety of space 
travel. Although now many feel that the death of Bonnie is to be attributed to “over-
instrumentation” of the unfortunate animal[12]. Minor bacterial and viral infections 
were not uncommon. Among the Apollo astronauts,  a range of diseases was reported, 
mainly of the eyes, skin and respiratory tract (including stomatitis, pharyngitis, 
recurrent inguinal and axillary infections). The astronaut Fred Haise developed a 
Pseudomonas aeruginosa urinary tract infection on Apollo, and this case was 
prominently suggested at that time to be a space-travel specific increased susceptibility 
towards viral infection via a publication in the authoritative medical journal JAMA[13]. 
Thus at that time, space-travel was associated with the diminished functioning of the 
immune system. However, the effect of space travel is probably not blank 
immunosuppression, and when appropriate measures are taken such as vigilant hygiene 
(which is relatively easy in the confined and isolated setting of space going vehicle) and 
a proper pre-flight medical examination of the crew, acute immunosuppression-related 
medical problems remain quite rare. Nevertheless, overt signs of mild immune 
suppressions are evident, for example, the re-activation of the varicella-zoster virus[14], 
herpes virus[15], and Epstein-Barr virus[16], but remain subclinical. It cannot be 
excluded, however, that during a long-term mission, like the proposed manned flight to 
Mars, diminished immunity could become a problem. And thus in the context of such 
long-duration space flight, knowledge on the molecular mechanisms that are 
responsible for space travel-associated immunosuppression have a practical importance 
that exceeds the scientifically fundamental question as to the interaction of the 
gravitational earth field and the human immune system. 
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Purpose and structure of this review 
Spaceflight causes deregulation of the human immune system and may compromise a 
crews wellbeing as during missions their health is continuously challenged by 
environmental conditions. Consequently, it is crucial to comprehend the biology of 
immune modulation under spaceflight circumstances possibly providing us with a 
means to uphold immune homeostasis under such conditions[17]. Life in the sterile and 
confined surroundings of a spacecraft in the presence of microgravity and cosmic 
radiation may alter the equilibrium between the human body and the microbiome. The 
combination of a deregulated immune system and an altered microbiome increase the 
risk of microbial infection and potentially the development of conditions related to 
reduced tolerance. This risk is further heightened by an increase in virulence of 
pathogens in microgravity. Health status of astronauts might potentially benefit from 
maintaining a healthy microbiome by specifically managing their diet on space in 
addition to probiotic therapies. This review focuses on the current 
knowledge/understanding of how spaceflight affects human immunity and 
microbiome[18]. Some of the impact on immune function certainly relate to 
psychological factors (cosmonauts can be expected to suffer from stress, wearing 
working schedules and anxiety), disturbance of circadian rhythms, environmental 
exposure to cosmic radiation and magnetic fields and substantial ergonomic discomfort 
(cramped conditions, inadequate lifestyle and nutritional regimen etc.)[15, 19]. 
However, there are good reasons to assume that the weightlessness itself negatively 
influences immune competence of the human body. Experimentation with crew 
members of the Apollo and Soyuz missions[20] showed reduced reactivity of peripheral 
blood lymphoid cells. And a landmark experiment conducted in Spacelab 1 in 1983 
demonstrated a near absent activation of peripheral blood leukocytes upon exposure to 
concanavalin A (Con-A) when compared to identical ground controls[21].  This 
observation sparked wide-spread interest into microgravity effects on the immune 
system. Although this original view has been confirmed in elegantly designed 
experiments in which controls were incubated in an in-flight 1×g reference 
centrifuge[22], many of the details as to how gravity and immune cell function interact 
remain obscure.  
In this review we shall look at the different levels at which microgravity might interact 
with the human immune system and analysing the available evidence, we shall 
conclude that especially  T cell[15, 21-24] and Natural Killer cell responses are 
negatively influenced[14-16, 19], but that innate immunity and especially granulocyte 
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responses are upregulated[25, 26]. Next, we would review the causes of these 
phenomena and conclude that they probably do not derive from differences in the 
extracellular milieu[27, 28] (which would have been a possibility in view of the 
significant effects on the bone marrow niche due to loss of bone[29-31]), but are the 
result of changed intracellular signal transduction under microgravity[32, 33]. Although 
data are limited, the effects on signaling most like involve alterations in Rac 
signaling[34] and thus microgravity provides new insight into the role of Rac and 
especially its downstream impact on cytoskeletal architecture in immune signal 
transduction[29].  Finally, we shall discuss the implications for human disease. These 
consequences are quite impressive: both functional studies[35] and GWAS[36] suggest 
that at least for one autoimmune disease, in case of Crohn’s disease defects in innate 
immunity are causative, leading to excessive innate responses. Thus indeed it is at least 
theoretically possible that useful information may be obtained from space 
experimentation on human immunity 
Microbiomes and humans 
The human body is the living space of microbial symbionts which is ten times more in 
number than all Homo sapiens cells[37]. The expression "microbiota" alludes to the 
organisms that live in a particular section (e.g., the human body, the gut, the dirt, and so 
forth.). The cumulative genomes of the total microbiota in the human body are alluded 
to as the "human microbiome"[37, 38]. The microbiome impacts biochemical, 
physiological and immunological pathways and is the principal line of protection from 
various diseases. The cooperation between the gastrointestinal frontier and the 
microbiome give off an impression of being a complex system that helps with keeping 
up appropriate immune capacity in the gut[39, 40]. The intestinal microbiome shapes 
the gastrointestinal insusceptible framework[41, 42]. Stable and pathogenic 
microorganisms go after supremacy[43, 44]. A  balance between useful and potentially 
harmful microscopic organisms is considered normal and adds to a robust and healthy 
human gut[44]. There is growing validation of the relationship between the changes in 
the balance of gut flora and several diseases[45]. 
Microbiomes and spaceflight 
The last decades have seen growing concerns about the effects of microgravity on the 
microbiome of astronauts during long-duration stay in space. Various studies[51],  have 
reported changes in gut microbiome physiology and composition. As mentioned  the 
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presence of a healthy gut microbiome is necessary to maintain immune homeostasis. As 
such the dysbiosis that results from prolonged stay in space may affect the health of 
astronauts causing higher susceptibility to opportunistic infections, reactivation of latent 
infections, induction of IBS and increased potential to develop diabetes or even cancer. 
A possible explanation as to why this dysbiosis occurs in space is the lack of microbial 
challenge while staying on board a space craft. Due to the confinement of the living 
space, a strict hygiene regime is maintained. This does not only concern the living 
quarters but also the food astronauts eat and the air they breathe. Not risking the chance 
to get sick by microbial infection, limits the natural competition commensal microbes 
would normally experience by intake of pathogenic microbes. Consequential some may 
experience a potential growth advantage altering the balance of the gut flora. 
The deleterious effect of prolonged stay in space on the microbiome may be countered 
by measures such as diet based therapies. These diets include vegetables, fresh fruits 
and fiber rich diets which enhanced the growth of butyrate-producing bacteria 
potentially reversing the profile of metabolites associated with human disease. This 
hypothesis is currently being tested by NASA using a combination of metabolomics, 
metatranscriptomics, 16s taxonomic profiling and immunological approaches. 
Alternatively the gut flora may be supplemented by probiotics or possibly fecal 
transplant pills. However, effects of such strategies still require investigation. 
Spaceflight long journey to the Mars by astronauts present a lot of challenges of which 
one among them is their inability to maintain a healthy microbiome population. This 
microbiome that forms the normal biota of the human intestine helps in protecting the 
host from infectious diseases, enhance immunity and breakdown  of food; A wide range 
of condition may arise due to imbalance in microbiome compositions these include 
syndrome of irritable bowel[46, 47], different cancer type[47] and depression[48]. 
During spaceflight travel, there is a paradigm shift from healthy to disease state which 
translates to decrease in microbiome diversity and enhance inflammation. cosmic 
radiation and Stress are among typical conditions experience during space flight 
travels[49, 50]. Changed in physiology of bacteria and promotion of dysbiosis of 
microbiome status[49].   
A successful return mission to the planet Mars takes more than a thousand days 
considering the most optimal conditions, a duration for which a healthy microbiome is 
imperative. It is therefore that space agencies have prioritized investigations on 
maintaining a healthy and balanced microbiome. Questions that need answering are: 
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Firstly, how to balance natural microbiota diversity during long term stay in space. 
Secondly, how can we combine a low pathogenic environment for the crew of a space 
craft without altering the normal composition of the commensal flora. Third, how can 
we restore normal gut flora after partial eradication by for example antibiotic treatment. 
And lastly, to what extend does cosmic radiation damage the diversity of the 
microbiome.[51]. 
Altered cytokine production does not provide a mechanical explanation for 
microgravity-induced immune suppression. 
Clinical strategies to interfere with the human immune system can involve either 
change in the extracellular or modification of cellular biochemistry operative in the 
immune effector cell. Examples of the former like the modification of cellular 
biochemistry by increasing the blood concentration of immunosuppressive 
corticoids[52] or the bio-neutralization of pro-inflammatory cytokine Tumour Necrosis 
Factor[53] by intravenous administration of anti-TNF antibodies are used with great 
therapeutic success in the treatment of autoimmune disease. An example of the latter is 
inhibition of Ca2+ transient-dependent activation of immune effector cells by 
cyclosporin-like compounds in transplantation medicine [54]. The effects of 
microgravity on immunity could be derived alternatively from altered cytokine 
production, thus altering the extracellular environment in which an immune response 
has to develop, or from autonomous cell mechanisms, in which the cellular response to 
extracellular cues is changed. The experiments with stimulation of ex vivo T cells 
would point to the latter; such reactions do in general not prominently involve 
alterations in cytokine milieu. Indeed, work in bone suggests that levels of 
immunosuppressive cytokines like TGF-ß are decreased instead of increased during 
microgravity and thus unlikely to account for space-related immunosuppression[30]. In 
agreement with the notion apparently that the effects of microgravity are cell-intrinsic 
rather than the consequence of an altered cytokine milieu, is the observation that in 
primary isolated rat lymphocytes, leptin (a hormone that famously regulates 
appetite[55], but is also prominent regulator of immunological[56] and histo-static[57] 
functions in the endodermal mucosal compartments) loses its capacity to stimulate 
proliferation under simulated microgravity[27]. Also efforts to measure the 
concentrations of cytokines and other immunologically relevant hormones in the 
peripheral blood of astronauts or experimental space-going rodents have never yielded 
convincing reductions in the profile of these humoral factors (e.g. Miller et al. J. Appl. 
Physiol. 78: 810-813), although also during investigations under conventional 1xg 
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conditions it is sometimes tricky to detect reflections of pathology in the cytokine 
profile of peripheral blood in the absence of fulminant disease[58]. Nevertheless, 
despite 30 years of frantic research and experimentation, there is no evidence that 
microgravity-related immunosuppression can be linked to changes in the external 
milieu. 
It is important to note however, that changes in intracellular signalling and extracellular 
milieu can never be regarded separately, as diminished intracellular signalling will 
result in diminished cytokine production, in turn affecting downstream responses and 
feedback loops, e.g., Con-A stimulated interleukin 2 secretions by T lymphocytes is 
negatively affected by simulated microgravity and this will without doubt aid the 
reduced mitogenic responsiveness to Con-A during microgravity in this cellular 
compartment[59].  Nevertheless, altered responsiveness to extracellular cues rather than 
a difference in the extracellular environment explains why immune cells behave 
differently during autoimmunity, focussing studies towards the influence of 
microgravity on cell-autonomous mechanisms. Some studies also found that LPS-
induced TNF-α expression in mouse macrophages was significantly suppressed under 
simulated microgravity. NF-κB activation and TNF-α mRNA stability were resistant to 
microgravity. The repressor of TNF-α promoter, HSF1, which was activated under 
simulated microgravity, may be one of the critical mechanisms for the reduced TNF-α 
expression in macrophages under microgravity[60]. The oxidative burst reaction in 
mammalian cells, necessary for example for the internalization and degradation of 
bacteria, depends on the presence of gravity[61]. The release of reactive oxygen species 
(ROS) during the oxidative burst reaction depends on gravity conditions. ROS release 
is 1.) reduced in microgravity, 2.) enhanced in hypergravity and 3.) responds rapidly 
and reversible to altered gravity within seconds. We substantiated the effect of altered 
gravity on oxidative burst reaction in two independent experimental systems, parabolic 
flights, and 2D clinostat/centrifuge experiments. Furthermore, the results obtained in 
simulated microgravity (2D clino-rotation experiments) were validated by experiments 
in real microgravity,  in both cases showing a pronounced reduction in ROS. Our 
analyses indicate that gravity-sensitive steps are located both in the initial activation 
pathways and in the final oxidative burst reaction itself, which could be explained by 
the role of cytoskeletal dynamics in the assembly and functionality of the NADPH 
oxidase complex[61]. 
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Space travel and microgravity effects on immune cell function are highly cell-type 
specific. 
Evidence that the immunosuppressive effects of space travel in general and 
microgravity, in particular, can be attributed to specific cell-autonomous mechanisms 
which impact on different compartments of the immune system, has over the past three 
decades slowly become more-and-more evident. Advancement in this field has been 
slow due to the apparent lack of experimental opportunities and the technical 
difficulties in the analysis of scientific work on the immune system in microgravity. 
The notion, however, that space travel in general and microgravity, in particular, are 
immunosuppressive was much fostered by the observation that Con-A stimulation of T 
cell compartment resulted in reduced mitogenic responses in this cell type under 
microgravity. Thus a lot of attention has been focused on this branch of immunity. 
Typically studies show that cell division is reduced between 50–89% at 0×g when 
compared to 1×g controls either in space or during simulated microgravity[22].A 
variety of studies indicates that microgravity interferes with the functionality of the NK 
cell compartment. NK cells isolated from astronauts are deficient in target cell killing in 
ex vivo assays (hence out of the context of a possible immunosuppressive cytokine 
milieu, suggesting that cellular factors are essential here)[15]. Although not well 
studied, maturation of dendritic cells, significant for the instruction of T cells in 
adaptive immunity is somewhat impaired under gravity[62]. In contrast neutrophil 
action seems to be enhanced under microgravity. Cosmonauts spending 1 to 22 months 
in microgravity (occupants of the Russian Mir space station) display increased 
granulocyte superoxide production and enhanced levels of surrogate markers for such 
increased granulocyte activity like elevated erythrocyte superoxide dismutase activity 
and glutathione oxidation[25]. Hence, if anything, immunity in the neutrophil 
compartment is slightly stimulated rather than inhibited by microgravity. The notion 
that space travel can specifically interfere with individual branches of protection 
without negatively influencing granulocyte immunology adds to the interest that 
identifying the molecular targets of microgravity may have. Evidence that defects in 
innate immunity contribute to the pathogenesis of the autoimmune disease is rapidly 
accumulating[63]. Recent genome-wide associations studies (GWAS) have been 
instrumental in identifying novel genetic risk factors predisposing to Crohn’s disease 
and many of the alleles involved confer reduced activity in the innate immune system 
[36]. In line with these genetic studies, patients with autoimmune disease were shown 
to exhibit diminished innate immunity as compared to healthy individuals[35] and 
genetic deficiencies in neutrophil function are highly similar to and clinically even 
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often mistaken for autoimmune disease[64]. Thus, for the treatment of autoimmune 
disease, immunosuppression in lymphocyte compartment without concomitant innate 
immunosuppression appears much more attractive as the blank immunosuppression, 
such as occurs with, for instance, steroid treatment, the mainstay of current treatment of 
autoimmune disease. Apparently, as microgravity does not seem to negatively affect 
neutrophil-dependent immunity, identifying the targets of microgravity on human 
immunity may prove exceedingly useful for identifying such targets. 
Altered signal transduction is important for microgravity effects on immune 
function  
Thus the available evidence suggests that different cell types alter their characteristics 
during microgravity and that these effects cell-autonomous, i.e., they do not majorly 
involve differences in the extracellular milieu, but involve an altered intracellular 
reaction to an extracellular stimulus. The most straightforward fashion in which such an 
effect could occur is that the interaction between extracellular cues and their 
corresponding receptors is disturbed during microgravity. This, however, does not seem 
to be the case, for instance, the binding of Con-A to T cell membrane glycoproteins 
remains unchanged, and patching and capping are only minimally retarded at 0×g[65]. 
Although not involving immunologically relevant cells, also the observation that the 
otherwise microgravity-sensitive EGF response in A431 cells does not require altered 
EGF receptor clustering on the surface of A431 cells supports this notion[66]. Thus it 
seems that subsequent intracellular biochemistry is the target here. Support for this idea 
comes from the observation that induction of early genes (i.e. genes which are activated 
transiently and rapidly in response to a wide variety of cellular stimuli and seem to 
serve an alarm bell for the nuclear machinery that alteration in its transcriptional 
programming are imminent and form the first nuclear reaction to an extracellular 
stimulus)[34, 32, 33], apparently limiting the possible interaction points of microgravity 
with immunity with the direct signaling machinery associated with transmitting the 
extracellular signals to the nucleus and possibly not necessarily involving altered 
reactions to secondary nucleus-derived signals. 
Altered signal transduction in immunological cells may be dependent on 
diminished Rac activation 
The nature of the effects of microgravity on cellular signal transduction remains 
unclear. It is tempting to speculate that these results may involve alterations in signaling 
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through the small GTPase Rac. Rac is a  pleiotropic regulator of many cellular 
processes, including the control of cell growth, cytoskeletal reorganization, and the 
activation of protein kinases and phospholipase A2[67]. Gene expression profiling in 
osteoblasts identified especially cox-2, c-myc, bcl2, TGF beta1, bFGF and PCNA  as 
being negatively targeted by microgravity[34], which are genes whose expression is 
downstream of the Rac effector pathways involving activation of the p38 MAPK and 
Jun-N-terminal kinases. Production of phospholipase A2-dependent pro-inflammatory 
lipid mediators is negatively affected by microgravity (Gravit Physiol. 2004 Jul;11(2): 
P41-2. Effect of simulated microgravity on PGE2-induced edema and hyperalgesia in 
rat paws: pharmacological data and biochemical correlates. Peana AT, Bennardini F, 
Buttu L, Pippia P, Meloni MA, Stuffler RG, Maccarrone M.). Also, the cytoskeletal 
effects of microgravity on growth factor-induced cytoskeletal remodeling seem 
consistent with an impact on Rac activation[68]. (Describe effects of expression of Rac. 
Inhibitory action of microgravity would fit well with differential effects of microgravity 
on alternative immunological compartments, whereas moderate Rac inhibition leads to 
diminished action of the adaptive immune system, such inhibition enhances effector 
function in phagocytes). Hence microgravity mirrors essential aspects of the known 
consequences of Rac inhibition on the immune system and it should prove interesting to 
directly assess the influence of space flight on GTP-loading of this GTPase or the 
phosphorylation state of its direct effectors, the p21-activated kinases (or PAKs). 
Effect of space flight-associated microgravity on stress-activated protein kinases in 
innate immunity. 
Spaceflight actively moderates human immunity but is in general well tolerated. 
Elucidation of the mechanisms by which zero gravity interacts with human immunity 
may provide clues for developing rational avenues to deal with exaggerated immune 
responses, e.g., as in autoimmune disease[69]. The human immune system, like all cell 
biological systems in our body, has developed in the continuous presence of the earth’s 
gravitational field. Thus it is conceivable that acute absence of this external force, as 
occurs during space flight, would influence functionality in this system. Indeed since 
the early days of space exploration, it has been evident that extra-atmospheric primates 
and humans experience reduced immune function[13, 21, 70]. 
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Activation of p38 map kinase is not affected by space flight associated 
microgravity.  
One of the most notable biochemical changes following LPS challenge is the 
phosphorylation and thereby activation of p38 MAP kinase[71, 72]. Inhibition of p38 
MAP kinase protects against endotoxemia in LPS challenged healthy volunteers[72], 
although clinical implementation of pharmacological p38 MAP kinase inhibition has 
not proven viable because of side effects and extreme vulnerability towards bacterial 
infection. Various genes, like PRKCA22, whose expression is known to be exquisitely 
sensitive to microgravity are identified to be regulated by p38 MAP kinase[73]. Hence, 
it is conceivable that activation of p38 MAPK is impaired during microgravity. As 
expected, the onboard 1xg control displayed p38 MAP kinase activation. In contrast, 
activation of p38 MAP kinase was not impaired in microgravity-exposed monocytes, if 
anything p38 MAP kinase activation appears to be increased. Thereby suggesting that 
space flight-associated microgravity does not interfere with LPS-induced pro-
inflammatory signal transduction per se and its effects, if present, are restricted to 
specific signaling pathways. 
LPS does not activate Jun-n-terminal kinase during space flight associated 
microgravity. 
 In general inflammatory stimuli coactivate  p38 MAP kinase and Jun-N-terminal 
kinase, as activation of both kinases displays similar kinetics[74]. Nevertheless, they 
are activated by different upstream kinases (MKK3/6 and MKK4/7 for p38 MAP kinase 
and Jun-N-terminal kinase, respectively[75]. Thus, at least theoretically, the possibility 
exists that space flight-associated microgravity targets Jun-N-terminal kinase without a 
concomitant effect on p38 MAP kinase. Surprisingly, during microgravity, the capacity 
of LPS to stimulate Jun-N-terminal kinase activation is lost, whereas monocytes 
stimulated with LPS during the onboard control condition were utterly Jun-N-terminal 
kinase activation proficient. Thus, microgravity evokes a dichotomy in immunological 
signaling, allowing p38 MAP kinase activation to proceed, but incompatible with LPS 
dependent Jun-N-terminal kinase activation. Although it does not involve 
immunologically relevant cells, the observation that the induction of c-Jun in A431 
cells by epidermal growth factor is absent in microgravity[32], fits well with our 
findings. Especially since it has been well established that Jun-N-terminal kinase is 
involved in the induction of c-Jun and p38 MAPK is not. 
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specific signaling pathways. 
LPS does not activate Jun-n-terminal kinase during space flight associated 
microgravity. 
 In general inflammatory stimuli coactivate  p38 MAP kinase and Jun-N-terminal 
kinase, as activation of both kinases displays similar kinetics[74]. Nevertheless, they 
are activated by different upstream kinases (MKK3/6 and MKK4/7 for p38 MAP kinase 
and Jun-N-terminal kinase, respectively[75]. Thus, at least theoretically, the possibility 
exists that space flight-associated microgravity targets Jun-N-terminal kinase without a 
concomitant effect on p38 MAP kinase. Surprisingly, during microgravity, the capacity 
of LPS to stimulate Jun-N-terminal kinase activation is lost, whereas monocytes 
stimulated with LPS during the onboard control condition were utterly Jun-N-terminal 
kinase activation proficient. Thus, microgravity evokes a dichotomy in immunological 
signaling, allowing p38 MAP kinase activation to proceed, but incompatible with LPS 
dependent Jun-N-terminal kinase activation. Although it does not involve 
immunologically relevant cells, the observation that the induction of c-Jun in A431 
cells by epidermal growth factor is absent in microgravity[32], fits well with our 
findings. Especially since it has been well established that Jun-N-terminal kinase is 
involved in the induction of c-Jun and p38 MAPK is not. 
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Effects of space flight-associated microgravity on erk activation. 
Although less pronounced than the effect on Jun-N-terminal kinase, inhibitory 
influence of microgravity on the capacity of LPS to provoke activation of the 
extracellular regulated kinase (ERK) was observed[69]. This corresponds with recent 
findings in T cells that show a minor effect of microgravity on ERK phosphorylation in 
unstimulated T cells[76]. Thus, the impact of microgravity is not solely restricted to the 
Jun-N-terminal kinase. Diminished activity of the immune system is among the 
foremost effects of space flight on the human body[77]. Importantly, this reduced 
activity of the immune system is well-tolerated. Over forty years of experience with 
manned space flight have now conclusively demonstrated that man can easily survive 
and work in weightless conditions, despite the chronic repression of the body’s immune 
functions[78]. 
This suggests that mimicking space-related immunosuppression on earth may be a 
fairly safe way of suppressing the action of the immune system. Although experimental 
requirements allowed for only 6 minutes of microgravity, there is good evidence that 
even a relatively short inhibition of kinases can have a substantial effect on the 
functionality of the innate immune system[79]. Therefore we feel that the observed 
effect on Jun-N-terminal kinase is relevant to the explanation of space flight-associated 
immunosuppression. The marked dichotomy between p38 MAP kinase and Jun-N-
terminal kinase is consistent with these observations: p38 MAP kinase is essential for 
fighting immediate bacterial threats, and thus its inhibition causes undesirable side 
effects in these and other respects[80]. On the other hand, the Jun-N-terminal kinase is 
more associated with chronic inflammatory responses[81, 82] whose inhibition 
represents a clear and for now unresolved clinical need. 
Conclusion and future direction.  
Immune system of space travellers diminishes upon spaceflight. Importantly, although 
this reduced activity of the immune system is likely to become a problem concerning 
the more extended missions currently being planned (especially a manned mission to 
Mars may yield specific challenges in this regard), space-related immunosuppression is 
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well-endured. Over forty years of experience with manned space flight have now 
conclusively demonstrated that man can easily survive and work in weightless 
conditions, despite the chronic repression of the body’s immune functions. This 
suggests that mimicking space-related immunosuppression on earth may be a relatively 
suppressing the immune system in patients suffering from excessive immune activation, 
like autoimmune disease, hence identification of the machinery responsible could 
provide significant benefit for earthly health care. 
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Summary 
Cancer is the generic term used to describe a group of diseases that involves a 
pathology characterized by abnormal and uncontrolled cell proliferation. 
Mechanistically, this group of diseases find its etiology in a disturbance of the 
cellular signaling pathways that in physiology tightly control tissue compartment 
size homeostasis but in cancer lose feedback control. The resulting growth 
physically impairs body function and can provoke substantial pain and suffering. To 
cure disease or at least improve quality of life, it is important to know how cancer 
patients respond to different treatment options and to develop new treatment 
modalities as current ones are often still largely inadequate.  
Theoretically, one might assume that the changes in genetic make-up that are 
associated with the cancerous process would create neoantigens and thus tumor cells 
should be subject to attack by the body’s immune system. Although, there is 
evidence that many tumors are to a certain extent constrained in their growth by 
immunity, evidently this control fails in many patients. In this context it is of 
substantial significance to study the tumor microenvironment as a whole, because it 
has valuable prognostic potential with respect as to how the disease course will react 
to the immunogenic mutation load.  
The studies presented in this thesis on gastric cancer appear to at least partially 
support this concept. The survival rate of a gastric cancer patient is dependent on the 
associated immune parameters within the tumor microenvironment. I feel it 
constitutes a prognostic marker that can be used to evaluate if an individual is at risk 
of cancer development, and if disease has developed can assist in treatment 
selection. An important goal in this respect, that has not yet been satisfactorily 
reached, is to determine a mechanistic signature (expression patterns of 
immunomodulatory molecules, ratios of immune suppressive cell types over 
immune effector cell types etcetera) that is associated with either success or failure 
in immunotherapy. The absence of such a predictive signature now greatly hampers 
implementation of immunocheckpoint therapy in gastric cancer, hence patients that 
might benefit from such therapy are being denied access to it whereas patients not 
benefiting from immunocheckpoint-directed therapy suffer its side effects. 
Nevertheless, the emerging capacity to better characterize both cancer cells for 
neoantigen expression and to precisely phenotype the tumor micro-environment will 
certainly improve matters in this respect. It is important to stress, however, that final 
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success in the battle against gastric cancer will depend not only on improved therapy 
in these late phases of disease. Gastric cancer remains an important contributor to 
overall mortality and especially cancer-related mortality when viewed globally. To 
deal with this problem it will be necessary to improve prevention, e.g. by widening 
opportunities for more active screening of subjects which are predisposed to develop 
gastric cancer, to improve the efficacy of screening procedures involved and to 
better understand the gastric cancer process as to open novel avenues for the rational 
treatment of disease, in particular opportunities for preventive therapy when atrophic 
gastritis develops should exist. My thesis has tried to make contributions here. My 
findings will be summarized and discussed in this chapter. I shall also provide future 
perspectives and issues that need to be addressed in additional studies. 
In chapter 2 I have prepared a comprehensive review of the relation between 
hedgehog signaling and (development of)  gastric cancer. Some of the related 
aspects I also reflect on in chapter 1, Hedgehog signaling has a pivotal role in the 
homeostasis of the healthy stomach, whereas loss of Hedgehog signaling is an 
important event in neoplastic transformation of the stomach. Loss of Hedgehog 
production in the parietal cells during atrophic gastritis drives excessive production 
of gastrin (among other events) in turn resulting in excess gastrin production which 
is an important disease-promoting occurrence. Once cancer has been established 
Hedgehog signaling may support the cancer process and especially have a trophic 
influence on the cancer stem cell compartment. Thus modulation of Hedgehog 
signaling with respect to gastrointestinal cancer development is pivotal at different 
phases of the gastric cancer process. Although Hedgehog antagonists have been used 
in different cancer types, the usage of Hedgehog antagonists for gastric cancer in 
clinical trials is still in its infancy. New therapeutic strategies need to be explored. 
Such development is hampered by the lack of knowledge on the mechanistic details 
of Hedgehog signaling and this aspect of carcinogenesis in the stomach and 
elsewhere in the gastrointestinal tract will be dealt with elsewhere in this thesis. 
 In chapter 3 I further evaluated immunotherapy checkpoint inhibition in gastric 
cancer. Gastric cancer stands out amongst other cancers as particularly aggressive 
and as a disease in which chemotherapy alone cannot satisfactorily help to change 
the final outcome due to constrained efficacy. A critical factor that guides both 
tumorigenicity of precancerous lesions and the outcome of cancer itself, is immune 
signaling and how it relates to heterogeneity of gastric cancer (thus not all cells may 
express the same neoantigen repertoire). We still cannot, however, distinguish those 
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tumors that can potentially be targeted by stimulation of immune monitoring. This 
will require full supplementation of information which is still lacking with respect to 
the multifaceted association between cancer, the tumor surroundings, and the 
immune system.  
Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4-therapy targeting  immune checkpoints 
have delivered hopeful outcomes in some preliminary clinical trials. However, we 
need to await the results from various ongoing and future clinical trials to properly 
address its full potential in gastric cancer. Also the possibilities of  several 
synergistic methodologies that may have a beneficial effect (vaccination, cytokine 
infusions etcetera), either with immunotherapy alone or in further combination with 
chemotherapy need to be addressed and indeed it appears that such investigations 
are now starting. Furthermore, plans to ascertain the possibilities offered by 
potential prognostic biomarkers with respect to the outcome of immunocheckpoint 
therapy in gastric cancer have already been launched, and I eagerly await the future 
results of such efforts. In this respect my conclusion is that understanding immune 
response patterns and better control of immune-therapy-associated side effects will 
prove vital for widespread adoption in clinical practice for the drugs whose use is 
now mostly restricted to clinical trials. From the currently available data and its 
evolving momentum a promising efficacy of immunotherapy agents is revealed but I 
hope that ongoing clinical trials and preclinical efforts will address the unanswered 
question I listed above. 
In chapter 4 I further explore the mechanistic details that drive Hedgehog signaling, 
which is an essential morphogen in explaining both physiology and pathology in the 
gastrointestinal tract. An aspect that has received relatively little attention in the 
main text of this chapter is that my findings describe a novel signaling cascade 
functioning through the SRC Homology 3 Domain-containing proteins which, I feel, 
may be activated directly by Hedgehog ligands but further investigation is necessary 
to substantiate this notion (e.g. through better analysis of the effects of Hedgehog on 
the kinome of Patched-deficient fibroblasts, which was not rigoursly done in this 
thesis). Together, I suggest that Sonic Hedgehog can stimulate Src activity via types 
I and type II noncanonical signaling pathways and that the latter may resemble ther 
effects of Hedgehog in axonal guidance in development. Thus I propose a model on 
the role of Smo interaction with Rho signaling that not only has relevance for the 
model systems described in this chapter but may also be relevant for formation and 
regulation of dendritic projections in the neural system (or, who knows, even in 
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projections of dendritic cells in immunity). Upon activation of the Src-Rho-Rac 
cascade by Hedgehog, actin cytoskeleton reorganization takes place independent of 
the activity of any transcription factor and necessary for the functionality of Sonic 
Hedgehog in physiology. This provoking idea suggests that Hedgehog signaling 
might regulate a cohort of physiological processes involving fluctuations of Ca2+, 
acutely affecting membrane potential and Ca2+-dependent signaling pathways, as 
my promotor showed during his PhD research on the link between actin 
reorganization and calcium fluxes. But obviously further research is necessary to 
substantiate this notion.  My findings on the new role of Hedgehog in actin 
cytoskeleton reorganization has thus prompted me to suggest further studies on the 
interactive parts of Sonic Hedgehog with other morphogenetic cascades during 
development and formation of dendritic projections. 
In chapter 5 gastric atrophy has been described as a precancerous condition and can 
be evaluated through routine endoscopy. Several studies assessed the agreement 
level in a variety of methods between endoscopy and histologic atrophy but differ in 
sensitivity, specificity, precision, and accuracy due to the lack of a gold standard to 
compare if the grouping is suitable or not. Information from our study on endoscopic 
grading evaluation has shown a reproducible kappa value, and such grading can be 
used to predict the precancerous condition of histologic atrophy during routine H. 
pylori screening practice in Africa and Middle-east. 
In chapter 6 we looked at the diversity of Helicobacter pylori genotypes and 
development of gastric cancer. Our results showed the relationship of babA2, babB 
negative and iceA1 positive genotype and the development of cases of gastric cancer 
was statistically significant. Further studies are required to determine the functions 
of babA2 and babB and their relationship with disease outcome, and whether the 
presence of these alleles indicates the presence of bacteria unlikely to confer 
progression towards gastric carcinoma. 
As evident from the above, it may prove necessary to stimulate immunity during 
full-blown gastric cancer. Immunocheckpoint-directed therapy may prove a way 
forward here, but may not be sufficient to reach the desired level of anticancer 
immunity. Knowledge of pathways that constrain immunity might help in this 
respect as the inhibition of those pathways may further stimulate anti-cancer 
immunity. In chapter 7 I explore this aspect by evaluating the effect of 
microgravity as an approach. Space travel is associated with diminished immunity 
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and thus knowledge of the pathways involved would provide novel targets to 
stimulate immunity. Excitingly from this analysis Rac/Rho signaling emerges as the 
pathway targeted by microgravity to inhibit immunity in space travel, implying that 
stimulation of this pathway might be beneficial in gastric cancer. The same pathway 
I identified as being downstream of Smoothened in Hedgehog signaling in chapter 
4. Thus the analysis in chapter 7 provides further rational for exploring the potential 
of targeting Hedgehog signaling in gastric cancer. A possibility might be the use of 
specific Smoothened agonists in combination with Patched antagonists, but requires 
further exploration. 
General discussion 
The importance of Hedgehog signaling in many forms of cancer in conjunction with 
its link to gastric developmental processes has prompted a substantial research effort 
investigating the potential usefulness of targeting Hedgehog signaling in gastric 
oncogenesis. As a result, in gastrin-mediated compartment expansion and viral or 
Helicobacter-dependent gastric carcinogenesis, the role of Hedgehog signaling is 
now relatively well understood. Furthermore, when the malignant disease is 
established, the evidence indicates that hedgehog signaling may provoke drug 
resistance. Now that the Hedgehog inhibitor Vismodegib has come available, which 
has proved useful in other kinds of cancer (especially basal cell carcinoma), it is 
tempting to propose clinical trials using this compound for patients who have gastric 
cancer, and accordingly various of such studies have now been initiated.  
Strikingly, however, reports of activating mutations in Hedgehog signaling cascades 
in gastric cancer are scarce, suggesting that such mutations confer little relative 
advantage to cancer cells bearing such mutations over those that do not have such 
mutations. Furthermore, on theoretical grounds, one can expect Hedgehog inhibition 
to interfere with the clinical effect of conventional medication used to treat gastric 
cancer.  
The data I obtained on Hedgehog signaling may be linked to those I obtained on 
immuno-checkpoint-directed therapy. Pembrolizumab was shown to have anti-tumor 
activity in patients diagnosed with advanced, PD-L1 expressing, gastric cancer while 
causing only limited adverse effects. Suggestive data showed an association between 
the related immune signature expression and efficacy of the immuno-checkpoint-
directed therapy, suggesting this may be a suitable prognostic marker for 
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identification of patients that will benefit from such a therapy. In addition, 
characterization of the tumor microenvironment and T cell cytotoxic functions may 
prove sensitive prognostic markers. Mono-therapy with Avelumab revealed an 
acceptable antitumor broad spectrum of activity, safety, and efficacy in gastric 
cancer patients. In a dose-escalation study involving MEDI4736. It has 
demonstrated an enhance antitumor activity and safety. Ongoing multicenter trials 
and development of  MEDI4736 as a single therapy is ongoing. MPDL3280A was 
well accepted with enhanced efficacy, safety, and antitumor activity. No adverse 
events were recorded in the MPDL3280A trial as the interaction between PD-1 and 
PD-L2 is not affected in response to  MPDL3280A. Now that my analysis revealed a 
relationship between Hedgehog signaling and immune signal transduction, it may be 
tempting to combine modulators of Hedgehog signaling with checkpoint-directed 
therapy. 
I propose a sonic hedgehog-initiated novel signaling pathway through Src–Rac 
cascades, which regulates actin cytoskeletal reorganization and endocytosis. In this 
framework, Smo coheres to and sequesters Rac in its active form when engaged with 
for instance the pharmacological compound Purmophamine (B) or Src. Smoothened 
is released from Patched inhibition in the presence of Sonic Hedgehog which is 
mediated by Gli-dependent transcriptional activity. Other extracellular signals might 
regulate secretion of Sonic Hedgehog at particular sites and times. Remarkably, Src 
and histamine have been shown to trigger Sonic Hedgehog secretion[53], inducing 
Ca2+ influx in the endothelial cells[54]. Suggesting the Sonic Hedgehog secretion in 
the fibroblast cells due to the Ca2+ influx. Calcium has repeatedly been reported to 
induce expression of Hedgehog ligands. It was reported that Ca2+ chelation inhibits 
Indian Hedgehog gene expression in chick chondrocytes [55]. We describe the 
impact of subcellular localization of Smoothened on its signaling ability and its 
chemotactic signaling capacity through a non-canonical pathway, and I feel small 
mutations in Smoothened may cause its activation in various cancers (but probably 
not gastric cancer). Importantly, pharmacological activation of Smoothened will 
activate immune relevant signaling and thus support anti-cancer immunity.  
My thesis also contributes to gastric cancer prevention. Gastric atrophy is thought to 
be a precursor for malignant neoplasm formation. Therefore, enhancements in 
techniques used for atrophy diagnosis might help identifying individuals at risk for 
gastric cancer. My findings have thus relevance for recommendations with respect to 
the examination and grading of atrophy. This will envisage in-depth histologic 
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atrophy and should function as a useful assessment tool for evaluation of 
premetastatic tumor conditions during an endoscopic investigation in routine clinical 
practice, particularly for patients in developing countries. 
Future Perspectives 
Hence the former, it seems expedient to restrict the experimental use of Hedgehog 
inhibitors to those gastric cancer patients that show exaggerated Hedgehog 
signaling. This is of relevance because currently multiple trials using Vismodegib 
for the treatment of gastric cancer are being conducted. Although as yet unpublished 
results indicate that using Hedgehog inhibitors for gastric cancer in unselected 
patients is not useful, whereas using Vismodegib in selected patients seems to yield 
better results. And thus, the use of Vismodegib for gastric cancer can serve as a 
powerful example of the necessity to further develop precision medicine. 
Accumulating preclinical as well as clinical studies has shown that the efficacy of 
checkpoint inhibition could be amplified through dual blockade or in combination 
with other immunotherapies such as cancer vaccines or adoptive cell therapy. As 
such, it is worth combining various immune reagents to achieve a maximal effect. 
Moreover, it is possible that further applications of this approach to traditional 
chemotherapy or radiation therapy could produce better clinical responses in patients 
with gastric cancer. 
Future studies should clarify the extent to which this novel signaling cascade is 
involved in other Sonic Hedgehog functions during development. For future 
research, we recommend an inter-observer agreement done in routine clinical 
practice among H. pylori-associated gastritis. Parietal cell antibodies should be 
measured in patients with autoimmune gastritis. Thus in conjunction I feel my thesis 
opens many novel avenues for future research aimed at better prevention and 
treatment of gastric cancer. In Conclusion, I feel my thesis opens many novel 
avenues for future research aimed at better prevention and treatment of gastric 
cancer. 
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Samenvatting  voor de leek 
Kanker is een ziekte die gekenschetst wordt door de volgende kernprincipes: er zijn 
cellen die zich ongecontroleerd delen en hier niet mee stoppen; de woekerende 
cellen verspreiden zich naar het omliggend weefsel en veroorzaken hier schade 
(infiltratie of invasieve groei ); de doorwoekerende cellen verplaatsen zich 
uiteindelijk ook naar verder weg gelegen plaatsen in het lichaam (uitzaaiing ofwel 
metastasering). De ziekte is de basis van onnoemelijk veel menselijk leed en met dit 
promotie-onderzoek heb ik geprobeerd een bijdrage te leveren aan het gevecht der 
mensheid tegen deze aandoening.  
Ik concentreer mij hierbij op maagkanker. De maag vormt een belangrijk onderdeel 
van het spijsverteringskanaal. De binnenzijde der maag is bedekt door een dikke 
slijmvlieslaag. Kliertjes binnen dit maagslijmvlies maken het maagsap. In het 
maagsap zit onder andere zoutzuur maar ook de spijsverteringsenzymen die nodig 
zijn voor de vertering van de maaltijd. Het zoutzuur is belangrijk voor het doden van 
de bacteriën welke we middels de voeding binnenkrijgen. Ook activeert zoutzuur de 
in maag aanwezige spijsverteringsenzymen. Maagkanker is oncologische ziekte 
uitgaande van de maag. In Nederland zijn er ongeveer tweeduizend gevallen per jaar 
van maagkanker. Daarmee heeft Nederland een relatief lage incidentie, zowel 
binnen de Europese Unie alsook mondiaal. Maagkanker verdeelt zich echter niet 
simpel via sociaal-economische lijnen: in Nigeria is de incidentie bijvoorbeeld ook 
laag. Ofschoon de vooruitzichten bij vroegtijdige opsporing van maagkanker zeker 
niet slecht zijn, is helaas zulke vroegtijdige opsporing eerder uitzondering dan regel. 
Het orgaan zit  diep in ons lichaam, een groeiende tumor is niet zichtbaar en geeft 
ook niet snel pijnklachten. Wanneer duidelijke symptomen manifest zijn is het dan 
ook vaak te laat. In dit proefschrift probeer ik meer inzicht te krijgen in zowel het 
ontstaan van maagkanker en een aanzet te geven tot betere behandeling. 
In dit opzicht moet eerst de bacterie Helicobacter pylori genoemd worden. 
Helicobacter pylori ('spiraalvormige bacterie van de maagportier') is een Gram-
negatieve bacterie die in de maag van mensen voorkomt. Deze bacterie, die gedijt in 
de extreme omgeving van het maagzuur, lijkt verantwoordelijk te zijn voor het 
ontstaan van maagkanker. Dit gebeurt middels een goed-gekarakteriseerd proces 
waarbij eerst ontsteking van het maagslijmvlies ontstaat, dat op een gegeven 
moment uitmondt in een verandering van het maagslijmvlies in een slijmvlies met 
duidelijke darmkarakteristieken waarna het weefsel een dysplastisch karakter krijgt 
50906 Adamu v2.indd   176 30-05-18   21:35
Nederlandse samenvatting
177
9
Nederlandse samenvatting 
 
173 
Samenvatting  voor de leek 
Kanker is een ziekte die gekenschetst wordt door de volgende kernprincipes: er zijn 
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Ik concentreer mij hierbij op maagkanker. De maag vormt een belangrijk onderdeel 
van het spijsverteringskanaal. De binnenzijde der maag is bedekt door een dikke 
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de bacteriën welke we middels de voeding binnenkrijgen. Ook activeert zoutzuur de 
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ook niet snel pijnklachten. Wanneer duidelijke symptomen manifest zijn is het dan 
ook vaak te laat. In dit proefschrift probeer ik meer inzicht te krijgen in zowel het 
ontstaan van maagkanker en een aanzet te geven tot betere behandeling. 
In dit opzicht moet eerst de bacterie Helicobacter pylori genoemd worden. 
Helicobacter pylori ('spiraalvormige bacterie van de maagportier') is een Gram-
negatieve bacterie die in de maag van mensen voorkomt. Deze bacterie, die gedijt in 
de extreme omgeving van het maagzuur, lijkt verantwoordelijk te zijn voor het 
ontstaan van maagkanker. Dit gebeurt middels een goed-gekarakteriseerd proces 
waarbij eerst ontsteking van het maagslijmvlies ontstaat, dat op een gegeven 
moment uitmondt in een verandering van het maagslijmvlies in een slijmvlies met 
duidelijke darmkarakteristieken waarna het weefsel een dysplastisch karakter krijgt 
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en uiteindelijk verwordt tot maagkanker. Echter vaak leidt een infectie met 
Helicobacter pylori niet tot maagkanker. Het blijkt dat verschillende stammen van 
de bacterie verschillende effecten hebben op de maag in dit opzicht. Een 
theoretische analyse in dit opzicht geef ik in Hoofdstuk één terwijl ik in Hoofdstuk 
vijf hier actief onderzoek naar doe. In dit laatste hoofdstuk analyseer ik zogenaamde 
plasmiden van de bacterie. Een plasmide is een cirkelvormige streng DNA die zich 
buiten het chromosomaal DNA bevindt van sommige eencellige organismen, zoals 
Helicobacter pylori. Door analyse van deze plasmiden in patiënten met en zonder 
ontwikkeling van maagzweer in maagkanker kon ik plasmiden identificeren die 
geassocieerd zijn met bescherming tegen het ontwikkelen van maagkanker. Het 
resultaat van deze analyse werd gepubliceerd in het vaktijdschrift Canadian Journal 
of Gastroenterology and Heptology (Dadashzadeh K, Peppelenbosch MP, Adamu 
AI. Helicobacter pylori Pathogenicity Factors Related to Gastric Cancer. Can J 
Gastroenterol Hepatol. 2017:7942489. doi: 10.1155/2017/7942489) Het bepalen 
van dergelijke plasmiden in patiënten met Helicobacter kan dus van nut zijn om de 
klinische strategie vast te stellen waar de patiënt de minste overlast (een onderzoek 
van de maag op het ontstaan van maagkanker middels endoscopie is tamelijk 
belastend) en het meeste profijt heeft. 
Volgend op bacteriële infectie treedt er ontsteking van de maagwand op. Bij een 
chronische maagslijmvliesontsteking door infectie met Helicobacter pylori kan 
slijmvlies van de maag permanent veranderen. Hierbij wordt het slijmvlies dunner. 
We noemen dit atrofische gastritis genoemd (atrofie is het  verschrompelen van het 
weefsel). Bij atrofische gastritis wordt het slijmvlies van de maag erg dun, en 
verliest het bijna alle maagzuur en enzym-producerende cellen. Men kan de 
diagnose van atrofische gastritis vermoeden gebaseerd op de typische klachten van 
de patiënt, maar voor definitieve diagnose is een  gastroscopie noodzakelijk. Bij zulk 
onderzoek kijkt de gastro-enteroloog middels een endoscoop (een flexibele slang) 
via de mondopening en de slokdarm in de maag. Tijdens een 
maagslijmvliesontsteking oogt het slijmvlies van de maag beschadigd en kan een 
verdere bevestiging van de diagnose worden verkregen. Voor definitieve diagnose 
kan de arts tijdens een gastroscopie hapjes weefsel (biopten) uit de maagslijmwand 
nemen. De patholoog onderzoekt deze biopten dan met de microscoop, en stelt de 
diagnose dan met zekerheid (of juist niet). In hoofdstuk zes onderzoek ik in welke 
mate voorlopige en definitieve diagnose met elkaar overeen komen. Dit blijkt heel 
mooi te zijn. Deze informatie kan met name belangrijk zijn voor de Derde Wereld 
waar de aanwezigheid van de mogelijkheden om pathologisch onderzoek te doen 
Nederlandse samenvatting 
 
175 
niet vanzelfsprekend is. Deze data werden wereldkundig gemaakt middels een 
publicatie in een vaktijdschrift (Adamu Ishaku Akyala, Kianoosh. Dadashzadeh, 
Alaba Ovye, David Ishaleku, Maikel P. Peppelenbosch. Agreement between 
Endoscopic assessment and Histological Diagnosis of helicobacter 
Pylori−Associated Gastric Atrophy and Intestinal Metaplasia. ARC Journal of 
Hepatology and Gastroenterology Volume 2, Issue 2, 2017, PP 12). 
Een langdurige maagslijmvliesontsteking kan veranderingen in het weefsel 
veroorzaken en op termijn ontaarden in maagkanker. In dit proefschrift richt ik mij 
op de onderliggende mechanismen en met name op het ontwikkelingsbiologische 
hormoon Hegdehog. In een literatuurstudie toon ik aan dat dit Hedgehog een 
belangrijke rol heeft bij het ontstaan van atrofische gastritis (Hoofdstuk twee). Deze 
analyse naar de rol van Hedgehogsignalering werd voor publicatie geaccepteerd in 
een vooraanstaande vaktijdschrift  (Adamu Ishaku Akyala en Maikel P. 
Peppelenbosch. Gastric cancer and Hedgehog signaling pathway: emerging new 
paradigms. Genes & Cancer (impact factor 5,39.)., Vol. 9 (1-2), January 2018). Een 
volgende studie gaat verder experimenteel de diepte in wat betreft 
Hedgehogsignalering (hoofdstuk vier) en karakteriseert op gedetailleerd moleculair 
niveau de processen die behoud van het kankerstamcelcompartiment door 
Hedgehog-productie bewerkstelligen (“Smo-dependent and independent pathways in 
non-canonical Hedgehog signaling “). Deze studie mag na revisie opnieuw worden 
aangeboden aan het prestigieuze tijdschrift iScience van Cell press.  
Uiteindelijk monden de boven beschreven processen uit in maagkanker. Deze ziekte 
is moeilijk te behandelen omdat hij slecht reageert op conventionele chemotherapie. 
Niet uitgezaaide ziekte kan chirurgisch goed behandeld maar bij metastase is zulks 
zinloos. Een mogelijkheid is echter het lichaam te helpen bij het bestrijden van 
kanker. Dit kan door het geven van immunocheckpointinhibitoren. Kankers weten 
vaak aan de reinigende werking van het immuunsysteem te ontkomen door 
moleculen te maken die ons immuunsysteem remmen. Deze zogenaamde 
immunocheckpoints zijn belangrijk om te voorkomen dat auto-immuunziekte 
ontstaat. Een methode om oncologische ziekte te bestrijden is het geven van 
antilichamen aan de patiënt die deze immunocheckpoints remmen. Het gevolg is dat 
de immuniteit versterkt wordt maar dit gaat vaak wel ten koste van bijwerkingen 
door auto-immuniteit. In hoofdstuk drie analyseer ik de mogelijkheden van 
dergelijke immunocheckpointinhibitoren bij de behandeling van maagkanker. Het 
lijkt er op dat ze beperkt effectief zijn en dat of de patiënten geselecteerd moeten 
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worden die het meeste baat hebben bij behandeling (iets waarvan ik concludeer dat 
dat vooralsnog niet mogelijk lijkt) of dat de werking van dergelijke middelen 
versterkt moet worden. De studie werd bij het ter perse gaan van het proefschrift 
gereviewed door het vaktijdschrift Canadian Journal of Gastroenterology and 
Heptology 
Dit laatste aspect (verdere stimulering van immuniteit) werk ik verder uit in 
hoofdstuk zeven. Het vinden van nieuwe immuunsysteem stimulerende 
behandelingen is één van de voornaamste uitdagingen in het contemporaine 
biomedische onderzoek in dit opzicht. We redeneerden dat als we weten wat het 
immuunsysteem remt, haar inhibitie therapeutisch potentieel zou hebben. Gedurende 
ruimtevlucht raakt het immuunsysteem onderdrukt en als we weten hoe dat gebeurd 
zouden we ook de betrokken processen kunnen remmen en daarmee juist het 
immuunsysteem in haar algemeenheid en antitumor immunologie in het bijzonder, 
kunnen stimuleren. We willen dus uitzoeken welk mechanisme ten grondslag ligt 
aan de ruimtevlucht-afhankelijke remming van het immuunsysteem . Een 
mogelijkheid is immuuncellen gedurende een ruimtevlucht met bacteriële 
bestanddelen te activeren en vervolgens de moleculaire processen die hierop volgen 
te vergelijken met deze op aarde. We analyseerden de data die uit dergelijke 
experimenten kwamen en we kwamen tot de conclusie dat één van de biochemische 
processen die we gevonden hadden in ons hedgehogonderzoek (de zogenaamde 
Rac/Rho signalering) hierbij belangrijk was. Hiermee lijken verschillende elementen 
uit dit promotieonderzoek op het zelfde spoor te komen en worden de contouren hoe 
verder onderzoek moet plaatsvinden om maagkanker succesvol te bestrijden 
duidelijk. Deze toekomstvisie geef ik mijn hoofdstuk acht. Hiermee komt het 
proefschrift tot een einde. Ik hoop dat het een bijdrage levert aan een wereld zonder 
sterfte aan maagkanker. 
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